Scale Biosciences, Inc. v. Parse Biosciences, Inc.
1:22-cv-01597
Overview
Case Number
1:22-cv-01597
Filing Date
2022-12-14
Status
Litigation filed
Court
District Court, D. Delaware (ded)
Presiding Judge
Christopher J. Burke
Nature of Suit
830 Patent
Jurisdiction Type
Federal Question
Cause of Action
35:1 Patent Infringement
Jury Demand
Plaintiff
Parties
Defendant
Parse Biosciences, Inc.
Represented By
19 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Tel: +1 (302) 571-5018
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Tel: +1 (302) 571-6727
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Tel: +1 (302) 571-6600
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Tel: +1 (302) 571-6600
Rodney Square, 1000 North King Street
Plaintiff
Scale Biosciences, Inc.
Represented By
22 Attorneys ListedRichards, Layton & Finger, PA
Tel: +1 (302) 658-6541
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Tel: +1 (302) 651-7869
Fax: +1 (302) 498-7869
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Tel: +1 (302) 651-7705
Richards, Layton & Finger, PA, One Rodney Square
Counter Claimant
The University of Washington
Represented By
11 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Tel: +1 (302) 571-5018
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Tel: +1 (302) 571-6727
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Tel: +1 (302) 571-6600
Rodney Square, 1000 North King Street
Nominal Defendant
Roche Sequencing Solutions, Inc.
Represented By
8 Attorneys ListedRichards, Layton & Finger, PA
Tel: +1 (302) 658-6541
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Tel: +1 (302) 651-7869
Fax: +1 (302) 498-7869
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Tel: +1 (302) 651-7705
Richards, Layton & Finger, PA, One Rodney Square
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Christopher J. Burke
Patents Involved
There are 7 patents involved in this case.
| Application Number | Patent Number | External Links |
|---|---|---|
| - | US10626442 | |
| - | US10982256 | |
| - | US11512341 | |
| - | US10900065 | |
| - | US11168355 | |
| - | US11427856 | |
| - | US11634752 |
Docket Entries
COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against Parse Biosciences, Inc., and Roche Sequencing Solutions, Inc. (Filing fee $ 402, receipt number ADEDC-4025968.) - filed by Scale Biosciences, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(mkr) (Entered: 12/14/2022)
2022-12-14
1
COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against Parse Biosciences, Inc., and Roche Sequencing Solutions, Inc. (Filing fee $ 402, receipt number ADEDC-4025968.) - filed by Scale Biosciences, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(mkr) (Entered: 12/14/2022)
2022-12-14
2
COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against Parse Biosciences, Inc., and Roche Sequencing Solutions, Inc. (Filing fee $ 402, receipt number ADEDC-4025968.) - filed by Scale Biosciences, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(mkr) (Entered: 12/14/2022)
2022-12-14
2
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 12/15/2022)
2022-12-14
1
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,626,442; 10,982,256 ;11,512,341. (mkr) (Entered: 12/15/2022)
2022-12-14
1
Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Scale Biosciences, Inc. (mkr) (Entered: 12/15/2022)
2022-12-14
1
Summons Issued as to Parse Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Attachments: # 1 Summons Issued)(mkr) (Entered: 12/15/2022)
2022-12-14
1
MOTION for Pro Hac Vice Appearance of Attorney Chelsea A. Loughran, Emma L. Frank, and Stephen S. Rabinowitz - filed by Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 12/16/2022)
2022-12-16
1
Return of Service Executed by Scale Biosciences, Inc.. (vfm) (Entered: 12/16/2022)
2022-12-16
1
CORRECTING ENTRY: Proof of Service uploaded per counsels' request. (vfm)
2022-12-16
1
No Actions
CORRECTING ENTRY:
2022-12-16
1
No Actions
- CORRECTING ENTRY
2022-12-16
1
No Actions
Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb)
2022-12-21
1
No Actions
SO ORDERED, re 6 MOTION for Pro Hac Vice Appearance of Attorney Chelsea A. Loughran, Emma L. Frank, and Stephen S. Rabinowitz filed by Scale Biosciences, Inc. Signed by Judge Colm F. Connolly on 12/21/2022. (nmf)
2022-12-21
1
No Actions
SO ORDERED
2022-12-21
1
No Actions
Case Assigned/Reassigned
2022-12-21
1
No Actions
Pro Hac Vice Attorney Chelsea Loughran,Stephen Rabinowitz, and Emma L. Frank for Scale Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)
2022-12-22
1
No Actions
Add Attorneys - PHV only
2022-12-22
1
No Actions
STANDING ORDER REGARDING BRIEFING IN ALL CASES. (kmd) (Entered: 12/28/2022)
2022-12-28
1
MOTION to Extend Time to Respond to Complaint re 1 Complaint, Unopposed - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/04/2023)
2023-01-04
1
SO ORDERED, re 9 MOTION to Extend Time to Respond to Complaint re 1 Complaint, Unopposed, filed by Scale Biosciences, Inc. Reset Answer Deadlines: Parse Biosciences, Inc. answer due 2/6/2023.Ordered by Judge Colm F. Connolly on 1/4/2023. (kmd)
2023-01-04
1
No Actions
~Util - Set/Reset Answer Deadline AND ~Util - Terminate Motions AND SO ORDERED
2023-01-04
1
No Actions
~Util - Terminate Motions AND SO ORDERED AND ~Util - Set/Reset Answer Deadline
2023-01-04
1
No Actions
~Util - Terminate Motions AND ~Util - Set/Reset Answer Deadline AND SO ORDERED
2023-01-04
1
No Actions
ORAL ORDER: It is HEREBY ORDERED that on or before January 24, 2023, the parties shall either (1) submit to the Clerk of Court an executed Form AO 85 Notice, Consent, and Reference of a Civil Action to a Magistrate Judge, indicating their consent to have a United States Magistrate Judge conduct all proceedings in this case including trial, the entry of final judgment, and post-trial proceedings; or (2) file a joint letter indicating that all the parties do not consent to a referral of this action to a Magistrate Judge. The letter should not indicate which party or parties did not consent. If all the parties consent, the case will be referred to Magistrate Judge Burke. Because of the Court's caseload, if the parties do not consent, the Court intends to assign the case to a visiting judge from another district. Ordered by Judge Colm F. Connolly on 1/17/2023. (nmf)
2023-01-17
1
No Actions
Oral Order
2023-01-17
1
No Actions
NOTICE of Appearance by Karen L. Pascale on behalf of Parse Biosciences, Inc. (Pascale, Karen) (Entered: 01/18/2023)
2023-01-18
1
MOTION for Pro Hac Vice Appearance of Attorney Anne Elise Herold Li, James K. Stronski, and Robert B. Kornweiss - filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 01/18/2023)
2023-01-18
1
SO ORDERED, re 11 MOTION for Pro Hac Vice Appearance of Attorney Anne Elise Herold Li, James K. Stronski, and Robert B. Kornweiss, filed by Parse Biosciences, Inc. Ordered by Judge Colm F. Connolly on 1/18/2023. (kmd)
2023-01-18
1
No Actions
SO ORDERED
2023-01-18
1
No Actions
Pro Hac Vice Attorney Anne E.H. Li and Robert B. Kornweiss for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)
2023-01-19
1
No Actions
Add Attorneys - PHV only
2023-01-19
1
No Actions
CONSENT to Jurisdiction by U.S. Magistrate Judge filed by Parse Biosciences, Inc., Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Case reassigned to Magistrate Judge Christopher J. Burke. Signed by Judge Colm F. Connolly on 1/24/2023. (nmf) (Entered: 01/24/2023)
2023-01-24
1
REMARK: The parties should be aware that the Court encourages the participation of newer attorneys in courtroom proceedings and at oral argument. Please see the Court's Standing Order Regarding Courtroom Opportunities for Newer Attorneys, a link to which is provided here for the parties' convenience:http://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrder2017.pdf (dlb)
2023-01-24
1
No Actions
Pro Hac Vice Attorney James K. Stronski for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
2023-01-24
1
No Actions
Remark: The parties should follow the Court's Standing Order Regarding Courtesy Copies, a copy of which is found on Judge Burke's portion of the District Court's webpage: https://www.ded.uscourts.gov/sites/ded/files/CJBCC2022.pdf (dlb) Modified on 1/24/2023 (Rabian, Michael).
2023-01-24
1
No Actions
Add Attorneys - PHV only
2023-01-24
1
No Actions
Remark re Newer Attorneys
2023-01-24
1
No Actions
Remark
2023-01-24
1
No Actions
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
1
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
ANSWER to 1 Complaint, with Jury Demand, COUNTERCLAIM against Scale Biosciences, Inc. by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
2
Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
1
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,900,065 ;11,168,355 ;11,427,856 . (Pascale, Karen) (Entered: 02/03/2023)
2023-02-03
1
ORAL ORDER: IT IS HEREBY ORDERED that the parties shall meet and confer and discuss, in person and/or by telephone, each of the matters listed on Judge Burke's Case Management Checklist ("Checklist"). Within thirty (30) days from the date of this Order, the parties shall jointly file the following: (i) a copy of the Checklist, indicating the names of Lead Counsel and Delaware Counsel for each party; (ii) a proposed Scheduling Order, which is consistent with Judge Burke's "Rule 16 Scheduling Order - Patent"; and (iii) a letter, not to exceed three pages, that contains the following: (a) a description of what this case is about; (b) the parties' positions regarding any disputes in the proposed Scheduling Order, and (c) a list of the three most significant topics (other than Scheduling Order disputes) discussed during the parties' review of the Checklist items, along with a brief description as to what was discussed as to those topics. Thereafter, the Court may schedule a Case Management Conference/Rule 16 Scheduling Conference to be held with Judge Burke. The Checklist and Scheduling Order can be found on Judge Burke's portion of the District Court's website. Ordered by Judge Christopher J. Burke on 1/6/2023. (dlb) (Entered: 02/06/2023)
2023-02-06
1
Oral Order
2023-02-06
1
No Actions
ANSWER to 1 Complaint, with Jury Demand of Parse Biosciences, Inc., Amended COUNTERCLAIM of Parse Biosciences, Inc. and The University of Washington against Scale Biosciences, Inc. by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit A through M)(Pascale, Karen) (Entered: 02/24/2023)
2023-02-24
1
STIPULATION TO EXTEND TIME for the parties to file the items required by the Court's Oral Order of February 6, 2023 to March 22, 2023 - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 02/28/2023)
2023-02-28
1
SO ORDERED D.I. 18 STIPULATION TO EXTEND TIME for the parties to file the items required by the Court's Oral Order of February 6, 2023 to March 22, 2023 filed by Parse Biosciences, Inc., The University of Washington.Ordered by Judge Christopher J. Burke on 3/1/23. (mlc)
2023-03-01
1
No Actions
SO ORDERED
2023-03-01
1
No Actions
ANSWER to 17 Answer to Complaint,, Counterclaim, by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 03/10/2023)
2023-03-10
1
MOTION for Pro Hac Vice Appearance of Attorney Stuart V.C. Duncan Smith - filed by Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 03/14/2023)
2023-03-14
1
NOTICE OF SERVICE of Scale Biosciences, Inc.'s First Set of Interrogatories to Parse Biosciences, Inc. and Scale Biosciences, Inc.'s First Set of Requests for Production of Documents to Parse Biosciences, Inc. filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 03/14/2023)
2023-03-14
1
AFFIDAVIT of Service for Complaint served on Robert Gunther, Outside Litigation Counsel for Nominal Defendant Roche Sequencing Solutions, Inc. on March 14, 2023, filed by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/14/2023)
2023-03-14
1
SO ORDERED D.I. 20 MOTION for Pro Hac Vice Appearance of Attorney Stuart V.C. Duncan Smith filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 3/15/2023. (dlb) (Entered: 03/15/2023)
2023-03-15
1
SO ORDERED
2023-03-15
1
No Actions
STIPULATION TO EXTEND TIME for Nominal Defendant Roche Sequencing Solutions, Inc. to Answer Complaint to through and including May 4, 2023 - filed by Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 03/17/2023)
2023-03-17
1
STIPULATION to File Second Amended Counterclaims by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit 1)(Pascale, Karen) (Entered: 03/17/2023)
2023-03-17
1
SO ORDERED D.I. 24 STIPULATION TO EXTEND TIME for Nominal Defendant Roche Sequencing Solutions, Inc. to Answer Complaint to through and including May 4, 2023 filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 3/17/2023. (dlb)
2023-03-17
1
No Actions
Pro Hac Vice Attorney Stuart V.C. Duncan Smith for Scale Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk)
2023-03-17
1
No Actions
~Util - Set/Reset Answer Deadline AND SO ORDERED
2023-03-17
1
No Actions
Add Attorneys - PHV only
2023-03-17
1
No Actions
ANSWER to 1 Complaint, with Jury Demand of Parse Biosciences, Inc.,, COUNTERCLAIM (SECOND AMENDED) of Parse Biosciences, Inc. and The University of Washington against Scale Biosciences, Inc. by The University of Washington, Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A through M)(Pascale, Karen) (Entered: 03/20/2023)
2023-03-20
1
SO ORDERED D.I. 25 Stipulation to File Second Amended Counterclaims filed by Parse Biosciences, Inc., The University of Washington. Signed by Judge Christopher J. Burke on 3/17/2023. (dlb)
2023-03-20
1
No Actions
SO ORDERED
2023-03-20
1
No Actions
Joint Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Case Management Order and Proposed Scheduling Order - re 16 Oral Order,,,,, SO ORDERED,. (Attachments: # 1 Exhibit A-Case Management Checklist, # 2 Exhibit B-Proposed Scheduling Order)(Farnan, Kelly) (Entered: 03/22/2023)
2023-03-22
1
SCHEDULING ORDER: Joinder of Parties due by 8/25/2023. Amended Pleadings due by 8/25/2023. Discovery due by 9/20/2024. Fact Discovery completed by 4/24/2024. Opening Expert Reports due by 5/24/2024. Rebuttal Expert Reports due by 6/21/2024. Status Report due by 1/26/2024. Dispositive Motions due by 10/18/2024. A Motion Hearing is set for 12/5/2024 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke Claim Construction Opening Brief due by 9/22/2023. Claim Construction Answering Brief due by 10/6/2023. Claim Construction Reply Brief due by 10/20/2023. Claim Construction Surreply Brief due by 11/3/2023. Joint Claim Construction Brief due by 11/15/2023. A Markman Hearing is set for 12/15/2023 at 11:00 AM before Judge Christopher J. Burke. A Pretrial Conference is set for 2/14/2025 at 03:00 PM in Courtroom 2A before Judge Christopher J. Burke. A Jury Trial is set for 3/3/2025 at 09:30 AM in Courtroom 2A before Judge Christopher J. Burke. Please see order for details and further deadlines. Signed by Judge Christopher J. Burke on 3/24/2023. (dlb) (Entered: 03/24/2023)
2023-03-24
1
ORAL ORDER: With the parties having no disputes as to the form of the proposed Scheduling Order (D.I. 28), the Court has today entered that Order. For now, the Court has reserved 10 days for trial at the parties request, but it reserves the right to determine in the future that a lesser amount of days are actually needed for trial. The Court will discuss trial length with the parties during the pre-trial conference (and perhaps before). To the extent that either party wishes the Court to schedule an in-person or telephonic Case Management Conference at this time, they should so inform the Court by letter. To the extent that the parties do not do so, the Court will not set a conference at this time. Ordered by Judge Christopher J. Burke on 3/24/2023. (dlb) (Entered: 03/24/2023)
2023-03-24
1
Oral Order
2023-03-24
1
No Actions
ANSWER to 26 Answer to Complaint,, Counterclaim, Answer to Second Amended Counterclaims by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 03/27/2023)
2023-03-27
1
NOTICE OF SERVICE of 1) Parse Biosciences Inc.'s First Set of Interrogatories (Nos. 1-12) to Scale Biosciences, Inc.; and 2) Parse Biosciences Inc.'s First Set of Requests for Production (Nos. 1-56) to Scale Biosciences, Inc. filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 03/28/2023)
2023-03-28
1
MOTION for Pro Hac Vice Appearance of Attorney Robert J. Gunther, Jr. and Madeleine C. Laupheimer - filed by Roche Sequencing Solutions, Inc.. (Metzler, Sara) (Entered: 03/29/2023)
2023-03-29
1
NOTICE OF SERVICE of Nominal Defendant Roche Sequencing Solutions, Inc.s Rule 26(a)(1) Initial Disclosures filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 03/29/2023)
2023-03-29
1
NOTICE OF SERVICE of Parse Biosciences Inc.'s and University of Washington's Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 03/29/2023)
2023-03-29
1
NOTICE OF SERVICE of Plaintiff and Counterclaim-Defendant Scale Biosciences, Inc.s Initial Disclosures filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 03/29/2023)
2023-03-29
1
STIPULATION TO EXTEND TIME to submit a protective order to through and including April 10, 2023 and the deadline for Plaintiff and Counterclaim-Plaintiff to provide licenses and/or settlement agreements to through and including April 10, 2023 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/31/2023)
2023-03-31
1
Disclosure Statement pursuant to Rule 7.1: identifying filed by Roche Sequencing Solutions, Inc.. (Metzler, Sara) (Entered: 04/03/2023)
2023-04-03
1
SO ORDERED D.I. 32 MOTION for Pro Hac Vice Appearance of Attorney Robert J. Gunther, Jr. and Madeleine C. Laupheimer filed by Roche Sequencing Solutions, Inc. Ordered by Judge Christopher J. Burke on 4/3/2023. (dlb)
2023-04-03
1
No Actions
SO ORDERED D.I. 36 STIPULATION TO EXTEND TIME to submit a protective order to through and including April 10, 2023 and the deadline for Plaintiff and Counterclaim-Plaintiff to provide licenses and/or settlement agreements to through and including April 10, 2023 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 4/3/2023. (dlb)
2023-04-03
1
No Actions
SO ORDERED
2023-04-03
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Rashad L. Morgan - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 04/04/2023)
2023-04-04
1
Pro Hac Vice Attorney Madeleine C. Laupheimer for Roche Sequencing Solutions, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)
2023-04-04
1
No Actions
Pro Hac Vice Attorney Robert J. Gunther, Jr for Roche Sequencing Solutions, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)
2023-04-04
1
No Actions
Add Attorneys - PHV only
2023-04-04
1
No Actions
PROPOSED ORDER Stipulated Protective Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 04/10/2023)
2023-04-10
1
NOTICE OF SERVICE of Licenses and File Histories filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 04/10/2023)
2023-04-10
1
PROTECTIVE ORDER. Signed by Judge Christopher J. Burke on 4/11/2023. (dlb) (Entered: 04/11/2023)
2023-04-11
1
NOTICE OF SERVICE of Counterclaimants' Initial Identification of Asserted Patents, Accused Products and Methods, and Damages Model filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 04/11/2023)
2023-04-11
1
NOTICE OF SERVICE of Plaintiff and Counterclaim Defendant Scale Biosciences, Inc.s Initial Identification of Accused Products and Damages Models filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 04/11/2023)
2023-04-11
1
SO ORDERED D.I. 38 MOTION for Pro Hac Vice Appearance of Attorney Rashad L. Morgan filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 4/11/2023. (dlb)
2023-04-11
1
No Actions
SO ORDERED
2023-04-11
1
No Actions
NOTICE OF SERVICE of 1) all licenses and/or settlement covering Counterclaim Plaintiffs' asserted patents; and 2) the file histories of Counterclaim Plaintiffs' asserted patents filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 04/13/2023)
2023-04-13
1
NOTICE OF SERVICE of 1) Parse Biosciences Inc.'s Responses to Scale Biosciences, Inc.'s First Set of Interrogatories (Nos. 1 11); and 2) Parse Biosciences Inc.'s Responses to Scale Biosciences, Inc.'s First Set of Requests for Production (Nos. 1 55) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 04/13/2023)
2023-04-13
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s and University of Washington's Initial ESI Disclosures filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 04/24/2023)
2023-04-24
1
NOTICE OF SERVICE of Initial Discovery Disclosures Required by the Delaware Default Standard for Discovery filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 04/24/2023)
2023-04-24
1
STIPULATION TO EXTEND TIME to serve Paragraph 3 Disclosures pursuant to the Delaware Default Standard for Discovery to April 28, 2023 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/24/2023)
2023-04-24
1
SO ORDERED D.I. 48 STIPULATION TO EXTEND TIME to serve Paragraph 3 Disclosures pursuant to the Delaware Default Standard for Discovery to April 28, 2023 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 4/25/2023. (dlb)
2023-04-25
1
No Actions
SO ORDERED
2023-04-25
1
No Actions
NOTICE OF SERVICE of Roche Sequencing Solutions, Inc.s Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 04/26/2023)
2023-04-26
1
Letter to Honorable Christopher J. Burke from Kelly E. Farnan regarding Amended Proposed Scheduling Order. (Attachments: # 1 Exhibit A- Proposed Amended Scheduling Order)(Farnan, Kelly) (Entered: 04/26/2023)
2023-04-26
1
NOTICE OF SERVICE of (1) Plaintiff and Counterclaim Defendant Scale Biosciences, Inc.s Responses to First Set of Interrogatories and (2) Plaintiff and Counterclaim Defendant Scale Biosciences, Inc.s Responses to First Set of Requests for Production filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 04/27/2023)
2023-04-27
1
AMENDED SCHEDULING ORDER: Joinder of Parties due by 8/25/2023. Amended Pleadings due by 8/25/2023. Discovery due by 9/20/2024. Fact Discovery completed by 4/24/2024. Opening Expert Reports due by 5/24/2024. Rebuttal Expert Reports due by 6/21/2024. Status Report due by 1/26/2024. Dispositive Motions due by 10/18/2024. A Motion Hearing is set for 12/5/2024 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke. Joint Claim Construction Brief due by 11/15/2023. A Markman Hearing is set for 12/15/2023 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke. Proposed Pretrial Order due by 1/24/2025. A Pretrial Conference is set for 2/14/2025 at 03:00 PM in Courtroom 2A before Judge Christopher J. Burke. A Jury Trial is set for 3/3/2025 at 09:30 AM in Courtroom 2A before Judge Christopher J. Burke.. Signed by Judge Christopher J. Burke on 5/2/23. (mlc) (Entered: 05/02/2023)
2023-05-02
1
STIPULATION and Proposed Order to Realign Roche Sequencing Solutions, Inc. as a Plaintiff by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 05/03/2023)
2023-05-03
1
NOTICE OF SERVICE of Counterclaim Plaintiffs Parse Biosciences, Inc. and University of Washington's core technical documents and sales figures filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 05/05/2023)
2023-05-05
1
NOTICE OF SERVICE of Plaintiff and Counterclaim Defendant Scale Biosciences, Inc.'s core technical documents and sales figures filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 05/08/2023)
2023-05-08
1
SO ORDERED D.I. 53 Stipulation filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 5/5/2023. (dlb)
2023-05-15
1
No Actions
SO ORDERED
2023-05-15
1
No Actions
NOTICE OF SERVICE of Parse Biosciences, Inc.'s and University of Washington's Initial Infringement Contentions filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 06/02/2023)
2023-06-02
1
NOTICE OF SERVICE of Plaintiffs' Preliminary Infringement Contentions filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc..(Metzler, Sara) (Entered: 06/02/2023)
2023-06-02
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s and University of Washington's Amended Initial Infringement Contentions filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 06/16/2023)
2023-06-16
1
NOTICE OF SERVICE of Scale Biosciences, Inc.'s Initial Invalidity Contentions filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/13/2023)
2023-07-13
1
NOTICE OF SERVICE of Parse Biosciences Inc.'s Initial Invalidity Contentions filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/13/2023)
2023-07-13
1
NOTICE OF SERVICE of 1) First Set of Requests for Production of Documents; 2) Second Set of Interrogatories; and 3) Second Set of Requests for Production of Documents filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/21/2023)
2023-07-21
1
Unopposed MOTION to Supplement the Complaint re 1 Complaint, - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Attachment A-Supplemental Complaint, # 2 Attachment B-Redlined Supplemental Complaint, # 3 Text of Proposed Order Proposed Order, # 4 7.1.1 Statement)(Farnan, Kelly) (Entered: 08/03/2023)
2023-08-03
1
NOTICE OF SERVICE of Parse Biosciences Inc.'s First Set of Interrogatories (Nos. 1-10) to Roche Sequencing Solutions, Inc.; and Parse Biosciences Inc.'s First Set of Requests for Production (Nos. 1-37) to Roche Sequencing Solutions, Inc. filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 08/04/2023)
2023-08-04
1
NOTICE OF SERVICE of Plaintiffs' Amended Preliminary Infringement Contentions filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc..(Metzler, Sara) (Entered: 08/08/2023)
2023-08-08
1
Letter to The Honorable Christopher J. Burke from Karen L. Pascale, Esq. regarding no objection to - re 62 Unopposed MOTION to Supplement the Complaint re 1 Complaint, . (Pascale, Karen) (Entered: 08/15/2023)
2023-08-15
1
NOTICE OF SERVICE of Parse Biosciences Inc.'s Initial Identification of Claim Terms/Phrases and Proposed Constructions filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 08/18/2023)
2023-08-18
1
NOTICE OF SERVICE of List of Claim Construction Terms and Proposed Constructions filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 08/18/2023)
2023-08-18
1
NOTICE OF SERVICE of 1) Parse Biosciences Inc.'s Responses to Scale Biosciences, Inc.'s Second Set of Interrogatories (Nos. 12 - 18); and 2) Parse Biosciences Inc.'s Responses to Scale Biosciences, Inc.'s Second Set of Requests for Production (Nos. 56 - 105) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 08/21/2023)
2023-08-21
1
STIPULATION and [Proposed] Order Regarding Parse and UW's Response to First Supplemental Complaint by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit 1)(Pascale, Karen) (Entered: 08/25/2023)
2023-08-25
1
SO ORDERED
2023-08-28
1
No Actions
SO ORDERED D.I. 62 Unopposed MOTION to Supplement the Complaint re 1 Complaint, filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. The Court notes that although the stipulation entered today permits the sides to propose a total of no more than 23 terms for construction, at the initial Markman hearing, the Court will receive briefing for no more than 10 terms or term sets ("terms") and will hear argument on no more than six terms (taking the remainder on the papers).Ordered by Judge Christopher J. Burke on 8/28/2023. (mlc)
2023-08-28
1
No Actions
SO ORDERED D.I. 69 Stipulation Regarding Parse and UW's Response to First Supplemental Complaint filed by Parse Biosciences, Inc., The University of Washington Ordered by Judge Christopher J. Burke on 8/29/2023. (dlb)
2023-08-29
1
No Actions
SO ORDERED
2023-08-29
1
No Actions
AMENDED COMPLAINT First Supplemental Complaint against Parse Biosciences, Inc.- filed by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Attachments: # 1 Exhibit A-442 Patent, # 2 Exhibit B-256 Patent, # 3 Exhibit C-341 Patent, # 4 Exhibit D-752 Patent)(Farnan, Kelly) (Main Document 70 replaced on 8/31/2023) (twk). (Entered: 08/30/2023)
2023-08-30
1
AMENDED COMPLAINT First Supplemental Complaint against Parse Biosciences, Inc.- filed by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Attachments: # 1 Exhibit A-442 Patent, # 2 Exhibit B-256 Patent, # 3 Exhibit C-341 Patent, # 4 Exhibit D-752 Patent)(Farnan, Kelly) (Main Document 70 replaced on 8/31/2023) (twk). (Entered: 08/30/2023)
2023-08-30
2
AMENDED COMPLAINT First Supplemental Complaint against Parse Biosciences, Inc.- filed by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Attachments: # 1 Exhibit A-442 Patent, # 2 Exhibit B-256 Patent, # 3 Exhibit C-341 Patent, # 4 Exhibit D-752 Patent)(Farnan, Kelly) (Main Document 70 replaced on 8/31/2023) (twk). (Entered: 08/30/2023)
2023-08-30
2
AMENDED COMPLAINT First Supplemental Complaint against Parse Biosciences, Inc.- filed by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Attachments: # 1 Exhibit A-442 Patent, # 2 Exhibit B-256 Patent, # 3 Exhibit C-341 Patent, # 4 Exhibit D-752 Patent)(Farnan, Kelly) (Main Document 70 replaced on 8/31/2023) (twk). (Entered: 08/30/2023)
2023-08-30
2
AMENDED COMPLAINT First Supplemental Complaint against Parse Biosciences, Inc.- filed by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Attachments: # 1 Exhibit A-442 Patent, # 2 Exhibit B-256 Patent, # 3 Exhibit C-341 Patent, # 4 Exhibit D-752 Patent)(Farnan, Kelly) (Main Document 70 replaced on 8/31/2023) (twk). (Entered: 08/30/2023)
2023-08-30
2
ANSWER to Amended Complaint, re: 70 Amended Complaint, with Jury Demand, Second Amended Patent Counterclaims of Parse Biosciences, Inc. and the University of Washington, and Tort, COUNTERCLAIM of Parse Biosciences, Inc. against Scale Biosciences, Inc. by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit A through M)(Pascale, Karen) (Main Document 71 replaced on 8/31/2023) (dlb). (Entered: 08/30/2023)
2023-08-30
1
ANSWER to Amended Complaint, re: 70 Amended Complaint, with Jury Demand, Second Amended Patent Counterclaims of Parse Biosciences, Inc. and the University of Washington, and Tort, COUNTERCLAIM of Parse Biosciences, Inc. against Scale Biosciences, Inc. by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit A through M)(Pascale, Karen) (Main Document 71 replaced on 8/31/2023) (dlb). (Entered: 08/30/2023)
2023-08-30
2
[SEALED] EXHIBIT re 71 Answer to Amended Complaint,, Counterclaim, (EXHIBIT N) by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 08/30/2023)
2023-08-30
1
REDACTED VERSION of 72 Exhibit to a Document by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 08/30/2023)
2023-08-30
1
CORRECTING ENTRY: D.I. 70 Amended Complaint replaced with corrected version per request of counsel. (twk)
2023-08-31
1
No Actions
- CORRECTING ENTRY
2023-08-31
1
No Actions
CORRECTING ENTRY: PDF at D.I. 71 replaced at request of filer. (dlb)
2023-08-31
1
No Actions
NOTICE OF SERVICE of University of Washington's Responses to Scale Biosciences, Inc.'s First Set of Requests for Production to University of Washington (Nos. 1-63) filed by The University of Washington.(Pascale, Karen) (Entered: 09/01/2023)
2023-09-01
1
STIPULATION TO EXTEND TIME for Scale Biosciences, Inc.'s response to the Second Amended Patent Counterclaims of Parse Biosciences, Inc. and the University of Washington and the Tort Counterclaims of Parse Biosciences, Inc. to through and including October 13, 2023 - filed by Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 09/07/2023)
2023-09-07
1
SO ORDERED
2023-09-07
1
No Actions
SO ORDERED, re 75 STIPULATION TO EXTEND TIME for Scale Biosciences, Inc.'s response to the Second Amended Patent Counterclaims of Parse Biosciences, Inc. and the University of Washington and the Tort Counterclaims of Parse Biosciences, Inc. to through and includin filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 9/7/2023. (dlb)
2023-09-07
1
No Actions
Joint Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Clarification and/or Modification of the Court's Oral Order - re SO ORDERED,,. (Farnan, Kelly) (Entered: 09/08/2023)
2023-09-08
1
CLAIM Construction Chart by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15)(Farnan, Kelly) (Entered: 09/08/2023)
2023-09-08
1
MOTION for Claim Construction - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 09/08/2023)
2023-09-08
1
MOTION for Claim Construction - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 09/08/2023)
2023-09-08
1
ORAL ORDER Setting Teleconference: The Court, having reviewed the parties' September 8, 2023 letter ("letter"), (D.I. 76), hereby ORDERS as follows: (1) A status teleconference regarding the Markman hearing and related briefing is set for September 18, 2023 at 2:00 PM before Judge Christopher J. Burke.; and (2) By no later than September 14, 2023, the parties shall provide the Court's Courtroom Deputy, Ms. Benyo, with the names and e-mail addresses of all individuals who will participate in the teleconference and a dial-in number for the call via e-mail.Ordered by Judge Christopher J. Burke on 9/12/2023. (dlb) (Entered: 09/12/2023)
2023-09-12
1
Order Setting Teleconference
2023-09-12
1
No Actions
NOTICE OF SERVICE of Parse Biosciences Inc.'s First Supplemental and Amended Invalidity Contentions filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 09/15/2023)
2023-09-15
1
Telephone Conference
2023-09-18
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Status Telephone Conference held on 9/18/2023. The Court held a status teleconference with the parties to discuss their September 8, 2023 letter, (D.I. 76), regarding the Markman hearing and related briefing. The Court ordered the parties to further meet and confer and submit a joint stipulation by close of business on September 22, 2023 regarding the form in which the Markman hearing will occur in light of the teleconference. Further substance of the Court's order will be reflected in the transcript. (Court Reporter Deanna Warner. Clerk: A. Herman)APPEARANCES: A. Barnard, R. Kornweiss, S. Lentz and K. Pascale for Plaintiffs; E. Frank, M. Laupheimer, S. Metzler, C. Loughran and S. Rabinowitz for Defendants. (mlc)
2023-09-18
1
No Actions
STIPULATION and Proposed Order Regarding Claim Construction Briefing re Telephone Conference,,, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 09/22/2023)
2023-09-22
1
SO ORDERED AND ~Util - Set Scheduling Order Deadlines
2023-09-22
1
No Actions
SO ORDERED D.I. 82 Stipulation Regarding Claim Construction Briefing filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc., ORDER, Setting Scheduling Order Deadlines. Ordered by Judge Christopher J. Burke on 9/22/2023. (dlb)
2023-09-22
1
No Actions
NOTICE OF SERVICE of Plaintiffs' Opening Brief on Claim Construction and Exhibits 9I and 16 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc..(Metzler, Sara) (Entered: 09/29/2023)
2023-09-29
1
NOTICE OF SERVICE of 1) Opening Claim Construction Brief of Parse Biosciences Inc. and University of Washington on the Parse Patents; and 2) Declaration of Joseph D. Puglisi, Ph.D. in Support of the Opening Claim Construction Brief of Parse Biosciences, Inc. and University of Washington on the Parse Patents filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 10/02/2023)
2023-10-02
1
NOTICE to Take Deposition of Dr. Joseph Puglisi on October 10, 2023 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 10/05/2023)
2023-10-05
1
NOTICE OF SERVICE of (1) Plaintiff Roche Sequencing Solutions, Inc.'s Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-10) and (2) Plaintiff Roche Sequencing Solutions, Inc.'s Objections and Responses to Defendant's First Set of Requests for Production (Nos. 1-37) filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 10/05/2023)
2023-10-05
1
ANSWER to 71 Answer to Amended Complaint,, Counterclaim,, COUNTERCLAIM against Scale Biosciences, Inc. by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 10/13/2023)
2023-10-13
1
NOTICE OF SERVICE of 1) Answering Claim Construction Brief of Parse Biosciences Inc. on the Scale Patents; and 2) Declaration of Joseph D. Puglisi, Ph.D. in Support of Answering Claim Construction Brief of Parse Biosciences, Inc. on the Scale Patents filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 10/13/2023)
2023-10-13
1
NOTICE OF SERVICE of Scale Biosciences Inc.'s Answering Brief to the Opening Claim Construction Brief of Parse Biosciences, Inc. and University of Washington on the Parse Patents and Exhibits 18-20 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc..(Metzler, Sara) (Entered: 10/13/2023)
2023-10-13
1
NOTICE to Take Deposition of Dr. Joseph Puglisi on October 20, 2023 filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 10/19/2023)
2023-10-19
1
NOTICE OF SERVICE of Reply Claim Construction Brief of Parse Biosciences, Inc. and University of Washington on the Parse Patents filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 10/27/2023)
2023-10-27
1
NOTICE of Service of Plaintiffs' Reply Brief on Claim Construction of the ScaleBio Asserted Patents and the Declaration of Peter A Sims, Ph.D. by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Metzler, Sara) (Entered: 10/27/2023)
2023-10-27
1
ANSWER to 87 Answer to Counterclaim, and Counterclaims by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 11/03/2023)
2023-11-03
1
NOTICE to Take Deposition of Dr. Peter A. Sims on November 8, 2023, beginning at 8:00 a.m. filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 11/03/2023)
2023-11-03
1
NOTICE OF SERVICE of Scale Biosciences, Inc.'s Sur-Reply Brief on Claim Construction of the Parse Asserted Patents filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 11/10/2023)
2023-11-10
1
NOTICE OF SERVICE of Sur-Reply Claim Construction Brief of Parse Biosciences, Inc. on the Scale Patents filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 11/10/2023)
2023-11-10
1
NOTICE of filing the following Non-Paper material(s) in multi media format: USB Drives (Technology Tutorial). Original Non-paper material(s) to be filed with the Clerk's Office. Notice filed by Sara M. Metzler on behalf of Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Metzler, Sara) (Entered: 11/15/2023)
2023-11-15
1
Letter to The Honorable Christopher J. Burke from Karen L. Pascale, Esq. regarding service of Parse Biosciences, Inc. and the University of Washington's technology tutorial. (Pascale, Karen) (Entered: 11/16/2023)
2023-11-16
1
NOTICE of filing the following Non-Paper material(s) in multi media format: USB Drive of the Technology Tutorial of Parse Biosciences, Inc. and the University of Washington. Original Non-paper material(s) to be filed with the Clerk's Office. Notice filed by Karen L. Pascale on behalf of Parse Biosciences, Inc., The University of Washington (Pascale, Karen) (Entered: 11/16/2023)
2023-11-16
1
MULTI MEDIA DOCUMENT filed by Parse Biosciences, Inc. in the form of a (1) USB drive. Filing related to 99 Notice of Filing Multi Media Materials, 98 Letter. (Media on file in Clerk's Office). (dlb) (Entered: 11/17/2023)
2023-11-17
1
JOINT CLAIM CONSTRUCTION BRIEF filed by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Metzler, Sara) (Entered: 11/17/2023)
2023-11-17
1
Joint APPENDIX re 101 Joint Claim Construction Brief by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 9I, # 2 Exhibit 16, # 3 Exhibit 17, # 4 Exhibit 18, # 5 Exhibit 19, # 6 Exhibit 20, # 7 Exhibit 21, # 8 Exhibit 22, # 9 Exhibit 24, # 10 Exhibit 25, # 11 Exhibit 26)(Metzler, Sara) (Entered: 11/17/2023)
2023-11-17
1
Joint Letter to The Honorable Christopher J. Burke from Kelly E. Farnan, Esq. regarding Markman Hearing. (Farnan, Kelly) (Entered: 11/17/2023)
2023-11-17
1
Multi Media Document
2023-11-17
1
No Actions
STATEMENT //Comments on Plaintiffs' Technology Tutorial by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 11/22/2023)
2023-11-22
1
ORAL ORDER: The Court, having reviewed the parties' joint letter regarding the Markman hearing, (D.I. 103), hereby ORDERS as follows: (1) The Court will permit each side, if they wish to, to put on some expert testimony at the hearing, so long as the experts' testimony is focused on subjects that will properly add value (like helping the Court understand what the technical aspects of the patent mean to a POSITA, or providing background on the technology at issue, etc.) and not on subjects that will not (like opining on how to assess the internal coherence of, or context of the language used in, the asserted patents).; (2) The Court is a bit worried though that if the parties do this, the time for argument on the six terms will be reduced to such an extent that the Court will not get much out of the argument part of the hearing, and/or that the parties won't be able to address all of the terms.; (3) As a result, if neither side presents expert testimony at the hearing, the total time allocated for the hearing will be three hours (split evenly per side). But if either side (or both) presents expert testimony, the total time allocated for the hearing will be three and a half hours (split evenly per side).; (4) Otherwise, the parties' proposals regarding the hearing (e.g., the terms to be argued, the order of argument of the terms, when live testimony is to occur) is acceptable to the Court and will be ADOPTED.; and (5) Additionally, on or before December 5, 2023, local and lead counsel for the parties shall meet and confer and file an amended joint claim construction chart that sets forth the terms that remain in dispute. The meet and confer shall focus on an attempt to reach agreement on any remaining disputed terms where possible and on an attempt to focus the dispute over the remaining terms in light of the parties' claim construction briefing. Accompanying any amended joint claim construction chart, the parties shall file a letter with the Court identifying by name each individual who participated in the meet and confer, when and how that meet and confer occurred and how long it lasted. If no agreements on constructions have been reached or if no dispute has been narrowed on the meet and confer, the letter shall so state and the parties need not file an amended joint claim construction chart. Ordered by Judge Christopher J. Burke on 11/27/2023. (dlb) (Entered: 11/27/2023)
2023-11-27
1
STATEMENT re 98 Letter Scale Bioscience's and Roche Sequencing Solutions, Inc.'s Comments on the Technology Tutorial from Parse Biosciences, Inc. and University of Washington by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 11/27/2023)
2023-11-27
1
Oral Order
2023-11-27
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Shannon Lentz and Mary LaFleur - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 12/05/2023)
2023-12-05
1
Joint Letter to The Honorable Christopher J. Burke from Kelly E. Farnan, Esq. regarding Claim Construction. (Attachments: # 1 Amended Joint Claim Construction Chart)(Farnan, Kelly) (Entered: 12/05/2023)
2023-12-05
1
MULTI MEDIA DOCUMENT filed by Scale Biosciences, Inc. in the form of a 2 USB Drives. Filing related to 97 Notice of Filing Multi Media Materials,. (Media on file in Clerk's Office). (dlb) (Entered: 12/08/2023)
2023-12-08
1
Multi Media Document
2023-12-08
1
No Actions
MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 12/11/2023)
2023-12-11
1
ORDER granting 110 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices . Signed by Judge Christopher J. Burke on 12/12/2023. (dlb) (Entered: 12/12/2023)
2023-12-12
1
MOTION [PARSE BIOSCIENCES, INC. AND UNIVERSITY OF WASHINGTON'S MOTION FOR EXEMPTION OF PERSONS FROM THE DISTRICT OF DELAWARE'S MAY 15, 2023 STANDING ORDER ON PERSONAL DEVICES] - filed by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 12/12/2023)
2023-12-12
1
SO ORDERED D.I. 112 MOTION [PARSE BIOSCIENCES, INC. AND UNIVERSITY OF WASHINGTON'S MOTION FOR EXEMPTION OF PERSONS FROM THE DISTRICT OF DELAWARE'S MAY 15, 2023 STANDING ORDER ON PERSONAL DEVICES] filed by Parse Biosciences, Inc., The University of Washington. Signed by Judge Christopher J. Burke on 12/12/2023. (dlb) (Entered: 12/12/2023)
2023-12-12
1
SO ORDERED
2023-12-12
1
No Actions
SO ORDERED D.I. 107 MOTION for Pro Hac Vice Appearance of Attorney Shannon Lentz and Mary LaFleur filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 12/12/2023. (dlb)
2023-12-12
1
No Actions
Markman Hearing
2023-12-15
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Markman Hearing held on 12/15/2023. The Court heard argument from the parties regarding certain of the disputed terms. (D.I. 78; D.I. 79) The Court took the matter under advisement. (Clerk: A. Herman) Appearances: K. Farnan, E. Frank, C. Loughran, S. Rabinowitz and S. Smith for Plaintiffs; A. Bernard, M. LaFleur, S. Lentz, A. Li, R. Kornweiss and K. Pascale for Defendants. (Court Reporter Deanna Warner) (dlb)
2023-12-15
1
No Actions
Pro Hac Vice Attorneys Mary E. LaFleur and Shannon Lentz for Parse Biosciences, Inc. and The University of Washington added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
2023-12-18
1
No Actions
Add Attorneys - PHV only
2023-12-18
1
No Actions
Official Transcript of Markman Hearing held on 12/15/23 before Judge Christopher Burke. Court Reporter Deanna Warner, Email: deanna_warner@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/16/2024. Redacted Transcript Deadline set for 1/26/2024. Release of Transcript Restriction set for 3/25/2024. (Warner, Deanna) (Entered: 12/26/2023)
2023-12-26
1
NOTICE OF SERVICE of 1) Parse Biosciences Inc.'s Second Set of Requests for Production (Nos. 57-81) to Scale Biosciences, Inc.; and 2) Parse Biosciences Inc.'s Second Set of Requests for Production (Nos. 38-44) to Roche Sequencing Solutions, Inc. filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 12/29/2023)
2023-12-29
1
NOTICE OF SERVICE of Plaintiff and Counterclaim Defendant Scale Biosciences, Inc.s First Supplemental Discovery Disclosures Required by the Delaware Default Standard for Discovery filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 01/08/2024)
2024-01-08
1
NOTICE OF SERVICE of 1) Counterclaimants' First Amended Identification of Asserted Patents, Accused Products and Methods, and Damages Model; and 2) Parse Biosciences, Inc.'s and University of Washington's Second Amended Infringement Contentions filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 01/16/2024)
2024-01-16
1
ORAL ORDER: The Court, having reviewed the parties' motions for claim construction, (D.I. 78; D.I. 79), and the briefing related thereto, (D.I. 101), having considered the legal standards related to claim construction, see Vytacera Bio, LLC v. CytomX Therapeutics, Inc., Civil Action No. 20-333-LPS-CJB, 2021 WL 4621866, at *2-3 (D. Del. Oct. 7, 2021), and noting for the parties that it will not consider arguments made for the first time at the December 15, 2023 Markman hearing that were not made in the briefing, (D.I. 114 ("Tr.") at 65, 81-82), hereby addresses the construction of term 1: "unique binding agent" ("UBA"). By the end of argument on this term at the hearing, the sole dispute was over whether the claims require that a UBA may bind only with one target molecule (Parse Biosciences, Inc.'s ("Parse") proposal), or whether it can bind to more than one target molecule (Scale Biosciences, Inc. and Roche Sequencing Solutions, Inc.'s (together, "Scale") proposal). The Court hereby ORDERS that the term be construed to mean "a molecule or assembly that is designed to bind with at least one target molecule, at least one target molecule surrogate, or both" (Scale's proposal). It does so for the following reasons: (1) The definition of UBA in the patent (the parties agree that this language in the patent is definitional), (D.I. 101 at 5, 13, 15, 19; Tr. at 34, 64), states that "UBAs are molecules or assemblies that are designed to bind with at least one target molecule, at least one target molecule surrogate, or both[,]" (442 patent, col. 17:18-20). The Court agrees with Scale that even though this sentence begins with the plural (i.e., "UBAs"), the most natural reading is that the sentence is describing how one UBA can bind (not, as Parse suggests, how UBAs in the collective can bind). After all, the definition is found in a section of the patent titled "Unique Binding Agent (UBA)[,]" (442 patent, col. 17:17), which seems to suggest that what is to be described in the sentence below is the properties of an individual UBA. And the sentence certainly reads this way to the Court. (Tr. at 63-64; D.I. 101 at 15) Therefore, because this definition states that UBAs can bind with "at least one" target molecule (i.e., potentially with more than one molecule), it better aligns with Scale's proposed construction.; (2) In its briefing, Parse argued that the language of claim 21 of the 442 patent supported its position because the claim refers to the use of "a unique binding agent [] that is complementary to a target RNA"--and that the use of "a" was a reference to "a single, not a plural[,]" such that this showed how one UBA is meant to bind to only one target. (D.I. 101 at 11-12; see also 442 patent, col. 59:35-36) However, as Scale rightly responded, the United States Court of Appeals for the Federal Circuit has held that references to "a" in a patent as a rule mean "one or more." See Convolve, Inc. v. Compaq Comput. Corp., 812 F.3d 1313, 1321 (Fed. Cir. 2016). For the reasons set out herein, the Court sees no clear reason to deviate from that general rule here.; (3) The specification also makes reference to a single UBA binding to "at least one target molecule[,]" (442 patent, col. 6:54-56; see also id., col. 17:18-20, 17:43-47), or the like, (id., col. 33:40-41; id., col. 39:34-35). It would be wrong to interpret a claim term in a way that excludes disclosed embodiments, especially "particularly preferred embodiments" as here. (Id., col. 15:44-47; Tr. at 43); see also Eko Brands, LLC v. Adrian Rivera Maynez Enters., Inc., 946 F.3d 1367, 1373 (Fed. Cir. 2020): Oatey Co. v. IPS Corp., 514 F.3d 1271, 1276 (Fed. Cir. 2008).; (4) Parse also points to language in the patents stating that "in some embodiments, the UBA is specific for one of the targets[,]" (442 patent, col. 2:33-34); this necessarily suggests that in some other embodiments, the UBA is not specific for one of the targets. See (Tr. at 36, 78-79); see also TwinStrand Bioscis., Inc. v. Guardant Health, Inc., C.A. No. 21-1126-GBW-SRF, 2023 WL 3773700, at *6 (D. Del. June 2, 2023); SX DJ Tech. Co. v. Autel Robotics USA LLC, C.A. No. 16-706-LPS (Consolidated), 2021 WL 1910037, at *4 (D. Del. May 12, 2021).; (5) Scale offered testimony from its expert, Dr. Peter Sims, indicating that in the relevant time period, a UBA was (and still is today) used to bind with more than one target molecule. (Tr. at 23-30) Although the intrinsic evidence is much more impactful here, this extrinsic evidence helped assure the Court that Scale's construction would not be anomalous in the real world.; (6) As for Parse's assertion that Scale's proposed construction would not give meaning to the word "unique" in UBA, Scale sufficiently explained to the Court why that is not so. (Tr. at 54); and (7) Lastly, the Court does not agree with Parse that all of the above references in the patent that make clear that a UBA can bind to more than one target molecule are explained away by the idea that a UBA could bind to multiple copies of the same molecule. (Tr. at 68-76, 91-92; D.I. 101 at 21) For one thing, Parse did not make this argument in its answering brief, and instead made it only belatedly in its sur-reply brief. (D.I. 101 at 11-15; id. at 21; Tr. at 70-73) Additionally, the Court agrees with Scale that such an explanation is not articulated in the patents, and that it is not natural to read the patents' reference to "at least one target molecule" as a plural reference only to copies of the same target molecule. (Tr. at 92). Ordered by Judge Christopher J. Burke on 1/18/2024. (dlb) (Entered: 01/18/2024)
2024-01-18
1
ORAL ORDER: With regard to the parties' motions for claim construction, (D.I. 78; D.I. 79), the Court now addresses the construction of term 2: "target molecules." As an initial matter, by the end of the Markman hearing, both parties agreed that target molecules are "molecules of interest... that are being detected or quantified." (Tr. at 93, 106-07; Parse's Markman Hearing Slides at Slide 20) This is not surprising, as the patent specification defines the term in just this way. (442 patent, col. 16:15-18) The real lingering dispute is over whether, as Parse suggests, target molecules are ones with a "known individual identity." (Tr. at 106; Parse's Markman Hearing Slides at Slide 20) Parse explains this to mean that you must know the identity of the molecule in advance (i.e., the identity cannot be "unknown"). (D.I. 101 at 23-24, 27) In the briefing, the dispute seemed to be that Scale believed that no portion of the target molecule need be known in advance (i.e., the target molecule could have a "known or unknown structure"), and Parse believed that the entirety of the structure had to be known in advance. (Id. at 22-27) Even at the Markman hearing, at times counsel suggested this was the other side's view. (Tr. at 96, 104-05, 109, 114) But then as the hearing went on, at times Scale's counsel seemed to suggest that you would know at least some portion of the identity of the target molecule (at least for certain types of molecules) in advance, though not necessarily the entire identity of the molecule. (Id. at 97, 100, 102) And Parse's counsel clarified that Parse's position was not that the entirety of the target molecule's structure was known in advance, but that at least some portion was known in advance. (Id. at 109) This all led to a very confused record. One problem for the Court is that neither party's proposed construction really gets to the nub of the parties' apparent dispute. Scale's proposal contains no wording at all directly related to this issue, and Parse's proposal is unclear as to how much of the identity of the molecule must be known. Additionally, as noted above, the parties seemed to be talking past each other on this issue at times, both in the briefing and during the hearing. In light of all of this, the Court declines to construe the term further at this time, beyond concluding that it means at least "molecules of interest... that are being detected or quantified." After further meeting and conferring, if the parties believe that a material dispute still remains as to the "known identity" issue in the future, then by no later than 21 days prior to the summary judgment motion filing deadline, the parties should advise the Court of this. The parties should also then let the Court know whether this term is expected to be relevant to any issues that will be raised in the forthcoming summary judgment briefing. Thereafter, if needed, the Court will set out a further process for resolving any remaining claim construction disputes regarding the term. Ordered by Judge Christopher J. Burke on 1/18/2024. (dlb) (Entered: 01/18/2024)
2024-01-18
1
Oral Order
2024-01-18
1
No Actions
NOTICE OF SERVICE of (1) Plaintiff Roche Sequencing Solutions, Inc.'s Supplemental Rule 26(a)(1) Initial Disclosures and (2) Roche Sequencing Solutions, Inc.'s Supplemental Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Roche Sequencing Solutions, Inc..(Farnan, Kelly) (Entered: 01/23/2024)
2024-01-23
1
ORAL ORDER: With regard to the parties' motions for claim construction, (D.I. 78; D.I. 79), the Court now addresses the construction of term 3: "uniquely labeling target molecules." Scale's proposed construction is: "creating labels that indicate the cells of origin of target molecules[,]" (D.I. 101 at 27), such that each label must indicate the cell of origin for the target molecule, (D.I. 101 at 27-29, 31; Tr. at 119-23, 128-29). The Court is not persuaded that this construction is correct. Scale argues that the structure of claims 1 and 19 shows why its proposal must be right, but the Court does not see it. Claim 1 requires "a method of uniquely labeling target molecules[.]" (442 patent, col. 57:62) Claim 19 requires that "the labeled target molecules from a single cell all comprise the same series of assembled nucleic acid tags." (Id., col. 59:25-27) It seems to the Court that claim 1 could allow for the labeling of target molecules that indicates the cell of origin or it could allow for labeling that indicates other characteristics (i.e., that the "unique labeling" would not necessarily require labeling to indicate cell of origin)--and that claim 19 then merely makes more specific use of the former of those options. Indeed, this is the argument Parse makes. (D.I. 101 at 29-32; Tr. at 124-27, 129-30) Scale also points to some embodiments in the specification that discuss labeling by cell origin. (442 patent, col. 4:25-51; id., col. 12:61-62; id., col. 16:51-52; D.I. 101 at 29; Tr. at 119) But, as Parse notes, these are merely embodiments, (D.I. 101 at 30), and the specification's notation that "some" embodiments have this feature, (442 patent, col. 12:61-62), necessarily suggests that in some other embodiments, labeling can indicate something other than the cell of origin. (See D.I. 118) That said, Parse did not provide any meaningful construction of this term that gets to the question of what "uniquely labeling" actually does mean. (Tr. at 129-30) Thus, although the Court is not prepared to adopt Scale's construction, Parse did not provide the Court with another more appropriate alternative. Since it seems like the parties may still dispute the term's meaning, it could be that the Court will ultimately need to construe the term in the future. But for now, the Court is at a loss as to how to do so. In light of all of this, the Court will not adopt a construction at this time. After further meeting and conferring, if the parties believe that a material dispute still remains as to the term that requires construction, then by no later than 21 days prior to the summary judgment motion filing deadline, the parties should advise the Court of this. The parties should also then let the Court know whether this term is expected to be relevant to any issues that will be raised in the forthcoming summary judgment briefing. Thereafter, if needed, the Court will set out a further process for resolving any remaining claim construction disputes regarding the term. Ordered by Judge Christopher J. Burke on 1/26/2024. (dlb) (Entered: 01/26/2024)
2024-01-26
1
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Interim Status Report - re 52 Scheduling Order,,,. (Farnan, Kelly) (Entered: 01/26/2024)
2024-01-26
1
Oral Order
2024-01-26
1
No Actions
NOTICE OF SERVICE of Roche Sequencing Solutions, Inc.s Objections and Responses to Defendants Second Set of Requests for Production (Nos. 38-44) filed by Roche Sequencing Solutions, Inc..(Farnan, Kelly) (Entered: 01/29/2024)
2024-01-29
1
NOTICE OF SERVICE of Scale Biosciences, Inc.s Responses to Parse Biosciences, Inc.s Second Set of Requests for Production of Documents filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 01/29/2024)
2024-01-29
1
STIPULATION TO EXTEND TIME for Certain Scheduling Order Deadlines to Various Dates - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 02/02/2024)
2024-02-02
1
SO ORDERED D.I. 125 STIPULATION TO EXTEND TIME for Certain Scheduling Order Deadlines to Various Dates filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. See Stipulation for details. Ordered by Judge Christopher J. Burke on 2/5/2024. (dlb)
2024-02-05
1
No Actions
SO ORDERED AND ~Util - Set Scheduling Order Deadlines
2024-02-05
1
No Actions
ORAL ORDER: With regard to the parties' motions for claim construction, (D.I. 78; D.I. 79), the Court now addresses the construction of term 4: "coupling." The court will construe this term to mean "directly or indirectly coupling" for the reasons that follow: (1) The parties' proposed constructions were not helpful here because they did not speak to the dispute, which is over whether the various components of claim 1 of the 442 patent that are coupled may be either directly or indirectly linked (Scale's position) or must only be directly linked (Parse's position). (D.I. 101 at 43-45; Tr. at 131, 138); (2) As an initial matter, it is worth noting that the term at issue is "coupling"; had the patentee wanted to make clear that only direct coupling is permitted, it could have used the phrase "directly coupling," but it did not.; (3) Additionally, claims 13 and 14 of the 442 patent provide indication that Scale's proposal is correct. Those claims, which depend from claim 1, require that a common linker be "coupled" to certain additional components (e.g., an epitope specific barcode ("ESB") and an antibody, or an aptamer). (442 patent, col. 59:1-13) And then the claims refer back to claim 1's coupling step (a) (i.e., "coupling a common linker sequence to target molecules") and explain that this step "comprises binding the antibodies comprising the common linker sequence and the epitope specific barcode sequence to the protein, peptide, or antigen [(i.e., the "target molecules")]" or "comprises binding the aptamer to the [target molecules]." (Id., col. 57:64-65; id., col. 59:6-8; id., col. 59:11-13) Although claim 13 uses both the words "coupled" and "binding" at different points, it certainly appears to allow for a world in which the common linker is linked to the target molecule by way of an intervening connection via one or more intermediate components (such as the ESB and/or the antibody and/or the aptamer). (D.I. 101 at 46; Tr. at 133-37, 144-46) A construction that only provides for direct coupling thus does not gibe with what is described in claims 13 and 14.; and (4) In his deposition, Parse's expert, Dr. Puglisi, appeared to acknowledge that claim 13 describes an example of the common linker and the target molecule being "indirectly coupled[,]" which is not consistent with Parse's proposed construction. (D.I. 102, ex. 25 at 137-38; D.I. 101 at 46; Tr. at 143). Ordered by Judge Christopher J. Burke on 2/6/2024. (dlb) (Entered: 02/06/2024)
2024-02-06
1
Oral Order
2024-02-06
1
No Actions
NOTICE OF SERVICE of (1) Scale Biosciences, Inc.'s Third Set of Interrogatories to Parse Biosciences, Inc. and (2) Scale Biosciences, Inc.'s Third Set of Requests for Production of Documents to Parse Biosciences, Inc. filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 02/13/2024)
2024-02-13
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Stanford University School of Medicine by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Document Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 02/14/2024)
2024-02-14
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Garry Nolan, M.D. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Document Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 02/14/2024)
2024-02-14
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Apprise Bio, Inc. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Document Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 02/14/2024)
2024-02-14
1
NOTICE OF SERVICE of 1) Parse Biosciences Inc.'s Third Set of Requests for Production (Nos. 82-91) to Scale Biosciences, Inc.; and 2) Parse Biosciences Inc.'s Third Set of Requests for Production (Nos. 45-54) to Roche Sequencing Solutions, Inc. filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 02/27/2024)
2024-02-27
1
NOTICE OF SERVICE of Plaintiff and Counterclaim Defendant Scale Biosciences, Inc.'s First Amended Identification of Asserted Patents, Accused Products and Methods, and Damages Model filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 03/08/2024)
2024-03-08
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Responses to Scale Biosciences, Inc.'s Third Set of Requests for Production of Documents (Nos. 106-126) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 03/14/2024)
2024-03-14
1
MOTION for Pro Hac Vice Appearance of Attorney Elissa Tenenbaum - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 03/18/2024)
2024-03-18
1
Pro Hac Vice Fee - Credit Card Payment received for Elissa Tenenbaum. ( Payment of $ 50, receipt number ADEDC-4363653).(Pascale, Karen) (Entered: 03/18/2024)
2024-03-18
1
NOTICE of Subpoena for Documents to Non-Party Illumina, Inc. by Scale Biosciences, Inc. (Attachments: # 1 Exhibit 1)(Metzler, Sara) (Entered: 03/18/2024)
2024-03-18
1
NOTICE OF SERVICE of Parse Biosciences Inc.'s Fourth Set of Requests for Production (Nos. 92-96) to Scale Biosciences, Inc. filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 03/18/2024)
2024-03-18
1
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-03-18
1
No Actions
SO ORDERED
2024-03-19
1
No Actions
SO ORDERED D.I. 134 MOTION for Pro Hac Vice Appearance of Attorney Elissa Tenenbaum filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 3/19/2024. (dlb)
2024-03-19
1
No Actions
NOTICE OF SERVICE of Roche Sequencing Solutions, Inc.s Objections and Responses to Parse Biosciences Inc.s Third Set of Requests for Production (Nos. 45-54) filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 03/28/2024)
2024-03-28
1
NOTICE OF SERVICE of Scale Biosciences, Inc.s Responses to Parse Biosciences, Inc.s Third Set of Requests for Production of Documents filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 03/28/2024)
2024-03-28
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Responses to Scale Biosciences, Inc.'s Third Set of Interrogatories (Nos. 19-22) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 03/28/2024)
2024-03-28
1
MOTION for Pro Hac Vice Appearance of Attorney Michelle Wang - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 04/03/2024)
2024-04-03
1
Pro Hac Vice Fee - Credit Card Payment received for Michelle Wang. ( re 141 MOTION for Pro Hac Vice Appearance of Attorney Michelle Wang )( Payment of $ 50, receipt number ADEDC-4376386).(Pascale, Karen) (Entered: 04/03/2024)
2024-04-03
1
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-04-03
1
No Actions
NOTICE of 30(b)(6) Deposition of Scale Biosciences, Inc. by Parse Biosciences, Inc. (Pascale, Karen) (Entered: 04/05/2024)
2024-04-05
1
NOTICE of 30(b)(6) Deposition of Roche Sequencing Solutions, Inc. by Parse Biosciences, Inc. (Pascale, Karen) (Entered: 04/05/2024)
2024-04-05
1
NOTICE to Take Deposition of University of Washington on May 14, 2024 filed by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A)(Metzler, Sara) (Entered: 04/05/2024)
2024-04-05
1
NOTICE to Take Deposition of Parse Biosciences, Inc. on May 15, 2024 filed by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A)(Metzler, Sara) (Entered: 04/05/2024)
2024-04-05
1
MOTION for Pro Hac Vice Appearance of Attorney Paul Keller - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 04/15/2024)
2024-04-15
1
Pro Hac Vice Fee - Credit Card Payment received for Paul Keller. ( re 147 MOTION for Pro Hac Vice Appearance of Attorney Paul Keller )( Payment of $ 50, receipt number ADEDC-4384713).(Pascale, Karen) (Entered: 04/15/2024)
2024-04-15
1
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-04-15
1
No Actions
NOTICE OF SERVICE of Parse Biosciences, Inc.'s and University of Washington's First Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 04/18/2024)
2024-04-18
1
NOTICE OF SERVICE of Responses to Parse Biosciences, Inc.s Fourth Set of Requests for Production of Documents filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 04/18/2024)
2024-04-18
1
NOTICE requesting Clerk to remove Robert B. Kornweiss as co-counsel. Reason for request: no longer associated with Crowell & Moring LLP. (Pascale, Karen) (Entered: 04/22/2024)
2024-04-22
1
STIPULATION and [Proposed] Order to Extend Deadlines by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/22/2024)
2024-04-22
1
NOTICE OF SERVICE of (1) Scale Biosciences, Inc.'s Fourth Set of Requests for Production of Documents to Parse Biosciences, Inc. and (2) Scale Biosciences, Inc.'s Second Set of Requests for Production of Documents to University of Washington filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 04/22/2024)
2024-04-22
1
SO ORDERED, D.I. 152 Stipulation and [Proposed] Order to Extend Deadlines filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 04/22/2024. (smg)
2024-04-22
1
No Actions
SO ORDERED AND ~Util - Set Scheduling Order Deadlines
2024-04-23
1
No Actions
SO ORDERED
2024-04-29
1
No Actions
SO ORDERED D.I. 147 MOTION for Pro Hac Vice Appearance of Attorney Paul Keller filed by Parse Biosciences, Inc., The University of Washington, and D.I. 141 MOTION for Pro Hac Vice Appearance of Attorney Michelle Wang filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 4/29/2024. (dlb)
2024-04-29
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Byron L. Pickard, R. Wilson Powers III, Ph.D., Chandrika Vira & Louis P. Panzica, Jr. - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 05/01/2024)
2024-05-01
1
Pro Hac Vice Fee - Credit Card Payment received for Byron L. Pickard, R. Wilson Powers III, Ph.D., Chandrika Vira, and Louis P. Panzica, Jr.. ( re 154 MOTION for Pro Hac Vice Appearance of Attorney Byron L. Pickard, R. Wilson Powers III, Ph.D., Chandrika Vira & Louis P. Panzica, Jr. )( Payment of $ 200, receipt number ADEDC-4396862).(Pascale, Karen) (Entered: 05/01/2024)
2024-05-01
1
-District Court Pro Hac Vice Fee - 04 Attorneys Credit Card Payment
2024-05-01
1
No Actions
SO ORDERED
2024-05-01
1
No Actions
SO ORDERED, D.I. 154 MOTION for Pro Hac Vice Appearance of Attorney Byron L. Pickard, R. Wilson Powers III, Ph.D., Chandrika Vira & Louis P. Panzica, Jr. filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 05/01/2024. (smg)
2024-05-01
1
No Actions
Pro Hac Vice Attorney Ralph W. Powers, III for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-05-02
1
No Actions
Pro Hac Vice Attorney Chandrika Vira for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-05-02
1
No Actions
Pro Hac Vice Attorney Louis P. Panzica, Jr for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-05-02
1
No Actions
Add Attorneys - PHV only
2024-05-02
1
No Actions
NOTICE OF SERVICE of Objections and Responses to Notice of 30(b)(6) Deposition filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 05/15/2024)
2024-05-15
1
MOTION for Pro Hac Vice Appearance of Attorney Christopher R. Noyes - filed by Roche Sequencing Solutions, Inc.. (Farnan, Kelly) (Entered: 05/17/2024)
2024-05-17
1
Pro Hac Vice Fee - Credit Card Payment received for Christopher R. Noyes. ( re 157 MOTION for Pro Hac Vice Appearance of Attorney Christopher R. Noyes )( Payment of $ 50, receipt number ADEDC-4409805).(Farnan, Kelly) (Entered: 05/17/2024)
2024-05-17
1
NOTICE requesting Clerk to remove Anne Elise Herold Li, James K. Stronski, Paul Keller, Michelle Wang, Shannon Lentz, Rashad L. Morgan, Mary E. LaFleur and Elissa N. Tenenbaum as co-counsel.. (Pascale, Karen) (Entered: 05/17/2024)
2024-05-17
1
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-05-17
1
No Actions
SO ORDERED
2024-05-20
1
No Actions
SO ORDERED, re 157 MOTION for Pro Hac Vice Appearance of Attorney Christopher R. Noyes filed by Roche Sequencing Solutions, Inc.. Ordered by Judge Christopher J. Burke on 05/20/2024. (smg)
2024-05-20
1
No Actions
NOTICE OF SERVICE of University of Washington's Objections and Responses to Scale Biosciences, Inc.'s Second Set of Requests for Production of Documents (Nos. 64 - 89) filed by The University of Washington.(Pascale, Karen) (Entered: 05/22/2024)
2024-05-22
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Objections and Responses to Scale Biosciences, Inc.'s Fourth Set of Requests for Production of Documents (Nos. 127 - 154) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 05/22/2024)
2024-05-22
1
Pro Hac Vice Attorney Christopher R. Noyes for Roche Sequencing Solutions, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-05-22
1
No Actions
Add Attorneys - PHV only
2024-05-22
1
No Actions
NOTICE OF SERVICE of Parse Biosciences Inc.'s Second Set of Interrogatories to Roche Sequencing Solutions, Inc. (Nos. 11-12); filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 05/29/2024)
2024-05-29
1
NOTICE OF SERVICE of Parse Biosciences Inc.'s Second Set of Interrogatories to Scale Biosciences, Inc. (Nos. 13-35) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 05/29/2024)
2024-05-29
1
STIPULATION to Extend the Case Schedule by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 05/29/2024)
2024-05-29
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Bruce Colston Trapnell, Jr., Ph.D. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Document Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 05/30/2024)
2024-05-30
1
NOTICE to Take Deposition of Non-Party Bruce Colston Trapnell, Jr., Ph.D. on June 21, 2024, beginning at 9:00 a.m. (PT) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 05/30/2024)
2024-05-30
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Jay Shendure, M.D., Ph.D. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Document Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 05/30/2024)
2024-05-30
1
NOTICE to Take Deposition of Non-Party Jay Shendure M.D., Ph.D. on June 21, 2024, beginning at 9:00 a.m. (PT) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 05/30/2024)
2024-05-30
1
MOTION for Pro Hac Vice Appearance of Attorney Brady P. Gleason and David Y. Wang - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 05/30/2024)
2024-05-30
1
SO ORDERED, D.I. 164 Stipulation to Extend the Case Schedule filed by Parse Biosciences, Inc., The University of Washington. (A 10-day Jury Trial is set for 5/27/2025 at 09:30 AM in Courtroom 2A before Judge Christopher J. Burke, A Dispositive Motion Hearing is set for 2/19/2025 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke, and A Pretrial Conference is set for 5/16/2025 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke.) Signed by Judge Christopher J. Burke on 05/30/2024. (smg) (Entered: 05/30/2024)
2024-05-30
1
Pro Hac Vice Fee - Credit Card Payment received for Brady P. Gleason and David Y. Wang. ( re 169 MOTION for Pro Hac Vice Appearance of Attorney Brady P. Gleason and David Y. Wang )( Payment of $ 100, receipt number ADEDC-4419100).(Pascale, Karen) (Entered: 05/30/2024)
2024-05-30
1
ORAL ORDER: The Court has kept the parties' reference to a 10-day trial in the amended Scheduling Order, (D.I. 164 ), but the parties should be aware that as the case proceeds closer to trial, the Court will allocate a certain amount of hours for the parties' trial presentations (and 10-day trials of any type, even in complex cases, are very rare in this District). The Court will also discuss with the parties in the future whether the trial will involve all patents at issue in the case (or whether more than one trial will be needed). Ordered by Judge Christopher J. Burke on 05/30/2024. (smg) (Entered: 05/30/2024)
2024-05-30
1
NOTICE OF SERVICE of First Supplemental Initial Disclosures filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 05/30/2024)
2024-05-30
1
-District Court Pro Hac Vice Fee - 02 Attorneys Credit Card Payment
2024-05-30
1
No Actions
Oral Order
2024-05-30
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Christopher M. Gallo, Ph.D. - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 05/31/2024)
2024-05-31
1
Pro Hac Vice Fee - Credit Card Payment received for Christopher M. Gallo, Ph.D.. ( re 174 MOTION for Pro Hac Vice Appearance of Attorney Christopher M. Gallo, Ph.D. )( Payment of $ 50, receipt number ADEDC-4419751).(Pascale, Karen) (Entered: 05/31/2024)
2024-05-31
1
NOTICE OF SERVICE of (1) Roche Sequencing Solutions, Inc.'s Objections and Responses to Parse Biosciences Inc.'s Notice of 30(b)(6) Deposition and (2) Plaintiff Roche Sequencing Solutions, Inc.'s Second Supplemental Rule 26(a)(1) Initial Disclosures filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 05/31/2024)
2024-05-31
1
SO ORDERED, re 169 MOTION for Pro Hac Vice Appearance of Attorney Brady P. Gleason and David Y. Wang filed by Parse Biosciences, Inc., The University of Washington, 174 MOTION for Pro Hac Vice Appearance of Attorney Christopher M. Gallo, Ph.D. filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 05/31/2024. (smg)
2024-05-31
1
No Actions
SO ORDERED
2024-05-31
1
No Actions
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-05-31
1
No Actions
Pro Hac Vice Attorney Christopher M. Gallo for Parse Biosciences, Inc. and The University of Washington added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-06-03
1
No Actions
Add Attorneys - PHV only
2024-06-03
1
No Actions
NOTICE OF SERVICE of Parse Biosciences, Inc.'s and University of Washington's Second Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 06/04/2024)
2024-06-04
1
Pro Hac Vice Attorney David Y. Wang for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-06-05
1
No Actions
Pro Hac Vice Attorney Byron L. Pickard for Parse Biosciences, Inc., and The University of Washington added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-06-05
1
No Actions
Pro Hac Vice Attorney Brady P. Gleason for Parse Biosciences, Inc., and The University of Washington added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2024-06-05
1
No Actions
Add Attorneys - PHV only
2024-06-05
1
No Actions
NOTICE OF SERVICE of Scale Biosciences, Inc.'s Fourth Set of Interrogatories to Parse Biosciences, Inc. (Nos. 23-36) filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 06/10/2024)
2024-06-10
1
MOTION for Pro Hac Vice Appearance of Attorney Arden E. Bonzo - filed by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 06/11/2024)
2024-06-11
1
Pro Hac Vice Fee - Credit Card Payment received for Arden E. Bonzo. ( re 179 MOTION for Pro Hac Vice Appearance of Attorney Arden E. Bonzo )( Payment of $ 50, receipt number ADEDC-4427777).(Metzler, Sara) (Entered: 06/11/2024)
2024-06-11
1
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-06-11
1
No Actions
SO ORDERED
2024-06-12
1
No Actions
SO ORDERED, D.I. 179 MOTION for Pro Hac Vice Appearance of Attorney Arden E. Bonzo filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 06/12/2024. (smg)
2024-06-12
1
No Actions
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Third Set of Interrogatories to Scale Biosciences, Inc. (No. 36) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 06/20/2024)
2024-06-20
1
NOTICE OF SERVICE of Plaintiff Roche Sequencing Solutions, Inc.'s Objections and Responses to Defendant's Second Set of Interrogatories (Nos. 11-12) filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 06/27/2024)
2024-06-27
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Objections and Responses to Notice of 30(B)(6) Deposition filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/03/2024)
2024-07-03
1
NOTICE OF SERVICE of University of Washington's Objections and Responses to Notice of 30(B)(6) Deposition filed by The University of Washington.(Pascale, Karen) (Entered: 07/03/2024)
2024-07-03
1
NOTICE OF SERVICE of (1) Scale Biosciences, Inc.'s First Set of Requests for Admission to Parse Biosciences, Inc. (Nos. 1-96); (2) Scale Biosciences, Inc.'s Responses to Parse Biosciences, Inc.'s Second Set of Interrogatories (Nos. 13-35); and (3) Scale Biosciences, Inc.'s Fifth Set of Interrogatories to Parse Biosciences, Inc. (No. 37) filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/03/2024)
2024-07-03
1
NOTICE OF SERVICE of 1) Parse Biosciences, Inc.'s Fourth Set of Interrogatories to Scale Biosciences, Inc. (No. 37); and 2) Parse Biosciences, Inc.'s Fifth Set of Requests for Production to Scale Biosciences, Inc. (Nos. 97-109) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/03/2024)
2024-07-03
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Toumy Guettouche, Ph.D. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Documents Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 07/08/2024)
2024-07-08
1
NOTICE to Take Deposition of Toumy Guettouche, Ph.D. on August 8, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/08/2024)
2024-07-08
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Maeve O'Huallachain, Ph.D. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Documents Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 07/08/2024)
2024-07-08
1
NOTICE to Take Deposition of Maeve O'Huallachain Ph.D. on August 1, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/08/2024)
2024-07-08
1
NOTICE of Subpoenas for Documents and Deposition to Non-Party Steven A. Sundberg, Ph.D. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Documents Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 07/08/2024)
2024-07-08
1
NOTICE to Take Deposition of Steven A. Sundberg, Ph.D. on August 2, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/08/2024)
2024-07-08
1
Amended NOTICE of of Subpoenas for Documents and Deposition to Non-Party Toumy Guettouche, Ph.D. by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 - Documents Subpoena, # 2 Exhibit 2 - Deposition Subpoena)(Pascale, Karen) (Entered: 07/10/2024)
2024-07-10
1
Amended NOTICE to Take Deposition of Toumy Guettouche, Ph.D. on August 8, 2024, beginning at 9:00 am (ET) filed by Parse Biosciences, Inc..(Pascale, Karen) Modified on 7/10/2024 (smg). (Entered: 07/10/2024)
2024-07-10
1
NOTICE to Take Deposition of Michael Yamamoto on July 18, 2024 filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/11/2024)
2024-07-11
1
NOTICE to Take Deposition of Joe Musmacker on July 19, 2024 filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/11/2024)
2024-07-11
1
NOTICE to Take Deposition of Jennifer McCullar on July 23, 2024 filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/11/2024)
2024-07-11
1
NOTICE to Take Deposition of Michael Skogen on July 24, 2024 filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/11/2024)
2024-07-11
1
NOTICE to Take Deposition of Melanie Masuda on July 18, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/15/2024)
2024-07-15
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Objections and Responses to Scale Biosciences, Inc.'s Fourth Set of Interrogatories (Nos. 23-36) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/15/2024)
2024-07-15
1
NOTICE OF SERVICE of First Supplemental Responses to Parse Biosciences, Inc.s First Set of Interrogatories (Nos. 1-12) filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/16/2024)
2024-07-16
1
STIPULATION Regarding the Parties' Customers' Use of the Parties' Products by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 07/17/2024)
2024-07-17
1
STIPULATION and Proposed Order Regarding Pretrial Depositions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 07/17/2024)
2024-07-17
1
NOTICE to Take Deposition of Garry Nolan, Ph.D. on August 19, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/17/2024)
2024-07-17
1
NOTICE to Take Deposition of Margaret Nakamoto, Ph.D. on August 2, 2024, beginning at 9:00 am (ET) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/17/2024)
2024-07-17
1
NOTICE to Take Deposition of Giovanna Prout on July 22, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/17/2024)
2024-07-17
1
NOTICE to Take Deposition of Frank Steemers, Ph.D. on July 31, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/17/2024)
2024-07-17
1
NOTICE to Take Deposition of Sean Scott on July 29, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/17/2024)
2024-07-17
1
SO ORDERED
2024-07-17
1
No Actions
SO ORDERED, D.I. 203 Stipulation and Proposed Order Regarding Pretrial Depositions filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 07/17/2024. (smg)
2024-07-17
1
No Actions
SO ORDERED, D.I. 202 Stipulation Regarding the Parties' Customers' Use of the Parties' filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 07/17/2024. (smg)
2024-07-17
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Jamie Dohopolski, Ryan N. Kaiser, and Cristen A. Corry - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 07/18/2024)
2024-07-18
1
Pro Hac Vice Fee - Credit Card Payment received for Jamie Dohopolski, Ryan N. Kaiser, and Cristen A. Corry. ( re 209 MOTION for Pro Hac Vice Appearance of Attorney Jamie Dohopolski, Ryan N. Kaiser, and Cristen A. Corry )( Payment of $ 150, receipt number ADEDC-4454253).(Pascale, Karen) (Entered: 07/18/2024)
2024-07-18
1
SO ORDERED
2024-07-18
1
No Actions
-District Court Pro Hac Vice Fee - 03 Attorneys Credit Card Payment
2024-07-18
1
No Actions
SO ORDERED, D.I. 209 MOTION for Pro Hac Vice Appearance of Attorney Jamie Dohopolski, Ryan N. Kaiser, and Cristen A. Corry filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 07/18/2024. (smg)
2024-07-18
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney of Kate Saxton - filed by Roche Sequencing Solutions, Inc.. (Metzler, Sara) (Entered: 07/19/2024)
2024-07-19
1
Pro Hac Vice Fee - Credit Card Payment received for of Kate Saxton. ( re 211 MOTION for Pro Hac Vice Appearance of Attorney of Kate Saxton )( Payment of $ 50, receipt number ADEDC-4456185).(Metzler, Sara) (Entered: 07/19/2024)
2024-07-19
1
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2024-07-19
1
No Actions
NOTICE OF SERVICE of Parse Biosciences, Inc.'s First Supplemental Objections and Responses to Scale Biosciences, Inc.'s Second Set of Interrogatories (Nos. 12-18) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/20/2024)
2024-07-20
1
NOTICE OF SERVICE of Scale Biosciences, Inc.'s Responses to Parse Biosciences, Inc.'s Third Set of Interrogatories (No. 36) filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 07/22/2024)
2024-07-22
1
NOTICE to Take Deposition of Alex Rosenberg on July 26, 2024 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 07/22/2024)
2024-07-22
1
NOTICE OF SERVICE of Non-Party Dr. Maeve OHuallachain's Objections and Responses to Parse's Rule 45 Subpoenas for Documents and Deposition in a Civil Action filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 07/22/2024)
2024-07-22
1
SO ORDERED
2024-07-22
1
No Actions
SO ORDERED, D.I. 211 MOTION for Pro Hac Vice Appearance of Attorney of Kate Saxton filed by Roche Sequencing Solutions, Inc. Ordered by Judge Christopher J. Burke on 07/22/2024. (smg)
2024-07-22
1
No Actions
NOTICE to Take Deposition of Tod Bedilion, Ph.D. on August 6, 2024 filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/31/2024)
2024-07-31
1
NOTICE to Take Deposition of Carolina Dallett on August 21, 2024 filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/31/2024)
2024-07-31
1
NOTICE to Take Deposition of Jan Berka, Ph.D. on August 28, 2024 filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/31/2024)
2024-07-31
1
NOTICE to Take Deposition of Thomas Albert, Ph.D. on August 15, 2024 filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 07/31/2024)
2024-07-31
1
NOTICE to Take Deposition of Georg Seelig on August 8, 2024 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 08/01/2024)
2024-08-01
1
NOTICE to Take Deposition of Charlie Roco on August 16, 2024 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 08/01/2024)
2024-08-01
1
NOTICE to Take Deposition of Richard Muscat on August 21, 2024 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 08/01/2024)
2024-08-01
1
NOTICE of of Subpoena upon non-party Britton Russell by Scale Biosciences, Inc. (Attachments: # 1 Exhibit 1)(Metzler, Sara) (Entered: 08/01/2024)
2024-08-01
1
NOTICE of Subpoena for the Deposition upon non-party John Walsh by Scale Biosciences, Inc. (Attachments: # 1 Exhibit 1)(Metzler, Sara) (Entered: 08/01/2024)
2024-08-01
1
NOTICE OF SERVICE of 1) Parse Biosciences, Inc.'s Objections and Responses to Scale Biosciences, Inc.'s First Set of Requests for Admission (Nos. 1-97); 2) Parse Biosciences, Inc.'s Objections and Responses to Scale Biosciences, Inc.'s Fifth Set of Interrogatories (No. 37); and 3) Parse Biosciences, Inc.'s Second Supplemental Objections and Responses to Scale Biosciences, Inc.'s Second Set of Interrogatories (Nos. 12-18) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 08/02/2024)
2024-08-02
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Second Supplemental and Amended Invalidity Contentions filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 08/02/2024)
2024-08-02
1
NOTICE OF SERVICE of (1) Scale Biosciences, Inc.'s Responses to Parse Biosciences, Inc.'s Fourth Set of Interrogatories (No. 37); (2) Scale Biosciences, Inc.'s First Supplemental Responses to Parse Biosciences, Inc.'s Second Set of Interrogatories (Nos. 13-35); (3) Scale Biosciences, Inc.'s Second Supplemental Responses to Parse Biosciences, Inc.'s First Set of Interrogatories (Nos. 1-12); (4) Scale Biosciences, Inc.'s Responses to Parse Biosciences, Inc.'s Fifth Set of Requests for Production of Documents (Nos. 97-109); (5) Scale Biosciences, Inc.'s Verification of Its Responses to Parse Biosciences, Inc.'s Interrogatories; and (6) Scale Biosciences, Inc.'s Privilege Log filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 08/02/2024)
2024-08-02
1
NOTICE to Take Deposition of Dr. Charles Roco on August 16, 2024 filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 08/08/2024)
2024-08-08
1
NOTICE OF SERVICE of Counterclaim-Plaintiffs' Final Supplemental Identification of All Accused Products and All Invalidity References filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 08/09/2024)
2024-08-09
1
NOTICE OF SERVICE of Plaintiff and Counterclaim Defendant Scale Biosciences, Inc.s Identification of Accused Products, Methods, and Systems and Invalidity References filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 08/09/2024)
2024-08-09
1
NOTICE to Take Deposition of Jacqueline Fidanza, Ph.D. on August 29, 2024, beginning at 9:00 am (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 08/12/2024)
2024-08-12
1
NOTICE requesting Clerk to remove Jamie Dohopolski as co-counsel.. (Pascale, Karen) (Entered: 08/13/2024)
2024-08-13
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s First Supplemental Objections and Responses to Scale Biosciences, Inc.'s Fourth Set of Interrogatories (Nos. 23-36) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 08/15/2024)
2024-08-15
1
NOTICE OF SERVICE of 1) Parse Biosciences, Inc.'s and University of Washington's Privilege Log with List of Attorneys; and 2) University of Washington's UW-Trapnell Privilege Log with List of Attorneys; filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 08/20/2024)
2024-08-20
1
STIPULATION TO EXTEND TIME for the parties to exchange final infringement contentions to through and including August 28, 2024 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 08/23/2024)
2024-08-23
1
SO ORDERED AND ~Util - Terminate Motions
2024-08-26
1
No Actions
SO ORDERED, re 236 STIPULATION TO EXTEND TIME for the parties to exchange final infringement contentions to through and including August 28, 2024 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 8/26/2024. (mpb)
2024-08-26
1
No Actions
NOTICE OF SERVICE of Parse Biosciences, Inc.'s and University of Washington's Final Infringement Contentions [Appendices A - C are Highly Confidential Outside Attorneys Eyes Only] filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 08/28/2024)
2024-08-28
1
NOTICE OF SERVICE of Plaintiffs Final Infringement Contentions filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc..(Metzler, Sara) (Entered: 08/28/2024)
2024-08-28
1
ORAL ORDER: With regard to the parties' motions for claim construction, (D.I. 78 ; D.I. 79 ), the Court now addresses the construction of the term "assayable polymer subunit (APS) / assayable oligonucleotide subunits," a term that was not argued at the Markman hearing. The briefing as to this term (as with that regarding some prior Markman disputes) was not as helpful as it might have been, (see D.I. 119 ; D.I. 121 ; D.I. 126 ), in that in it, as the parties themselves noted, they at times seemed to be "misaligned" or to be "side-step[ping]" the need to make clear statements about key disputes, (D.I. 101 at 41-42). Plaintiffs' proposed construction was "component(s) of a molecular complex that provide a package of information" and Defendant's was "detectable components such as polymer subunits or small molecules that can be linked to each other within a COB [(cell originating barcode)]." (Id. at 37) The Court, doing its best to identify the key issues, determines that the term needs no further construction (at least for now) and should be afforded its plain and ordinary meaning. In support, it concludes the following: (1) To the extent the parties are disagreeing about whether it is appropriate to refer to APSs as providing a "package of information"(Plaintiffs) or as "detectable" components (Defendant), (id. at 42), the Court will adopt neither of the proposals. It is not clear that there is actually a live dispute about the use of either phrase (as Defendant says only that the "package" phraseology is not "clear"—not that it is wrong—and Plaintiffs do not seem to dispute that ABSs must be "detectable"). (Id. at 41-42) And so the Court is not yet convinced that construing the term to include one or both phrases is necessary or would resolve a dispute about claim scope.; (2) To the extent that the parties disagree over Defendant's addition of "such as polymer subunits or small molecules," (id. at 42), the Court also declines to include that phraseology in a construction. It is undisputed that this proposal is simply meant to provide non-limiting examples as to what an APS can be, (id. at 38 (citing 442 patent, col. 4:23-24); id. at 42), and the Court sees no need to unduly highlight certain exemplary APSs at the expense of others in a way that might confuse or mislead the jury, see 511 Innovations, Inc. v. HTC Am., Inc., Case No. 2:15-cv-1524-JRG-RSP, 2016 WL 6403156, at *13 (E.D. Tex. Oct. 26, 2016); Unither Pharma, Inc. v. Daily Wellness Co., Nos. C 02-05284 JW, 2005 WL 6220096, at *20 (N.D. Cal. Nov. 30, 2005).; and (3) To the extent the parties are disagreeing over whether APSs must be linked to each other within a COB, (D.I. 101 at 42), the Court is not convinced that they must be, based on the record before it. And so it will not adopt Defendant's proposed "can be linked to each other within a COB" language. Despite Plaintiffs raising the issue, (id. at 38-39), Defendant never explained how this proposed language (with its use of the words "can be") would mandate APS linkage (which seems to be Defendant's intent). But even if Defendant's proposal could be read to have that impact, the Court cannot conclude that such a limitation would be appropriate. Plaintiffs argue to the contrary that "APSs need not be linked to each other[,]" (id. at 39; see also id. at 41-42), and in support, they note that the patent seems to repeatedly describe this type of linkage as a possibility but not a requirement. (442 patent, col. 4:61-63 ("In some embodiments, the APSs in a first set is linkable to the APSs in a second set.") (emphasis added) (cited in D.I. 101 at 39); 442 patent at FIG. 2; id., col. 13:34-36 (noting that Figure 2, which shows APSs linked together in a COB, is simply "one embodiment") (emphasis added) (cited in D.I. 101 at 42)) Ordered by Judge Christopher J. Burke on 9/4/2024. (smg) (Entered: 09/04/2024)
2024-09-04
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s and University of Washington's Supplemental Final Infringement Contentions filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 09/04/2024)
2024-09-04
1
Oral Order
2024-09-04
1
No Actions
ORAL ORDER: With regard to the parties' motions for claim construction ("motions"), (D.I. 78 ; D.I. 79 ), the Court now addresses the construction of term 5 (i.e., the fifth term that was to be argued at the Markman hearing, though because the parties ran out of time, it ended up being submitted on the papers), which is the last term that the Court must address in order to fully resolve the motions: "A method of cell-specifically labeling RNA molecules within a plurality of cells." This term is found in Defendant's 065, 856 and 355 patents. (D.I. 101 at 52) As an initial matter, the Court notes that it will not consider arguments made for the first time in reply or sur-reply briefs (particularly Defendant's argument about the claims' preambles not being limiting). (Id. at 61) With that said, the Court now addresses the parties' two main disputes: (1) their dispute about how the labels at issue are generated or created, wherein Plaintiffs propose that the labels must be the product of "multiple rounds" of appending "well-specific tags," and Defendant disagrees that this is a requirement; and (2) their dispute about whether the claimed tagging methods take place only "within intact cells" (Plaintiffs' proposal) or simply "within a plurality of cells" (Defendant's proposal)—with there being no dispute that an "intact" cell is one that has not been lysed, (see id. at 62-64; D.I. 102, ex. 24 at 83-84). Plaintiffs argue that both of their proposals should be adopted, in light of the doctrine of prosecution disclaimer. See Comput. Docking Station Corp. v. Dell, Inc., 519 F.3d 1366, 1374-75 (Fed. Cir. 2008) ("The doctrine of prosecution disclaimer protects the public's reliance on definitive statements made during prosecution by precluding patentees from recapturing through claim interpretation specific meanings clearly and unmistakably disclaimed during prosecution.") (internal quotation marks, citations and brackets omitted); see also (D.I. 101 at 55-61). The Court agrees. That is because during prosecution of the 065 patent, in an effort to overcome rejection of the claims, the patentee clearly and repeatedly stated that the cell-specific labels described in the patent's claims were "the product of multiple rounds of appending well-specific tags to cDNAs within each cell[,]" (D.I. 77, ex. 13F at PARSE0000964 (emphasis added); see also id. at PARSE0000965, PARSE0000968, PARSE0000970), and emphasized that such tagging occurs with regard to "intact cells" or "unlysed cells[,]" (see id. at PARSE0000968, PARSE0000970 (certain emphasis added, certain emphasis in original); see also id. at PARSE0000964). Cf. Hockerson-Halberstadt, Inc. v. Avia Grp. Int'l, Inc., 222 F.3d 951, 957 (Fed. Cir. 2000). Indeed, as if to hammer home the point, the patentee noted that these were some of the "key features of the claimed methods[.]" (D.I. 77, ex. 13F at PARSE0000964) Despite Defendant's argument to the contrary, (D.I. 101 at 63), the Court sees no reason why any other aspect of the patent claims' language would directly contradict or conflict with Plaintiffs' proposed construction. And there is no question here that if disclaimer was made as to the claims of the 065 patent (as it was), then it should also apply as to the use of the same term in the 856 and 355 patents. (Id. at 61 (citing Ormco Corp. v. Align Tech., Inc., 498 F.3d 1307, 1314 (Fed. Cir. 2007)) For all of these reasons, the Court will construe this term to mean "A method of generating labels that identify the cell of origin of RNA molecules, where the cell-specific labels are the product of multiple rounds of appending well-specific tags to cDNAs within intact cells." Ordered by Judge Christopher J. Burke on 9/5/2024. (smg) (Entered: 09/05/2024)
2024-09-05
1
Oral Order AND ~Util - Terminate Motions
2024-09-05
1
No Actions
Joint Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding a request to schedule a discovery teleconference. (Pascale, Karen) (Entered: 09/09/2024)
2024-09-09
1
MOTION for Hearing re 242 Letter /Teleconference to Resolve Discovery Dispute - filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/09/2024)
2024-09-09
1
Add Attorneys - PHV only
2024-09-09
1
No Actions
Pro Hac Vice Attorney Kate Saxton for Roche Sequencing Solutions, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (cdd)
2024-09-09
1
No Actions
ORAL ORDER: The Court, having reviewed the parties' September 9, 2024 letter regarding Defendant's one discovery dispute, (D.I. 242 ), hereby ORDERS as follows: (1) By September 17, 2024, Defendant shall file with the Court a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues.; (2) By September 23, 2024, Plaintiffs may file a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining that party's reasons for its opposition.; (3) By September 27, 2024, Defendant shall file with the Court a reply letter brief, not to exceed one (1) single-spaced page, in no less than 12-point font.; (4) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; and (5) The Court will plan to resolve the disputes on the papers, unless: (a) it determines after reviewing the briefing that oral argument is needed; or (b) any party advises the Court in advance that, were argument to be set, a newer attorney will argue the dispute(s), see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf. If either of those circumstances occurs, then the Court will schedule oral argument on the dispute(s) in the future. Ordered by Judge Christopher J. Burke on 9/11/2024. (smg) (Entered: 09/11/2024)
2024-09-11
1
Oral Order
2024-09-11
1
No Actions
NOTICE OF SERVICE of Scale Biosciences, Inc.'s Final Invalidity Contentions filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 09/13/2024)
2024-09-13
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Final Invalidity Contentions filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 09/13/2024)
2024-09-13
1
[SEALED] Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding Opening Letter Brief Regarding Discovery Dispute - re 244 Oral Order,,,,,,. (Attachments: # 1 Exhibit A through K)(Pascale, Karen) (Entered: 09/17/2024)
2024-09-17
1
[SEALED] Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Opposition to Defendant's Discovery Dispute Letter - re 247 Letter. (Attachments: # 1 Exhibit L, # 2 Exhibit M, # 3 Exhibit N)(Farnan, Kelly) (Entered: 09/23/2024)
2024-09-23
1
STIPULATION TO EXTEND TIME to file redacted version of Parse's Opening Letter Brief Regarding Discovery Dispute to September 25, 2024 - filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/24/2024)
2024-09-24
1
SO ORDERED, D.I. 249 STIPULATION TO EXTEND TIME to file redacted version of Parse's Opening Letter Brief Regarding Discovery Dispute to September 25, 2024 filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 9/24/2024. (smg)
2024-09-24
1
No Actions
REDACTED VERSION of 247 Letter //Opening Letter Brief by Parse Biosciences, Inc.. (Attachments: # 1 Table of Contents, # 2 Exhibit A through K)(Pascale, Karen) (Entered: 09/25/2024)
2024-09-25
1
Deficiency re Courtesy Copies (CJB cases)
2024-09-25
1
No Actions
SO ORDERED
2024-09-25
1
No Actions
NOTICE: Per Magistrate Judge Burke's Standing Order Regarding Courtesy Copies, which requires two (2) courtesy copies of all briefs (including letter briefs), as well as any documents filed in support of such briefs (i.e., appendices, exhibits, declarations, affidavits, tutorials, etc.) and one (1) copy of any other document filed (e.g., letters and stipulations), please submit to the Clerk's Office a copy of D.I. # 247 . (smg)
2024-09-25
1
No Actions
STIPULATION Regarding Discovery Dispute re 242 Letter, 248 Letter, 247 Letter, 244 Oral Order,,,,,, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/27/2024)
2024-09-27
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Third Supplemental Objections and Responses to Scale Biosciences, Inc.'s Second Set of Interrogatories (Nos. 12-18) [with Exhibit A] filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 09/27/2024)
2024-09-27
1
SO ORDERED, D.I. 251 Stipulation Regarding Discovery Dispute re 242 Letter, 248 Letter, 247 Letter, 244 Oral Order filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 9/27/2024. (smg)
2024-09-27
1
No Actions
SO ORDERED
2024-09-27
1
No Actions
REDACTED VERSION of 248 Letter by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit L, # 2 Exhibit M, # 3 Exhibit N)(Farnan, Kelly) (Entered: 09/30/2024)
2024-09-30
1
NOTICE OF SERVICE of 1) Opening Expert Report of DeForest McDuff, Ph.D.; 2) Opening Expert Report of Lior Pachter, Ph.D.; 3) Opening Expert Report of Rahul Satija, Ph.D.; and 4) Opening Expert Report of Sylvia D. Hall-Ellis, Ph.D. filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 10/11/2024)
2024-10-11
1
NOTICE OF SERVICE of (1) Opening Expert Report of Drew D. Mooney Regarding Damages Arising from Parse's Infringement of the Asserted ScaleBio Claims; (2) Opening Expert Report of Maria Fe Paz de Paz Regarding the Single Cell Analysis Market; (3) Opening Expert Report of Alex K. Shalek, Ph.D. Regarding Invalidity of the Challenged Parse Claims; (4) Opening Expert Report of Peter A. Sims, Ph.D. Regarding Parse's Infringement of the Asserted ScaleBio Claims; and (5) Opening Expert Report of Peter A. Sims, Ph.D. Regarding Invalidity of the Challenged Parse Claims filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 10/11/2024)
2024-10-11
1
STIPULATION OF PARTIAL DISMISSAL by Parse Biosciences, Inc., Scale Biosciences, Inc.. (Pascale, Karen) (Entered: 10/22/2024)
2024-10-22
1
SO ORDERED, D.I. 256 Stipulation of Partial Dismissal filed by Parse Biosciences, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 10/22/2024. (smg)
2024-10-22
1
No Actions
SO ORDERED
2024-10-23
1
No Actions
STIPULATION and [Proposed] Order Extending Time to exchange rebuttal expert reports through and including November 12, 2024 by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 11/07/2024)
2024-11-07
1
SO ORDERED AND ~Util - Set Deadlines
2024-11-08
1
No Actions
SO ORDERED, D.I. 257 Stipulation filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 11/8/2024. (smg)
2024-11-08
1
No Actions
NOTICE OF SERVICE of 1) Rebuttal Expert Report of DeForest McDuff, Ph.D. (with Exhibit Sections A-C); 2) Rebuttal Expert Report of Lior Pachter, Ph.D. on Non-Infringement (with Appendix A); and 3) Rebuttal Expert Report of Rahul Satija, Ph.D. on Validity of U.S. Patent Nos. 10,900,065, 11,168,355, 11,427,856 (with Appendix A) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 11/13/2024)
2024-11-13
1
NOTICE OF SERVICE of (1) Rebuttal Expert Report of Drew D. Mooney Regarding Damages Arising from ScaleBio's Infringement of the Asserted Parse Claims; (2) Rebuttal Expert Report of Alex K. Shalek, Ph.D. Regarding Non-infringement of the Asserted Parse Claims; and (3) Rebuttal Expert Report of Peter A. Sims, Ph.D. Regarding Validity of the Asserted ScaleBio Claims filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 11/13/2024)
2024-11-13
1
STIPULATION and [Proposed] Order to Modify Case Schedule by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 11/27/2024)
2024-11-27
1
STIPULATION TO EXTEND TIME to Serve Reply Expert Reports to December 13, 2024 - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 12/06/2024)
2024-12-06
1
SO ORDERED, D.I. 261 STIPULATION TO EXTEND TIME to Serve Reply Expert Reports to December 13, 2024 filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 12/6/2024. (smg)
2024-12-06
1
No Actions
SO ORDERED AND ~Util - Set Deadlines/Hearings
2024-12-06
1
No Actions
ORAL ORDER: The Court, having reviewed the parties’ proposed stipulation, (D.I. 260 ), hereby ORDERS that it is REJECTED. The Court will alter and extend the deadlines for completion of expert discovery and the filing of summary judgment and Daubert motions, as the parties request. But doing so will unduly reduce the time the Court has to review and resolve those motions prior to the pretrial conference, and so the remaining dates in the schedule will need to be pushed back as well. Therefore the currently-operative dates in the Scheduling Order, including the dates for the pretrial conference and trial, are VACATED. By no later than December 12, 2024, the parties shall provide the Court with a joint letter that sets out all of the two-week periods that they are jointly available for trial from June 2025 through March 2026. The Court will then pick a new pretrial conference date and new dates for trial—and thereafter the parties can fill in other dates that work for them for the remainder of the operative schedule leading up to the pretrial conference (leaving at least four months between the date of filing case dispositive and Daubert motions and the date of the pretrial conference). Ordered by Judge Christopher J. Burke on 12/9/2024. (smg) (Entered: 12/09/2024)
2024-12-09
1
1 - Terminate Deadlines and Hearings AND Oral Order AND ~Util - Set Deadlines
2024-12-09
1
No Actions
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding the December 9, 2024 oral order - re 262 Oral Order. (Farnan, Kelly) Modified on 12/16/2024 (smg). (Entered: 12/12/2024)
2024-12-12
1
NOTICE of Appearance by James S. Green, Jr on behalf of Jay Shendure, Bruce Colston Trapnell, Jr. (Green, James) (Entered: 12/16/2024)
2024-12-16
1
NOTICE OF SERVICE of 1) Reply Expert Report of DeForest McDuff, Ph.D.; 2) Reply Expert Report of Lior Pachter, Ph.D. on Invalidity; and 3) Reply Expert Report of Rahul Satija, Ph.D. on Infringement filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 12/17/2024)
2024-12-17
1
NOTICE OF SERVICE of (1) Reply Expert Report of Drew D. Mooney Regarding Damages Arising from Parse's Infringement of the Asserted ScaleBio Claims; (2) Reply Expert Report of Alex K. Shalek, Ph.D. Regarding Invalidity of the Challenged Parse Claims; (3) Reply Expert Report of Maria Fe Paz de Paz Regarding the Single Cell Analysis Market (4) Reply Expert Report of Peter A. Sims, Ph.D. Regarding Parse's Infringement of the Asserted ScaleBio Claims; and (5) Reply Expert Report of Peter A. Sims, Ph.D. Regarding Invalidity of the Challenged Parse Claims filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 12/17/2024)
2024-12-17
1
CORRECTING ENTRY: D.I. 264 NOTICE of Appearance Removed from docket due to erroneous filing. (cdd)
2024-12-17
1
No Actions
- CORRECTING ENTRY
2024-12-17
1
No Actions
ORAL ORDER: The Court, having reviewed the parties’ December 12, 2024 joint letter, (D.I. 263 ), hereby ORDERS as follows: (1) The Court will set new trial-related dates as follows: (a) a proposed Pretrial Order is due by October 3, 2025.; (b) a Pretrial Conference is set for October 10, 2025 at 2:00 PM in Courtroom 2A before Judge Christopher J. Burke.; (c) A 10-day Jury Trial is set to begin on October 20, 2025 at 9:30 AM in Courtroom 2A before Judge Christopher J. Burke.; and (d) Though the Court is holding 10 days for trial, it will allocate a certain number of hours for the parties’ trial presentations at a later date (which may amount to less than 10 trial days in total), and will discuss with the parties whether the trial will involve all patents at issue in the case. (See D.I. 172); and (2) By no later than December 31, 2024, the parties shall submit to the Court a proposed Scheduling Order for the remainder of the case, which is consistent with Judge Burke’s "Rule 16 Scheduling Order – Patent.” Judge Burke’s Scheduling Order can be found on Judge Burke's portion of the District Court's website. Case dispositive and Daubert motion deadlines included in the proposed Scheduling Order shall be calculated so that briefing is completed appropriately four (4) months prior to the Pretrial Conference. If the parties have disputes regarding portions of the proposed Scheduling Order, they may note them in the Order and briefly address their respective positions in an accompanying cover letter which shall be no longer than two (2) single-spaced pages. Ordered by Judge Christopher J. Burke on 12/18/2024. (smg) (Entered: 12/18/2024)
2024-12-18
1
Pro Hac Vice Attorney Arden E. Bonzo for Scale Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (scs)
2024-12-18
1
No Actions
Oral Order
2024-12-18
1
No Actions
Add Attorneys - PHV only
2024-12-18
1
No Actions
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding case schedule - re 266 Oral Order,,,,,,. (Attachments: # 1 Exhibit B, # 2 Exhibit C)(Farnan, Kelly) (Entered: 12/31/2024)
2024-12-31
1
ORAL ORDER: The Court, having reviewed Defendant's December 31, 2024 joint letter regarding the Scheduling Order, (D.I. 267 ), hereby ORDERS that a status teleconference is set for January 8, 2025 at 10:00 a.m. before Judge Christopher J. Burke. During the teleconference, the Court will address the parties' disputes and provide guidance. By no later than January 6, 2025 the parties shall provide the Court's Courtroom Deputy, Ms. Grimes, with the names and e-mail addresses of all individuals who will participate in the teleconference and a dial-in number for the call via e-mail. Ordered by Judge Christopher J. Burke on 01/03/2025. (smg) (Entered: 01/03/2025)
2025-01-03
1
Order Setting Teleconference
2025-01-03
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Scheduling Teleconference held on January 8, 2025 to discuss the parties' joint proposed schedule. The transcript will serve as the Court's Order. For the reasons stated during the teleconference, by no later than January 10, 2025, the parties shall submit a joint proposed Scheduling Order in accordance with the guidance provided by the Court. The Court will enter a Scheduling Order based upon the parties' submission. (Clerk: E. Rose; Court reporter: Deanna Warner) Appearances: K. Farnan, S. Metzler, S. Rabinowitz, C. Loughran, S. Duncan Smith, E. Frank, A. Bonzo, and K. Saxton for Plaintiffs; K. Pascale, T. Powers, C. Vira, and B. Pickard for Defendants. (smg)
2025-01-08
1
No Actions
Telephone Conference
2025-01-08
1
No Actions
Official Transcript of Scheduling Conference held on 1/8/25 before Judge Christopher Burke. Court Reporter Deanna Warner, Email: deanna_warner@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/30/2025. Redacted Transcript Deadline set for 2/10/2025. Release of Transcript Restriction set for 4/9/2025. (Warner, Deanna) (Entered: 01/09/2025)
2025-01-09
1
PROPOSED ORDER Second Amended Scheduling Order by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Metzler, Sara) (Entered: 01/10/2025)
2025-01-10
1
NOTICE to Take Deposition of Alex K. Shalek, Ph.D. on January 17, 2025, beginning at 9:00 am (ET) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 01/13/2025)
2025-01-13
1
NOTICE to Take Deposition of Drew D. Mooney, CPA, ABV, CFF on February 5, 2025, beginning at 9:00 am (ET) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 01/13/2025)
2025-01-13
1
NOTICE to Take Deposition of Maria Fe Paz De Paz, M.D., Ph.D., MBA on January 29, 2025, beginning at 9:00 am (ET) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 01/13/2025)
2025-01-13
1
NOTICE to Take Deposition of Peter A. Sims, Ph.D. on January 24, 2025, beginning at 9:00 am (ET) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 01/13/2025)
2025-01-13
1
SO ORDERED, D.I. 270 Proposed Second Amended Scheduling Order. ( Discovery due by 2/10/2025. Expert Discovery due by 2/10/2025. Dispositive Motions due by 2/24/2025. Proposed Pretrial Order due by 10/3/2025. A Motion Hearing is set for 5/7/2025 at 11:00 AM in Courtroom 2A before Judge Christopher J. Burke. A Pretrial Conference is set for 10/10/2025 at 02:00 PM in Courtroom 2A before Judge Christopher J. Burke. A 10-day Jury Trial is set for 10/20/2025 at 09:30 AM/09:00 AM in Courtroom 2A before Judge Christopher J. Burke. ) Signed by Judge Christopher J. Burke on 1/13/2025. (smg)
2025-01-13
1
No Actions
~Util - Set Deadlines/Hearings
2025-01-13
1
No Actions
NOTICE to Take Deposition of DeForest McDuff, Ph.D on January 28, 2025 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 01/14/2025)
2025-01-14
1
NOTICE to Take Deposition of Lior Pachter, Ph.D on February 10, 2025 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 01/14/2025)
2025-01-14
1
NOTICE to Take Deposition of Rahul Satija, Ph.D on January 22, 2025 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 01/14/2025)
2025-01-14
1
STIPULATION Regarding the Nucleic Acid Sequences Used in the Parties' Products by Scale Biosciences, Inc. (Metzler, Sara) Modified on 1/31/2025 (smg). (Entered: 01/30/2025)
2025-01-30
1
SO ORDERED, D.I. 278 Stipulation Regarding the Nucleic Acid Sequences Used in the Parties' Products filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 01/30/2025. (smg)
2025-01-30
1
No Actions
SO ORDERED
2025-01-31
1
No Actions
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding disputed terms. (Farnan, Kelly) (Entered: 02/03/2025)
2025-02-03
1
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan, Esq. regarding Request the Scheduling of a Discovery Teleconference. (Farnan, Kelly) (Entered: 02/04/2025)
2025-02-04
1
ORAL ORDER: The Court, having reviewed the parties’ February 4, 2025 letter, (D.I. 280 ), hereby ORDERS as follows: (1) By February 13, 2025, Plaintiffs shall file with the Court a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the issues in dispute and their position on those issues.; (2) By February 20, 2025, Defendant may file a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining that party's reasons for its opposition.; (3) By February 26, 2025, Plaintiffs shall file with the Court a reply letter brief, not to exceed one (1) single-spaced page, in no less than 12-point font.; (4) The moving party shall file a Motion To Resolve Discovery Dispute.; (5) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; and (6) The Court will plan to resolve the disputes on the papers, unless: (a) it determines after reviewing the briefing that oral argument is needed; or (b) any party advises the Court in advance that, were argument to be set, a newer attorney will argue the dispute(s), see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf. If either of those circumstances, occurs, then the Court will schedule oral argument on the dispute(s) in the future. Ordered by Judge Christopher J. Burke on 02/06/2025. (smg) (Entered: 02/06/2025)
2025-02-06
1
Oral Order
2025-02-06
1
No Actions
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Supplemental Objections and Responses to Scale Biosciences, Inc.'s First Set of Requests for Admission (Nos. 1-97) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 02/07/2025)
2025-02-07
1
STIPULATION Regarding Certain References Cited By The Parties by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. (Metzler, Sara) (Entered: 02/10/2025)
2025-02-10
1
Joint Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding a request to schedule a discovery teleconference. (Pascale, Karen) (Entered: 02/10/2025)
2025-02-10
1
MOTION for Hearing re 284 Letter /Teleconference to Resolve Discovery Dispute - filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/10/2025)
2025-02-10
1
SO ORDERED
2025-02-10
1
No Actions
SO ORDERED, D.I. 283 Stipulation Regarding Certain References Cited By The Parties filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 02/10/2025. (smg)
2025-02-10
1
No Actions
ORAL ORDER: The Court, having reviewed the parties’ February 10, 2025 letter regarding Defendant’s discovery dispute, (D.I. 284 ), and Defendant’s motion for teleconference to resolve a discovery dispute, (D.I. 285 ), hereby ORDERS as follows: (1) By February 18, 2025, Defendant shall file with the Court a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues.; (2) By February 24, 2025, Plaintiff Roche Sequencing Solutions, Inc. shall file a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the reasons for its opposition.; (3) By February 27, 2025, Defendant shall file with the Court a reply letter brief, not to exceed one (1) single-spaced page, in no less than 12-point font.; (4) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; and (5) The Court will plan to resolve the disputes on the papers, unless: (a) it determines after reviewing the briefing that oral argument is needed; or (b) any party advises the Court in advance that, were argument to be set, a newer attorney will argue the dispute(s), see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf. If either of those circumstances, occurs, then the Court will schedule oral argument on the dispute(s) in the future. Ordered by Judge Christopher J. Burke on 02/11/2025. (smg) (Entered: 02/11/2025)
2025-02-11
1
Oral Order
2025-02-11
1
No Actions
STIPULATION Regarding Non-Infringement of Certain ScaleBio Products and Technologies by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 02/13/2025)
2025-02-13
1
[SEALED] Letter to The Honorable Christopher J. Burke from Sara M. Metzler regarding Parse BioSciences, Inc.'s Answers to Scale Biosciences, Inc.'s Requests for Admission - re 281 Oral Order. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G - Proposed Order)(Metzler, Sara) Modified on 2/14/2025 (smg). (Entered: 02/13/2025)
2025-02-13
1
NOTICE OF SERVICE of Counterclaim-Plaintiffs' Election of Asserted Claims Per Case Narrowing Step Two filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 02/18/2025)
2025-02-18
1
[SEALED] Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding Opening Letter Brief Regarding Roche Discovery Dispute - re 284 Letter. (Attachments: # 1 Exhibit A through M, # 2 Exhibit N - Proposed Order)(Pascale, Karen) (Entered: 02/18/2025)
2025-02-18
1
NOTICE OF SERVICE of Plaintiffs narrowing pursuant to Paragraph 2 of the Second Amended Scheduling Order (D.I. 270) filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 02/18/2025)
2025-02-18
1
ORAL ORDER: The Court, has reviewed the parties’ proposed stipulation (“stipulation”) regarding Scale Biosciences, Inc.’s non-infringement of certain patent claims as applied to certain products. (D.I. 287 ) The Court is concerned that the stipulation might run afoul of the Federal Circuit’s guidance in AlterWAN, Inc. v. Amazon.com, Inc., 63 F.4th 18, 23 (Fed. Cir. 2023), particularly as to whether the stipulation contains sufficient “factual context as to ‘how the disputed claim construction rulings relate to the accused products[,]’” id. (citation omitted). By no later than February 21, 2025, the parties shall file a joint letter of no more than two single-spaced pages, which provides their input as to whether any further changes to the proposed stipulation should be made in light of the guidance in AlterWAN. Ordered by Judge Christopher J. Burke on 02/19/2025. (smg) (Entered: 02/19/2025)
2025-02-19
1
Oral Order
2025-02-19
1
No Actions
[SEALED] Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding a response to Plaintiff's Letter regarding Parse's Objections and Responses to Scale Biosciences, Inc.'s Requests for Admission - re 288 Letter,. (Attachments: # 1 Exhibit 1 and 2)(Pascale, Karen) (Entered: 02/20/2025)
2025-02-20
1
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Response to the Court's Oral Order - re 292 Oral Order. (Attachments: # 1 Stipulation)(Farnan, Kelly) Modified on 2/26/2025 (sam). (Entered: 02/21/2025)
2025-02-21
1
[SEALED] Letter to Honorable Christopher J. Burke from Kelly E. Farnan regarding Response to DI 290. (Attachments: # 1 Exhibit O)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752 - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752 - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
2
[SEALED] STATEMENT re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752 Concise Statement of Undisputed Facts by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752 - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Attachment 1 replaced on 2/25/2025) (sam). (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752 - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Attachment 1 replaced on 2/25/2025) (sam). (Entered: 02/24/2025)
2025-02-24
2
STATEMENT re 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752 Concise Statement of Undisputed Facts by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
2
STATEMENT re 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims Concise Statement of Undisputed Facts by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
2
STATEMENT re 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims Concise Statement of Undisputed Facts by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Certain Expert Opinion of Dr. Rahul Satija - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Certain Expert Opinion of Dr. Rahul Satija - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
2
MOTION to Preclude Certain Expert Opinion of Dr. Lior Pachter - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Certain Expert Opinion of Dr. Lior Pachter - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
2
MOTION to Preclude Certain Expert Opinion of Dr. DeForest McDuff - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Certain Expert Opinion of Dr. DeForest McDuff - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
2
[SEALED] OPENING BRIEF in Support re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims, 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752, 306 MOTION to Preclude Certain Expert Opinion of Dr. DeForest McDuff, 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims, 305 MOTION to Preclude Certain Expert Opinion of Dr. Lior Pachter, 304 MOTION to Preclude Certain Expert Opinion of Dr. Rahul Satija filed by Scale Biosciences, Inc..Answering Brief/Response due date per Local Rules is 3/10/2025. (Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Emma L. Frank (VOLUME I) re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, 306 MOTION to Preclude Certain Expert Opinion of Dr. DeForest McDuff, 304 MOTION to Preclude Certain Expert Opinion of Dr. Rahul Satija, 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims, 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752, 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims, 305 MOTION to Preclude Certain Expert Opinion of Dr. Lior Pachter Volume I by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Emma L. Frank (VOLUME II) re 308 Declaration, by Scale Biosciences, Inc. (Attachments: # 1 Exhibit 16, # 2 Exhibit 17, # 3 Exhibit 18, # 4 Exhibit 19, # 5 Exhibit 20)(Metzler, Sara) Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying Soley on an Unverified Conversation and Unsupported Deposition Testimony - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying on the Roche License for Failure to Apportion - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying on the Roche License for Failure to Apportion - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
2
MOTION to Preclude Maria Fe Paz De Paz, M.D., Ph.D., MBA's Opinions Regarding Her Definition of the Market and Competition Between Parse and Scale - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION to Preclude Maria Fe Paz De Paz, M.D., Ph.D., MBA's Opinions Regarding Her Definition of the Market and Competition Between Parse and Scale - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
2
[SEALED] DECLARATION of Emma L. Frank (VOLUME III) re 309 Declaration by Scale Biosciences, Inc. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
2
[SEALED] STATEMENT re 314 MOTION for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement //Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
2
[SEALED] STATEMENT re 316 MOTION for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features //Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
2
[SEALED] DECLARATION of Emma L. Frank (VOLUME IV) re 308 Declaration, by Scale Biosciences, Inc. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) Modified on 2/25/2025 (sam). Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
[SEALED] STATEMENT re 318 MOTION for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents //Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Emma L. Frank (VOLUME V) re 308 Declaration, by Scale Biosciences, Inc. (Attachments: # 1 Exhibit 49, # 2 Exhibit 50, # 3 Exhibit 51, # 4 Exhibit 52, # 5 Exhibit 53)(Metzler, Sara) Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #4: Parse's Accused Products, When Used for Nuclei, Do Not Infringe the '442, '256, or '341 Patents - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
MOTION for Summary Judgment #4: Parse's Accused Products, When Used for Nuclei, Do Not Infringe the '442, '256, or '341 Patents - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
2
[SEALED] STATEMENT re 322 MOTION for Summary Judgment #4: Parse's Accused Products, When Used for Nuclei, Do Not Infringe the '442, '256, or '341 Patents //Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Emma L. Frank (VOLUME VI) re 308 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 54-part 1, # 2 Exhibit 54-part 2, # 3 Exhibit 55)(Metzler, Sara) Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
[SEALED] OPENING BRIEF in Support re 310 MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying Soley on an Unverified Conversation and Unsupported Deposition Testimony, 318 MOTION for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents, 311 MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying on the Roche License for Failure to Apportion, 316 MOTION for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features, 322 MOTION for Summary Judgment #4: Parse's Accused Products, When Used for Nuclei, Do Not Infringe the '442, '256, or '341 Patents, 314 MOTION for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement, 312 MOTION to Preclude Maria Fe Paz De Paz, M.D., Ph.D., MBA's Opinions Regarding Her Definition of the Market and Competition Between Parse and Scale filed by Parse Biosciences, Inc..Answering Brief/Response due date per Local Rules is 3/10/2025. (Pascale, Karen) (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Peter A. Sims, Ph.D. re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752 by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 12, # 2 Exhibit 13, # 3 Exhibit 14)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Alex K. Shalek, Ph.D. re 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims, 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 29, # 2 Exhibit 30, # 3 Exhibit 31)(Metzler, Sara) (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Brady P. Gleason (VOLUME I) re 325 Opening Brief in Support - by Parse Biosciences, Inc. (Attachments: # 1 Exhibit 1 through 17)(Pascale, Karen) Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
[SEALED] DECLARATION of Brady P. Gleason (VOLUME II) re 325 Opening Brief in Support - by Parse Biosciences, Inc. (Pascale, Karen) Modified on 2/25/2025 (sam). (Entered: 02/24/2025)
2025-02-24
1
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
1
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
2
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
2
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
2
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
2
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
2
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
2
REDACTED VERSION of 288 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 02/25/2025)
2025-02-25
2
CORRECTING ENTRY: Proposed order at D.I. 298 has been replaced per request of filing counsel to reference correct claims. (sam)
2025-02-25
1
No Actions
- CORRECTING ENTRY
2025-02-25
1
No Actions
ORAL ORDER: The Court, having reviewed the parties' newly-submitted stipulation, (D.I. 294 -1), and their explanation relating thereto, (D.I. 294 ), has today "So Ordered" the stipulation. That said, to the extent this case does not resolve by agreement of the parties, the Court may, prior to trial, again address the AlterWAN issue with the parties as it relates to this new stipulation. Ordered by Judge Christopher J. Burke on 02/26/2025. (sam) (Entered: 02/26/2025)
2025-02-26
1
[SEALED] Letter to The Honorable Christopher J. Burke from Sara M. Metzler regarding Reply Letter re Parse Biosciences Answers to Request for Admission - re 293 Letter,. (Metzler, Sara) (Entered: 02/26/2025)
2025-02-26
1
MOTION to Resolve Discovery Dispute re 280 Letter - filed by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 02/26/2025)
2025-02-26
1
REDACTED VERSION of 290 Letter, to The Honorable Christopher J. Burke from Karen L. Pascale regarding Opening Letter Brief Regarding Roche Discovery Dispute by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/26/2025)
2025-02-26
1
SO ORDERED, D.I. 294 Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Response to the Court's Oral Order. (D.I. 292) Ordered by Judge Christopher J. Burke on 02/26/2025. (sam)
2025-02-26
1
No Actions
SO ORDERED
2025-02-26
1
No Actions
Oral Order
2025-02-26
1
No Actions
[SEALED] Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding a reply in support of Parse's Opening Letter Brief regarding Roche Discovery Dispute - re 290 Letter,. (Attachments: # 1 Exhibit P)(Pascale, Karen) (Entered: 02/27/2025)
2025-02-27
1
REDACTED VERSION of 293 Letter, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/28/2025)
2025-02-28
1
STIPULATION TO EXTEND TIME for the parties to submit redacted versions of the papers filed in support of their Motions for Summary Judgment to through and including March 10, 2025 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/03/2025)
2025-03-03
1
REDACTED VERSION of 295 Letter by Roche Sequencing Solutions, Inc.. (Attachments: # 1 Exhibit O)(Metzler, Sara) (Entered: 03/03/2025)
2025-03-03
1
SO ORDERED, D.I. 337 STIPULATION TO EXTEND TIME for the parties to submit redacted versions of the papers filed in support of their Motions for Summary Judgment to through and including March 10, 2025 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 03/03/2025. (sam)
2025-03-03
1
No Actions
SO ORDERED
2025-03-03
1
No Actions
REDACTED VERSION of 332 Letter by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/05/2025)
2025-03-05
1
REDACTED VERSION of 335 Letter by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/06/2025)
2025-03-06
1
STIPULATION TO EXTEND TIME to submit redacted versions of the papers filed in support of their Motions for Summary Judgment (D.I. 297, 307, 308, 309, 313, 315, 317, 319, 320, 321, 323, 324, 325, 326, 327, 328, 329) to March 12, 2025 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/10/2025)
2025-03-10
1
SO ORDERED
2025-03-11
1
No Actions
SO ORDERED, D.I. 341 STIPULATION TO EXTEND TIME to submit redacted versions of the papers filed in support of their Motions for Summary Judgment (D.I. 297, 307, 308, 309, 313, 315, 317, 319, 320, 321, 323, 324, 325, 326, 327, 328, 329) to March 12, 2025 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 03/11/2025. (sam)
2025-03-11
1
No Actions
REDACTED VERSION of 315 Statement, Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
1
REDACTED VERSION of 317 Statement, //Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
1
REDACTED VERSION of 320 Statement, Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
1
REDACTED VERSION of 323 Statement, Concise Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
1
REDACTED VERSION of 325 Opening Brief in Support,,,,, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
1
REDACTED VERSION of 328 Declaration of Brady P. Gleason (VOLUME I) by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit 1 through 17)(Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
1
REDACTED VERSION of 328 Declaration of Brady P. Gleason (VOLUME I) by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit 1 through 17)(Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
2
REDACTED VERSION of 329 Declaration of Brady P. Gleason (VOLUME II) by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit 18, # 2 Exhibit 19 through 34)(Pascale, Karen) (Entered: 03/12/2025)
2025-03-12
1
STIPULATION TO EXTEND TIME to submit redacted versions of the papers filed in support of its Motions for Summary Judgment (D.I. 297, 307, 308, 309, 313, 319, 321, 324, 326, 327) to March 13, 2025 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/12/2025)
2025-03-12
1
REDACTED VERSION of 297 Statement by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
REDACTED VERSION of 307 Opening Brief in Support,,, by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 308 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 15)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 309 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 16, # 2 Exhibit 17, # 3 Exhibit 18, # 4 Exhibit 19, # 5 Exhibit 20)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 313 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 21, # 2 Exhibit 22, # 3 Exhibit 23, # 4 Exhibit 24, # 5 Exhibit 25, # 6 Exhibit 26, # 7 Exhibit 27, # 8 Exhibit 28, # 9 Exhibit 32, # 10 Exhibit 33, # 11 Exhibit 34, # 12 Exhibit 35)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 319 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 36, # 2 Exhibit 37, # 3 Exhibit 38, # 4 Exhibit 39, # 5 Exhibit 40, # 6 Exhibit 41, # 7 Exhibit 42, # 8 Exhibit 43, # 9 Exhibit 44, # 10 Exhibit 45, # 11 Exhibit 46, # 12 Exhibit 47, # 13 Exhibit 48)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
2
REDACTED VERSION of 326 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 12, # 2 Exhibit 13, # 3 Exhibit 14)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
REDACTED VERSION of 327 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 29, # 2 Exhibit 30)(Metzler, Sara) (Entered: 03/13/2025)
2025-03-13
1
SO ORDERED
2025-03-13
1
No Actions
SO ORDERED, D.I. 349 STIPULATION TO EXTEND TIME to submit redacted versions of the papers filed in support of its Motions for Summary Judgment (D.I. 297, 307, 308, 309, 313, 319, 321, 324, 326, 327) to March 13, 2025 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 03/13/2025. (sam)
2025-03-13
1
No Actions
PROPOSED ORDER (CORRECTED) Granting Parse Biosciences, Inc.'s discovery dispute motion re 290 Letter, to The Honorable Christopher J. Burke from Karen L. Pascale regarding Opening Letter Brief Regarding Roche Discovery Dispute - re 284 Letter by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/20/2025)
2025-03-20
1
[SEALED] ANSWERING BRIEF in Opposition re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims, 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752, 306 MOTION to Preclude Certain Expert Opinion of Dr. DeForest McDuff, 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims, 305 MOTION to Preclude Certain Expert Opinion of Dr. Lior Pachter, 304 MOTION to Preclude Certain Expert Opinion of Dr. Rahul Satija filed by Parse Biosciences, Inc..Reply Brief due date per Local Rules is 3/31/2025. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] STATEMENT re 315 Statement, of Facts re Parse's Summary Judgment #1 by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] STATEMENT re 317 Statement, Concise Statement of Facts re Parse's Summary Judgment #2 by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] DECLARATION of Brady P. Gleason re 359 Answering Brief in Opposition,,, of Scale Biosciences, Inc.'s Summary Judgment and Daubert Motions by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A through P)(Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] STATEMENT re 320 Statement, Concise Statement of Facts re Parse's Summary Judgment #3 by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] DECLARATION of Lior Pachter, Ph.D. re 359 Answering Brief in Opposition,,, to Scale Biosciences, Inc.'s Summary Judgment and Daubert Motions by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A)(Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] STATEMENT re 323 Statement, Concise Statement of Facts re Parse's Summary Judgment #4 by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] ANSWERING BRIEF in Opposition re 310 MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying Soley on an Unverified Conversation and Unsupported Deposition Testimony, 318 MOTION for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents, 311 MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying on the Roche License for Failure to Apportion, 316 MOTION for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features, 322 MOTION for Summary Judgment #4: Parse's Accused Products, When Used for Nuclei, Do Not Infringe the '442, '256, or '341 Patents, 314 MOTION for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement, 312 MOTION to Preclude Maria Fe Paz De Paz, M.D., Ph.D., MBA's Opinions Regarding Her Definition of the Market and Competition Between Parse and Scale filed by Scale Biosciences, Inc..Reply Brief due date per Local Rules is 3/31/2025. (Metzler, Sara) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] STATEMENT re 297 Statement //Response to Concise Statement of Undisputed Facts re: 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752 by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] DECLARATION of Peter A. Sims, PH.D. re 366 Answering Brief in Opposition,,,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A-B)(Metzler, Sara) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] STATEMENT re 297 Statement //Counter Statement of Undisputed Facts to Concise Statement of Undisputed Facts re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752 by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
STATEMENT re 299 Statement //Response to Concise Statement of Undisputed Facts re 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752 by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
STATEMENT re 299 Statement //Counter Statement of Undisputed Facts to Concise Statement of Undisputed Facts re 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752 by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
STATEMENT re 301 Statement //Response to Concise Statement of Undisputed Facts re 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
STATEMENT re 301 Statement //Counter Statement of Undisputed Facts to Concise Statement of Undisputed Facts re 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
STATEMENT re 303 Statement //Response to Concise Statement of Undisputed Facts re 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
STATEMENT re 303 Statement //Counter Statement of Undisputed Facts to Concise Statement of Undisputed Facts re 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/24/2025)
2025-03-24
1
[SEALED] DECLARATION of Emma L. Frank re 366 Answering Brief in Opposition,,,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 03/24/2025)
2025-03-24
1
STIPULATION TO EXTEND TIME to file redacted versions of Daubert and Summary Judgment Oppositions to April 7, 2025 - filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 03/28/2025)
2025-03-28
1
SO ORDERED, D.I. 377 STIPULATION TO EXTEND TIME to file redacted versions of Daubert and Summary Judgment Oppositions to April 7, 2025 filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 03/31/2025. (sam)
2025-03-31
1
No Actions
SO ORDERED
2025-03-31
1
No Actions
REDACTED VERSION of 360 Statement by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 361 Statement by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 363 Statement by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 365 Statement by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 366 Answering Brief in Opposition,,,,, by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 368 Declaration by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 368 Declaration by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 368 Declaration by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 376 Declaration,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F, # 5 Exhibit G, # 6 Exhibit H, # 7 Exhibit I, # 8 Exhibit J, # 9 Exhibit K, # 10 Exhibit L, # 11 Exhibit M, # 12 Exhibit N, # 13 Exhibit O, # 14 Exhibit P, # 15 Exhibit Q, # 16 Exhibit R, # 17 Exhibit S, # 18 Exhibit T, # 19 Exhibit U, # 20 Exhibit V)(Metzler, Sara) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 359 Answering Brief in Opposition,,, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 362 Declaration, of Brady P. Gleason by Parse Biosciences, Inc.. (Attachments: # 1 Redacted versions of Exhibits A - P)(Pascale, Karen) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 362 Declaration, of Brady P. Gleason by Parse Biosciences, Inc.. (Attachments: # 1 Redacted versions of Exhibits A - P)(Pascale, Karen) (Entered: 04/07/2025)
2025-04-07
2
REDACTED VERSION of 364 Declaration, of Lior Pachter, Ph.D. by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 367 Statement /Response to Statement by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 04/07/2025)
2025-04-07
1
REDACTED VERSION of 369 Statement, //Counter Statement of Undisputed Facts by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 04/07/2025)
2025-04-07
1
STIPULATION regarding Roche's Contribution to ScaleBio's Products and the Asserted Patents by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 04/15/2025)
2025-04-15
1
[SEALED] REPLY BRIEF re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims, 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752, 306 MOTION to Preclude Certain Expert Opinion of Dr. DeForest McDuff, 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims, 305 MOTION to Preclude Certain Expert Opinion of Dr. Lior Pachter, 304 MOTION to Preclude Certain Expert Opinion of Dr. Rahul Satija filed by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] STATEMENT re 369 Statement, [Response to Parse Biosciences, Inc.'s Counter-Statements to Scale Biosciences, Inc.'s Concise Statement of Undisputed Facts in Support of Its Motion for Summary Judgment of Infringement of U.S. Patent No. 11,634,752] by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] STATEMENT re 371 Statement, [Response to Parse Biosciences, Inc.'s Counter-Statements to Scale Biosciences, Inc.'s Concise Statement of Undisputed Facts in Support of Its Motion for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752] by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] STATEMENT re 373 Statement, [Response to Parse Biosciences, Inc.'s Counter-Statements to Scale Biosciences, Inc.'s Concise Statement of Undisputed Facts in Support of Its Motion for Summary Judgment for Non-Infringement of the Asserted Parse Claims] by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] REPLY BRIEF re 310 MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying Soley on an Unverified Conversation and Unsupported Deposition Testimony, 318 MOTION for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents, 311 MOTION to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying on the Roche License for Failure to Apportion, 316 MOTION for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features, 322 MOTION for Summary Judgment #4: Parse's Accused Products, When Used for Nuclei, Do Not Infringe the '442, '256, or '341 Patents, 314 MOTION for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement, 312 MOTION to Preclude Maria Fe Paz De Paz, M.D., Ph.D., MBA's Opinions Regarding Her Definition of the Market and Competition Between Parse and Scale filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] STATEMENT re 375 Statement [Response to Parse Biosciences, Inc.'s Counter-Statements to Scale Biosciences, Inc.'s Concise Statement of Undisputed Facts in Support of Its Motion for Summary Judgment Regarding Invalidity of the Challenged Parse Claims] by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] DECLARATION of Brady P. Gleason re 395 Reply Brief,,,, //in Support of Counterclaim Plaintiffs' Motions for Summary Judgment and Motions to Exclude Expert Opinions and Testimony by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit 35 through 42)(Pascale, Karen) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] DECLARATION of Emma L. Frank re 296 MOTION for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, 306 MOTION to Preclude Certain Expert Opinion of Dr. DeForest McDuff, 304 MOTION to Preclude Certain Expert Opinion of Dr. Rahul Satija, 300 MOTION for Summary Judgment of Non-Infringement of the Asserted Parse Claims, 298 MOTION for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752, 302 MOTION for Summary Judgment of Invalidity of the Challenged Parse Claims, 305 MOTION to Preclude Certain Expert Opinion of Dr. Lior Pachter by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 56, # 2 Exhibit 57, # 3 Exhibit 58, # 4 Exhibit 59)(Metzler, Sara) (Entered: 04/17/2025)
2025-04-17
1
[SEALED] DECLARATION of Lior Pachter, Ph.D. re 368 Declaration // in Response to the March 24, 2025 Second Declaration of Peter A. Sims, PH.D. Regarding the Asserted ScaleBio Claims by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit A through M)(Pascale, Karen) (Entered: 04/17/2025)
2025-04-17
1
SO ORDERED
2025-04-22
1
No Actions
SO ORDERED, D.I. 390 Stipulation regarding Roche's Contribution to ScaleBio's Products and the Asserted Patents by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 04/22/2025. (sam)
2025-04-22
1
No Actions
REDACTED VERSION of 395 Reply Brief,,,, by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 397 Declaration, of Brady P. Gleason by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit 35 through 42)(Pascale, Karen) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 397 Declaration, of Brady P. Gleason by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit 35 through 42)(Pascale, Karen) (Entered: 04/24/2025)
2025-04-24
2
REDACTED VERSION of 399 Declaration, of Lior Pachter, Ph.D. by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit A through M)(Pascale, Karen) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 399 Declaration, of Lior Pachter, Ph.D. by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Exhibit A through M)(Pascale, Karen) (Entered: 04/24/2025)
2025-04-24
2
REDACTED VERSION of 391 Reply Brief,, by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 392 Statement, by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 393 Statement, by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 394 Statement, by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 396 Statement, by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 04/24/2025)
2025-04-24
1
REDACTED VERSION of 398 Declaration,,, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 56, # 2 Exhibit 57, # 3 Exhibit 58, # 4 Exhibit 59)(Metzler, Sara) (Entered: 04/24/2025)
2025-04-24
1
ORAL ORDER: Pursuant to the Court's recent communications with the parties, the Court hereby ORDERS that the summary judgment and Daubert motion hearing, (D.I. 270 ), is rescheduled to June 12, 2025 at 11:00 a.m. Ordered by Judge Christopher J. Burke on 04/30/2025. (sam) (Entered: 04/30/2025)
2025-04-30
1
1 - Terminate Hearings AND Oral Order AND ~Util - Set Hearings
2025-04-30
1
No Actions
ORAL ORDER: The Court, having reviewed Plaintiff Scale Biosciences Inc.'s ("Plaintiff") discovery dispute motion ("Motion"), (D.I. 333 ), in which Plaintiff seeks an order compelling Defendant to "provide proper answers" to certain requests for admission ("RFA") or to have the RFAs deemed admitted, and the briefing related thereto, (D.I. 288 ; D.I. 293 ; D.I. 332 ), hereby ORDERS that the Motion is GRANTED-IN-PART and DENIED-IN-PART for the reasons and in the manner that follows: (1) One of Defendant's objections that applies to at least the Court's decision on the disputes over RFA 19 and RFAs 35-51 is that the RFAs are improperly compound, in part because they ask a question whereby, in order to properly answer the question, Defendant would have to assess multiple different accused products or versions of those products (e.g., "Admit that the following graphic illustrates, at least in part, the operation of the Parse Mini, Parse Mid Products, and Parse Mega Products" or "Admit that Parse's Evercode WT v3 product is representative of its Evercode WT Mini v3, its Evercode WT Mega v3 products, and Evercode WT Mega v3 with INTEGRA ASSIST PLUS Barcoding products"). (D.I. 288, ex. B at 33, 45; see D.I. 293 at 1-2) As to this dispute, both sides cite in support to the Court's prior decision in Integra Lifescis. Corp. v. HyperBranch Med. Tech., Inc., Civil Action No. 15-819-LPS-CJB, 2017 WL 11558094 (D. Del. Oct. 3, 2017). (D.I. 288 ; D.I. 293 ; D.I. 332 ) As the Court noted in Integra, an RFA is "required to be simple and direct, and limited to singular relevant facts." Integra, 2017 WL 11558094, at *4 (internal quotation marks and citation omitted). In Integra, the Court assessed an RFA, for example, that asked the plaintiffs to admit that "none of the applications for the Patents-in-Suit expressly disclosed the use of ‘polyethyleneimine,' ‘PEI,' or ‘Lupasol' prior to the filing of continuation-in-part Application No. 12/156,085 on May 29, 2008." Id. (certain internal quotation marks omitted). The Court concluded that this RFA was an improper compound RFA because it required "an assessment of multiple factual inquiries (e.g., Does Application X expressly disclose polyethyleneimine? Does Application X expressly disclose PEI? Does Application X expressly disclose Lupasol? Does Application Y expressly disclose polyethyleneimine?, etc.)." Id.; see also id. at *6 (concluding that another RFA that asked plaintiffs to admit "that a particular reference ‘is prior art to every asserted claim of the Patents-in-Suit'" was unduly compound, as it "requests a response as to multiple claims across multiple patents'); D. Del. LR 26.1(a). RFA 19 and RFAs 35-51 (with the exception of RFAs 41-43, 45 and 48) are similarly improper—in that each requires Defendant to engage in separate, detailed factual inquiries as to whether a statement is true (e.g., that the graphic illustrates the operation of a product, or that one product is representative of another product) as it relates to multiple accused products or product versions. See, e.g., Confluent Surgical, Inc. v. HyperBranch Med. Tech., Inc., Civil Action No. 17-688-LPS-CJB, Oral Order (D. Del. Feb. 6, 2019) (citing Integra, 2017 WL 11558094, at *4; D. Del. LR 26.1(a)) (ordering the plaintiff to separate and re-serve RFAs that were originally directed to multiple accused products, for this reason). Thus, the Court DENIES Plaintiff's request as to these RFAs.; (2) With regard to RFAs 41-43, 45 and 48, Defendant objects additionally on the grounds that: (a) Plaintiff's requests are vague and ambiguous because they use the words "representative of" (even though that term was further defined by Plaintiff) and "material"; (b) compound (in that they ask about representativeness "for purposes of any allegation reflected in [Plaintiff's] infringement allegations"); and (c) are a matter for expert testimony. (D.I. 293 at 2 (emphasis omitted)) The Court disagrees. As to the first objection, the concepts of representativeness or materiality are not foreign to patent litigators (and even if there was ambiguity, then Defendant should supply its own definition and admit, deny or qualify its admission accordingly). See Integra, 2017 WL 11558094, at *5; (D.I. 332 at 1). As to the second objection, the request is not problematic; if Defendant thinks that the one product is not representative of the other for any material reason, it can just respond "Deny." And as to the third objection, the fact that Plaintiffs may have the burden of showing representativeness or that the issue may be further explored in expert discovery is no barrier to the Plaintiff propounding an RFA on this subject and getting an answer from Defendant. (D.I. 332 at 1) Thus, the request as to these RFAs is GRANTED and Defendant should supplement its answer to these RFAs within 14 days from today's date.; (3) With regard to RFAs 26-33, Defendant's sole objection related to purported uncertainty about which product(s) were being asked about. (D.I. 293 at 1-2) But by the end of the briefing, it was made clear that the question only relates to "a single product"—"the Evercode WT v3 mid-sized products." (D.I. 332 at 1) To the extent that this is a reference to one version of one product (as Plaintiff says), then Plaintiff's request here is GRANTED and Defendant should supplement its answer to these RFAs within 14 days from today's date.; and (4) With regard to RFA 63, which asks Defendant to admit that "[Defendant] competes with [Plaintiff] on price[,]" to the Court, this RFA seems to be inquiring about price competition as to the parties' respective products. But Plaintiff asserts that the request is "not about any particular product" or the "parties' products[.]" (D.I. 288 at 2) If that is so, then the Court doesn't understand the RFA or what it is actually asking about (i.e., How could the parties compete on price other than as to their products?). And so it agrees with Defendant that the RFA is vague and ambiguous and need not be responded to on that basis. Plaintiff's request is thus DENIED as to RFA 63. Ordered by Judge Christopher J. Burke on 05/23/2025. (sam) (Entered: 05/23/2025)
2025-05-23
1
ORAL ORDER: The Court hereby ORDERS as follows with respect to the June 12, 2025 hearing on the parties' case dispositive motions/Daubert motions: (1) The Court will allocate three hours for argument, to be split equally between the sides.; (2) It has become clear to the Court that for a hearing on summary judgment and/or Daubert motions to be most fruitful, it makes best sense to require the parties to each select one motion that they will offer argument on to the Court. (Ideally, the total briefing in relation to this motion will amount to less than 30 pages.) This will all allow for a detailed and focused argument as to what the parties believe to be their most important motion, and will allow the Court to meaningfully prepare for argument in a reasonable period of time.; and (3) Accordingly, the Court hereby ORDERS that by no later than May 29, 2025, the parties shall submit a joint letter advising the Court of the motion that each side selects to be argued at the June 12, 2025 hearing (and shall also state how many pages of briefing are associated with that motion, and provide citations to that briefing). Ordered by Judge Christopher J. Burke on 05/23/2025. (sam) (Entered: 05/23/2025)
2025-05-23
1
Oral Order
2025-05-23
1
No Actions
Order on Motion for Miscellaneous Relief
2025-05-23
1
No Actions
ORAL ORDER: The Court, having reviewed Defendant's discovery dispute motion ("Motion"), (D.I. [285), in which it seeks an order compelling Plaintiff Roche Sequencing Solutions, Inc. ("Roche") to provide certain discovery regarding its document preservation, collection, and production process, (D.I. 290, ex. N), and the briefing related thereto, (D.I. 290 ; D.I. 295 ; D.I. 335 ), hereby ORDERS that the Motion is GRANTED for the reasons and in the manner that follows: (1) In seeking the requested relief, Defendant is asking for “discovery on discovery”; our Court has noted that such discovery is typically not permitted unless the movant makes a “threshold showing that significant, relevant, and non-cumulative information has been withheld or overlooked” in the case. Brit. Telecomms. PLC v. IAC/Interactivecorp, Civil Action No. 18-366-WCB, 2020 WL 1043974, at *7 (D. Del. Mar. 4, 2020) (internal quotation marks and citations omitted).; (2) Here, Defendant has made such a showing, where: (a) As of May 30, 2024, Roche had produced only 19 e-mails to Defendant in this case. (D.I. 290, ex. A at 3; id., ex. C at 1) Defendant suggested to Roche at that time that in light of this sparse e-mail production, something must be off with Roche’s document collection procedures. (Id., ex. A at 3) But Roche wrote back saying that the paucity of e-mails it had produced was explainable and was due to the specifics of its document retention policy. (Id., ex. C at 1) There is no indication in the record that Roche then did anything more to look into why it had produced only 19 e-mails at the time—including whether this might’ve been due to a problem with its document search or collection efforts.; (b) After an August 2024 deposition of a Roche Rule 30(b)(6) witness, who stated that he did not know when Roche put a litigation hold in place in this case, (id., ex. G at 174-75), Defendant asked Roche to provide that date, (id., ex. H at 19, 29, 31). Roche fought doing so for months, claiming that the date itself was privileged information. (Id., ex. H at 12, 17, 19, 28, 30) Then in December 2024, Roche disclosed that the litigation hold had not been put into place until November 2023—approximately 11 months after this case was filed. (Id., ex. H at 12) Roche acknowledges that its failure to issue a litigation hold until November 2023 was an “error[.]” (D.I. 295 at 1); (c) After Defendant sought additional information about Roche’s document preservation efforts, in February 2025, Roche told Defendant for the first time that it had made another “error[]”—i.e., it had now identified additional e-mail repositories that had never been reviewed in the case, but should have been. (D.I. 290, ex. H at 8; D.I. 295 at 1) (Thus, Roche’s prior statement about how the reason it had only produced 19 e-mails was due to the specifics of its document retention policy appears to have not been entirely correct.). As of the time of the briefing for this Motion, Roche was still in the process of producing responsive e-mails, even though fact discovery has long closed. (D.I. 295 at 2; D.I. 335, ex. P at 1); and (d) Even in light of Roche’s late production of these e-mails, there is still an open question as to whether Roche has appropriately retained (and produced) relevant documents. The answer to this question appears to turn, at least in part, on a dispute about when Roche should have reasonably anticipated litigation in this matter. Roche suggests that a reasonable party in its position would not have foreseen litigation until this case was filed in December 2022, or perhaps no earlier than June 2022, (D.I. 295 at 2); Defendant argues the proper date goes back to 2021 (and that if this is correct, that means that Roche’s late litigation hold resulted in relevant documents being needlessly deleted), (D.I. 290 at 2; D.I. 335 at 1). The Court is not resolving that “anticipation of litigation” issue now. But it notes that Defendant has produced some evidence that seems to support its position—such as Roche privilege logs that appear to disclose that employees of Roche and Plaintiff Scale Biosciences, Inc. were discussing the prospect of “this litigation” as early as November 2021. (D.I. 290, ex. L at 72, 92); (3) Everybody makes mistakes, and there is not necessarily anything nefarious about what has happened here. Maybe, in the end, Defendant will have received from Roche all of the documents it is entitled to in discovery. But there can be no dispute that Roche’s document collection efforts (and its explanations regarding the same) have been delayed, shifting and error-filled—and that there is still real question about whether Roche retained and produced all of the documents it should have in this matter. Therefore, and for the reasons set out above, the required threshold showing has been made.; and (4) In its briefing, Roche did not specifically object to any particular form of relief sought in Defendant’s proposed order, (D.I. 290, ex. N), and so the Court has no basis to determine that any item requested therein is inappropriate. Thus, Roche shall provide the requested information to Defendant no later than 21 days from today’s date. Ordered by Judge Christopher J. Burke on 05/27/2025. (sam) (Entered: 05/28/2025)
2025-05-27
1
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding June 12, 2025 Summary Judgment Hearing - re 411 Oral Order,,,,. (Farnan, Kelly) (Entered: 05/28/2025)
2025-05-28
1
Order on Motion for Hearing
2025-05-28
1
No Actions
MOTION for Exemption from Standing Order on Personal Devices - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 06/06/2025)
2025-06-06
1
NOTICE OF SERVICE of Parse Biosciences, Inc.'s Second Supplemental Objections and Responses to Scale Biosciences, Inc.'s First Set of Requests for Admission (Nos. 1 - 97) filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 06/06/2025)
2025-06-06
1
ORDER granting D.I. 414 Motion for Exemption from Standing Order on Personal Devices - filed by Scale Biosciences, Inc. Signed by Judge Christopher J. Burke on 06/09/2025. (sam) (Entered: 06/09/2025)
2025-06-09
1
MOTION for Exemption from Standing Order on Personal Devices - filed by Roche Sequencing Solutions, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) (Entered: 06/11/2025)
2025-06-11
1
ORDER granting D.I. 417 MOTION for Exemption from Standing Order on Personal Devices - filed by Roche Sequencing Solutions, Inc. Signed by Judge Christopher J. Burke on 06/11/2025. (sam) (Entered: 06/11/2025)
2025-06-11
1
Minute Entry for proceedings held before Judge Christopher J. Burke - Motion Hearing held on 6/12/25. The Court heard argument regarding Plaintiff Scale Biosciences, Inc.'s Motion for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, (D.I. 296 ), and Defendant Parse Biosciences, Inc.'s Motion for Summary Judgment #1, (D.I. 314 ). The Court took the motions under advisement. Appearances: K. Farnan, S. Metzler, S. Rabinowitz, C. Loughran, S. Duncan Smith, E. Frank and A. Bonzo for Plaintiff Scale Biosciences, Inc.; K. Farnan, S. Metzler and B. Ozdamar for Plaintiff Roche Sequencing Solutions, Inc.; K. Pascale, B. Pickard, T. Powers and B. Gleason for Defendant Parse Biosciences, Inc. (Court Reporter: Stacy Ingram; Clerk: E. Rose)(sam)
2025-06-12
1
No Actions
Oral Argument
2025-06-13
1
No Actions
Official Transcript of Summary Judgement/Daubert Motion hearing held on 06-12-25 before Judge Burke. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/7/2025. Redacted Transcript Deadline set for 7/17/2025. Release of Transcript Restriction set for 9/15/2025. (Ingram, Stacy) (Entered: 06/16/2025)
2025-06-16
1
Notice of Service
2025-06-18
1
NOTICE OF SERVICE of Roche Sequencing Solutions, Inc.s Response to the Courts May 28, 2025 Order (D.I. 412) filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 06/20/2025)
2025-06-20
1
- CORRECTING ENTRY
2025-06-20
1
No Actions
CORRECTING ENTRY: Per Counsel's request, D.I. 420 has been removed for refiling to reflect the correct party that filed it. (mpb)
2025-06-20
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Matthew D. Powers, Paul T. Ehrlich, William P. Nelson, Azra M. Hadzimehmedovic, Aaron M. Nathan, Samantha A. Jameson, Daniel Kazhdan, and Danielle C. Pfifferling - filed by Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 08/08/2025)
2025-08-08
1
Pro Hac Vice Fee - Credit Card Payment received for Matthew D. Powers, Paul T. Ehrlich, William P. Nelson, Azra M. Hadzimehmedovic, and Aaron M. Nathan. ( re 421 MOTION for Pro Hac Vice Appearance of Attorney Matthew D. Powers, Paul T. Ehrlich, William P. Nelson, Azra M. Hadzimehmedovic, Aaron M. Nathan, Samantha A. Jameson, Daniel Kazhdan, and Danielle C. Pfifferling )( Payment of $ 250, receipt number ADEDC-4755367).(Farnan, Kelly) (Entered: 08/08/2025)
2025-08-08
1
Pro Hac Vice Fee - Credit Card Payment received for Samantha A. Jameson, Daniel Kazhdan, and Danielle C. Pfifferling. ( re 421 MOTION for Pro Hac Vice Appearance of Attorney Matthew D. Powers, Paul T. Ehrlich, William P. Nelson, Azra M. Hadzimehmedovic, Aaron M. Nathan, Samantha A. Jameson, Daniel Kazhdan, and Danielle C. Pfifferling )( Payment of $ 150, receipt number ADEDC-4755369).(Farnan, Kelly) (Entered: 08/08/2025)
2025-08-08
1
-District Court Pro Hac Vice Fee - 05 Attorneys Credit Card Payment
2025-08-08
1
No Actions
-District Court Pro Hac Vice Fee - 03 Attorneys Credit Card Payment
2025-08-08
1
No Actions
NOTICE of Appearance by Frederick L. Cottrell, III on behalf of Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Cottrell, Frederick) (Entered: 08/11/2025)
2025-08-11
1
Disclosure Statement - Rule 7.1
2025-08-14
1
Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate 10X Genomics, Inc., Other Affiliate 10x Genomics Research, Inc. for Scale Biosciences, Inc. filed by Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 08/15/2025)
2025-08-15
1
MOTION for Pro Hac Vice Appearance of Attorney Daniel M. Radke, Nathaniel D. Cook, John C. Pierce, Richa Patel and Sidhi Gosain - filed by Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 08/15/2025)
2025-08-15
1
Pro Hac Vice Fee - Credit Card Payment received for Daniel M. Radke, Nathaniel D. Cook, John C. Pierce, Richa Patel, and Sidhi Gosian. ( re 426 MOTION for Pro Hac Vice Appearance of Attorney Daniel M. Radke, Nathaniel D. Cook, John C. Pierce, Richa Patel and Sidhi Gosain )( Payment of $ 250, receipt number ADEDC-4766996).(Farnan, Kelly) (Entered: 08/15/2025)
2025-08-15
1
-District Court Pro Hac Vice Fee - 05 Attorneys Credit Card Payment
2025-08-15
1
No Actions
- CORRECTING ENTRY
2025-08-15
1
No Actions
CORRECTING ENTRY: Previous 7.1 Disclosure Statement has been removed for failure to add corporate parents and other affiliates when docketing. Counsel is advised to refile and add all parties in CM/ECF as directed by docketing prompts. (sam)
2025-08-15
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney Anna G. Phillips and Paige E. Cloud - filed by Parse Biosciences, Inc., The University of Washington. (Pascale, Karen) (Entered: 08/18/2025)
2025-08-18
1
Pro Hac Vice Fee - Credit Card Payment received for Anna G. Phillips and Paige E. Cloud. ( re 428 MOTION for Pro Hac Vice Appearance of Attorney Anna G. Phillips and Paige E. Cloud )( Payment of $ 100, receipt number ADEDC-4768768).(Pascale, Karen) (Entered: 08/18/2025)
2025-08-18
1
SO ORDERED, D.I. 426 Motion for Pro Hac Vice Appearance of Attorney Daniel M. Radke, Nathaniel D. Cook, John C. Pierce, Richa Patel and Sidhi Gosain - filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 08/18/2025. (sam)
2025-08-18
1
No Actions
SO ORDERED, D.I. 421 Motion for Pro Hac Vice Appearance of Attorney Matthew D. Powers, Paul T. Ehrlich, William P. Nelson, Azra M. Hadzimehmedovic, Aaron M. Nathan, Samantha A. Jameson, Daniel Kazhdan, and Danielle C. Pfifferling - filed by Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 08/18/2025. (sam)
2025-08-18
1
No Actions
-District Court Pro Hac Vice Fee - 02 Attorneys Credit Card Payment
2025-08-18
1
No Actions
Order on Motion to Appear Pro Hac Vice
2025-08-18
1
No Actions
ORAL ORDER: IT IS HEREBY ORDERED that by no later than September 26, 2025, the parties must make a further good faith attempt, either telephonically or in person, to resolve the case via settlement. By no later than that date, the parties shall file a joint statement indicating the status of any settlement discussions. Any joint statement should not disclose the substance of any offers, counteroffers, or other negotiations. If the parties anticipate any further settlement discussions or mediation efforts will be conducted thereafter, the parties shall indicate that in their submission and state when those efforts are expected to occur. Otherwise, if the parties resolve the matter earlier than the above date, they shall promptly advise the Court. Ordered by Judge Christopher J. Burke on 08/19/2025. (sam) (Entered: 08/19/2025)
2025-08-19
1
Oral Order
2025-08-19
1
No Actions
Pro Hac Vice Attorney Nathaniel D. Cook,Paul T. Ehrlich,Sidhi Gosain,Azra M. Hadzimehmedovic,Samantha A. Jameson,Daniel Kazhdan,Aaron Nathan,William P Nelson,Richa B. Patel,Danielle C. Pfifferling,John C. Pierce,Matthew D. Powers,Daniel M. Radke for Scale Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (oam)
2025-08-20
1
No Actions
Add Attorneys - PHV only
2025-08-20
1
No Actions
NOTICE to Take Deposition of Garth Rosengren on August 26, 2025, beginning at 9:00a.m. (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 08/21/2025)
2025-08-21
1
NOTICE to Take Deposition of Roche Sequencing Solutions, Inc. pursuant to Fed. R. Civ. P. 30(b)(6) (SUPPLEMENTAL) on August 26, 2025, beginning at 9:00a.m. (PT) filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 08/21/2025)
2025-08-21
1
ORAL ORDER: The Court, having reviewed Defendant Parse Biosciences, Inc.’s Motion for Summary Judgement No. 4: Parse’s Accused Products, When Used for Nuclei, Do Not Infringe the '442, '256 or '341 Patents (“Motion”), (D.I. 322 ), and the briefing related thereto, (D.I. 325 at 34-36; D.I. 366 at 32), hereby ORDERS that the Motion is DENIED as MOOT in light of Plaintiff Scale Biosciences, Inc.’s (“Scale”) representation that it “no longer asserts that using such products with extracted nuclei without cells infringes the [a]sserted [m]ethod [c]laims[,]” (D.I. 366 at 32), and the fact that Defendant did not respond to or otherwise contest Scale’s assertion, (D.I. 395 ). Ordered by Judge Christopher J. Burke on 08/25/2025. (sam) (Entered: 08/25/2025)
2025-08-25
1
NOTICE OF SERVICE of Roche Sequencing Solutions, Inc.'s Objections and Responses to Counterclaim Plaintiffs' Notice of Supplemental Deposition of Roche Sequencing Solutions, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Roche Sequencing Solutions, Inc..(Metzler, Sara) (Entered: 08/25/2025)
2025-08-25
1
SO ORDERED, D.I. 428 Motion for Pro Hac Vice Appearance of Attorney Anna G. Phillips and Paige E. Cloud - filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 08/25/2025. (sam)
2025-08-25
1
No Actions
Order on Motion for Summary Judgment
2025-08-25
1
No Actions
Order on Motion to Appear Pro Hac Vice
2025-08-25
1
No Actions
Add Attorneys - PHV only
2025-09-04
1
No Actions
Pro Hac Vice Attorney Anna G. Phillips & Paige E. Cloud for Parse Biosciences, Inc. & The University of Washington added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (slk)
2025-09-04
1
No Actions
NOTICE OF SERVICE of Counterclaim-Plaintiffs' Election of Asserted Claims Per Case Narrowing Step Three filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 09/05/2025)
2025-09-05
1
ORAL ORDER: The Court hereby ORDERS that by no later than COB on September 16, 2025, the parties shall file a joint letter of no more than (2) two single-spaced pages that lists the currently asserted claims in the case (i.e., the claims still asserted after the September 5, 2025 case narrowing deadline). (D.I. 419 at 160-61; D.I. 435 ) The letter should also advise the Court if the parties’ reduction of the number of asserted claims as of September 5 had any impact on the pending summary judgment and Daubert motions that the Court is working to resolve. Ordered by Judge Christopher J. Burke on 09/15/2025. (sam) (Entered: 09/15/2025)
2025-09-15
1
NOTICE OF SERVICE of Supplemental Expert Report of DeForest McDuff, Ph.D. filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 09/15/2025)
2025-09-15
1
NOTICE OF SERVICE of the Supplemental Expert Report of Drew D. Mooney Regarding Damages (with Supplemental Exhibits 1 and 3 through 8 and Supplemental Rebuttal Exhibit 5) filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 09/15/2025)
2025-09-15
1
Oral Order
2025-09-15
1
No Actions
Joint Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Response to Court's Oral Order - re 436 Oral Order,,. (Farnan, Kelly) (Entered: 09/16/2025)
2025-09-16
1
NOTICE OF SERVICE of Counterclaim-Plaintiffs' Identification of Prior Art Pursuant to 35 U.S.C. § 282 filed by Parse Biosciences, Inc., The University of Washington.(Pascale, Karen) (Entered: 09/19/2025)
2025-09-19
1
NOTICE OF SERVICE of Counterclaim Defendant's Statement Pursuant to 35 U.S.C. Section 282 filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 09/19/2025)
2025-09-19
1
NOTICE of Appearance by Anne Shea Gaza on behalf of Parse Biosciences, Inc., The University of Washington (Gaza, Anne) (Entered: 09/22/2025)
2025-09-22
1
NOTICE of Appearance by Samantha G. Wilson on behalf of Parse Biosciences, Inc., The University of Washington (Wilson, Samantha) (Entered: 09/22/2025)
2025-09-22
1
CORRECTING ENTRY: Main Document at D.I. 442 has been replaced to reflect a corrected signature. (cdd)
2025-09-22
1
No Actions
- CORRECTING ENTRY
2025-09-22
1
No Actions
Joint STATUS REPORT Regarding Settlement Discussions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 09/26/2025)
2025-09-26
1
NOTICE OF SERVICE of Subpoena to Appear and Testify at Trial to Georg Seelig, Ph.D. filed by Scale Biosciences, Inc..(Farnan, Kelly) (Entered: 09/30/2025)
2025-09-30
1
MOTION to Strike Portions of Mr. Mooney's Supplemental Expert Report and Theory of Section 271(F) Infringement - (EXPEDITED CONSIDERATION REQUESTED) - filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 10/01/2025)
2025-10-01
1
[SEALED] Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding in Support of Parse's Motion - re 446 MOTION to Strike Portions of Mr. Mooney's Supplemental Expert Report and Theory of Section 271(F) Infringement - (EXPEDITED CONSIDERATION REQUESTED). (Attachments: # 1 Exhibit A - Text of Proposed Order, # 2 Exhibit B through H)(Pascale, Karen) (Entered: 10/01/2025)
2025-10-01
1
[SEALED] MOTION for Sanctions Under Fed. R. Civ. P. 37(e) - (EXPEDITIED CONSIDERATION REQUESTED) - filed by Parse Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 7.1.1 Certification, # 3 Certificate of Service, # 4 Exhibit A through Y, # 5 Text of Proposed Order)(Pascale, Karen) (Entered: 10/02/2025)
2025-10-02
1
STIPULATION regarding expedited briefing re 448 MOTION for Sanctions Under Fed. R. Civ. P. 37(e) - (EXPEDITIED CONSIDERATION REQUESTED) by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 10/03/2025)
2025-10-03
1
[SEALED] Proposed Pretrial Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 10/03/2025)
2025-10-03
1
[SEALED] EXHIBIT re 450 Proposed Pretrial Order Volume I (Exhibits 1-9) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 10/03/2025)
2025-10-03
1
[SEALED] EXHIBIT re 450 Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Attachment 1 replaced on 10/6/2025) (mpb). (Entered: 10/03/2025)
2025-10-03
1
[SEALED] EXHIBIT re 450 Proposed Pretrial Order Volume III (Exhibits 16-18) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 16, # 2 Exhibit 17, # 3 Exhibit 18)(Farnan, Kelly) (Attachment 2 replaced on 10/6/2025) (mpb). (Entered: 10/03/2025)
2025-10-03
1
NOTICE of Scale Biosciences, Inc's Supplemental Authority by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Attachments: # 1 Exhibit A)(Farnan, Kelly) (Entered: 10/03/2025)
2025-10-03
1
STATEMENT re 454 Notice (Other) Parse's Response to Plaintiffs' Notice of Subsequent Authority by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 10/05/2025)
2025-10-05
1
NOTICE of Appearance by Danielle I. Bell on behalf of Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Bell, Danielle) (Entered: 10/06/2025)
2025-10-06
1
ORAL ORDER: The Court hereby ORDERS as follows: (1) Friday's pre-trial conference will now begin at 11:00 a.m. in Courtroom 2A.; and (2) Counsel shall be prepared to argue at the pre-trial conference any pending motion (or any portion of any pending motion), including summary judgment or Daubert motions, that has not been resolved as of the time of the pre-trial conference. This will exclude the portion of Parse Biosciences, Inc.'s Motion for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement, (D.I. 314), that relates to the '752 patent, and Scale Biosciences, Inc.'s Motion for Summary Judgment of Infringement of the '752 patent, (D.I. 296), as those motions/portions thereof were previously argued, and the Court expects to resolve them this week. Ordered by Judge Christopher J. Burke on 10/6/2025. (mlc) (Entered: 10/06/2025)
2025-10-06
1
Proposed Voir Dire by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 10/06/2025)
2025-10-06
1
VERDICT SHEET by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. . (Farnan, Kelly) (Entered: 10/06/2025)
2025-10-06
1
STIPULATION TO EXTEND TIME the deadline for the parties' proposed preliminary and final jury instructions is extended from 2:00 PM on October 6, 2025 (D.I. 270) to 9:00 p.m. on October 6, 2025 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 10/06/2025)
2025-10-06
1
Proposed Jury Instructions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Joint Proposed Preliminary Jury Instructions. (Metzler, Sara) (Entered: 10/06/2025)
2025-10-06
1
Proposed Jury Instructions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Joint Proposed Final Jury Instructions. (Metzler, Sara) (Entered: 10/06/2025)
2025-10-06
1
SO ORDERED
2025-10-06
1
No Actions
SO ORDERED D.I. 449 Stipulation regarding expedited briefing re 448 MOTION for Sanctions Under Fed. R. Civ. P. 37(e) filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 10/6/2025. (mlc)
2025-10-06
1
No Actions
CORRECTING ENTRY: Per counsel's request, Attachment 1 to D.I. 452 and Attachment 2 to D.I. 453 have been replaced to reflect that the full exhibits have been filed. (mpb)
2025-10-06
1
No Actions
SO ORDERED D.I. 460 STIPULATION TO EXTEND TIME the deadline for the parties' proposed preliminary and final jury instructions is extended from 2:00 PM on October 6, 2025 (D.I. 270) to 9:00 p.m. on October 6, 2025 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 10/6/2025. (mlc)
2025-10-06
1
No Actions
- CORRECTING ENTRY
2025-10-06
1
No Actions
Oral Order
2025-10-06
1
No Actions
ORAL ORDER: The Court, having reviewed Scale’s motions to exclude certain expert opinions of Dr. Rahul Satija and Dr. Lior Pachter (“the experts”) on any issue that is analyzed through the lens of a person of ordinary skill in the art (“POSITA”) (“Motions”), (D.I. 304 ; D.I. 305 ), the briefing related thereto, (D.I. 307 at 49-50; D.I. 359 at 48-50; D.I. 391 at 25), and having considered the relevant legal standards relating to these Daubert Motions, see 360Heros, Inc. v. GoPro, Inc., 569 F. Supp. 3d 198, 201-02 (D. Del. 2021); Pers. Audio, LLC v. Google LLC, Civil Action No. 17-1751-CFC-CJB, 2021 WL 5038740, at *1-2 (D. Del. Oct. 25, 2021), hereby ORDERS that the Motions are DENIED for the reasons that follow: (1) “To offer expert testimony from the perspective of a [POSITA] in a patent case—like for claim construction, validity, or infringement—a witness must at least have ordinary skill in the art. Without that skill, the witness’ opinions are neither relevant nor reliable.” Kyocera Senco Indus. Tools Inc. v. Int'l Trade Comm’n, 22 F.4th 1369, 1376-77 (Fed. Cir. 2022). Scale asserts that although the experts agree that a POSITA would typically have an advanced degree in “molecular biology, genetics, biochemistry, biophysics, chemistry, or a related discipline” (along with possessing other relevant experience helpful to a case like this, which is about single-cell sequencing), the experts don’t have a degree in any of these disciplines, as Dr. Pachter’s advanced degree is in Mathematics, and Dr. Satija’s advanced degree is in Statistics. (D.I. 307 at 49 (citations omitted)); (2) The Court agrees with Parse that the experts have an advanced degree in a “related discipline” to molecular biology—and that they also have substantial work experience in the field of molecular biology. (D.I. 359 at 49); (3) As to Dr. Satija, his doctoral thesis was on statistical analysis of DNA sequencing data, and in obtaining his degree, he worked in a building called the Oxford Center for Gene Function, did “extensive work in genetics” and “utilized extensive cutting-edge techniques in molecular biology[;]” he is currently a core faculty member at the New York Genome Center and a tenured professor at the Center for Genomics and Systems Biology at New York University, his primary area of research is in the development of genomic technologies (such as those involving DNA sequencing, cell barcoding, and computational analysis related thereto), he has personally generated cDNA, he has used and developed “many experimental techniques related to next-generation sequencing analysis” and he has supervised others who have generated cDNA using reverse transcription from fixed cells. (D.I. 313, ex. 22 at ¶¶ 7, 10-11; D.I. 362, ex. I at 32, 43-44, 49-52); (4) As for Dr. Pachter, his doctoral thesis in part concerned methods for analysis of genome sequences, and he did graduate work with a molecular biologist who ran the human genome project; he also has work experience with splicing genes and in collaborating on and overseeing experiments relating to molecular biology (including those relating to fixing cells and barcoding nucleic acids in cells), and he has experience in developing experimental technologies for genomics (including with methods relating to cell barcoding). (D.I. 308, ex. 9 at ¶¶ 4-5; D.I. 362, ex. L at 22, 24-28, 239); and (5) In short, it is certainly true that the experts’ advanced degrees and their relevant experience relate to the computational side of genomics and to analyzing data generated from single-cell sequencing. But in light of the record, it is also accurate to say that their degrees are in a “related discipline” to molecular biology, and that the experts have plenty of first-hand experience in that field and with cell sequencing/barcoding more generally. They are qualified by “knowledge, skill, [and] experience” to give testimony from the perspective of a POSITA in this case. Fed. R. Evid. 702; cf. In re Paoli R.R. Yard PCB Litig., 916 F.2d 829, 855-56 (3d Cir. 1990). Scale’s Motions seemed to nitpick in a manner that loses the forest for the trees; if anything, the filing of the Motions only educated the Court about how well-credentialed the experts appear to be. Ordered by Judge Christopher J. Burke on 10/07/2025. (sam) (Entered: 10/07/2025)
2025-10-07
1
Order on Motion to Preclude AND Order on Motion to Preclude
2025-10-07
1
No Actions
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) (Entered: 10/08/2025)
2025-10-08
1
ORDER Granting D.I. 464 MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Scale Biosciences, Inc. Signed by Judge Christopher J. Burke on 10/08/2025. (sam) (Entered: 10/08/2025)
2025-10-08
1
MEMORANDUM OPINION. Signed by Judge Christopher J. Burke on 10/08/2025. (sam) (Entered: 10/08/2025)
2025-10-08
1
ORDER: For the reasons stated in the Memorandum Opinion issued this same date, (D.I. 466 ), IT IS HEREBY ORDERED that Defendant Parse Biosciences, Inc.'s "Motion for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement[,]" (D.I. 314 ), filed pursuant to Federal Rule of Civil Procedure 56, is GRANTED as it related to the '752 patent. Signed by Judge Christopher J. Burke on 10/08/2025. (sam) (Entered: 10/08/2025)
2025-10-08
1
ORAL ORDER: The Court hereby ORDERS that, in light of its Memorandum Opinion and Order issued today, (D.I. 466 ; D.I. 467 ), the following Motions are DENIED as MOOT: (1) Scale's Motion for Summary Judgment of Infringement of U.S. Patent No. 11,634,752, (D.I. 296 ); (2) Scale's Motion for Summary Judgment Regarding Validity of U.S. Patent No. 11,634,752, (D.I. 298 ); (3) Parse's Motion to Strike Portions of Mr. Mooney's Supplemental Expert Report and Theory of § 271(f) Infringement, (D.I. 446 ); and (4) Any portion of any other pending motion to the extent it relates to the 752 patent, (see e.g., D.I. 316 ; D.I. 318 ). Ordered by Judge Christopher J. Burke on 10/08/2025. (sam) (Entered: 10/08/2025)
2025-10-08
1
Order on Motion for Summary Judgment AND Order on Motion to Strike
2025-10-08
1
No Actions
STIPULATION TO EXTEND TIME regarding public versions of sealed pretrial and trial filings (see Stipulation for details) to November 21, 2025 - filed by Parse Biosciences, Inc., The University of Washington. (Wilson, Samantha) (Entered: 10/09/2025)
2025-10-09
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Roche Sequencing Solutions, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) Modified on 10/9/2025 (sam). (Entered: 10/09/2025)
2025-10-09
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Roche Sequencing Solutions, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) Modified on 10/9/2025 (sam). (Entered: 10/09/2025)
2025-10-09
2
ORDER Granting D.I. 470 Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Roche Sequencing Solutions, Inc. Signed by Judge Christopher J. Burke on 10/09/2025. (sam) (Entered: 10/09/2025)
2025-10-09
1
ORAL ORDER: With regard to the portion of Scale Biosciences, Inc.’s (“Scale”) Motion for Summary Judgment of Invalidity of the Challenged Parse Claims, (D.I. 302 ), that turns on the assertion that claim 25 of the 065 patent is invalid for lack of written description because the 433 Application (the “Application”) from which it issued does not disclose reverse transcription primers that comprise a barcode sequence (the “primers at issue”), (D.I. 307 at 38-40), it is DENIED. The issue here comes down to a dispute between the parties’ experts about whether, inter alia, particular portions of the Application like paragraph 43 and Figures 1 and 8 would disclose the primers at issue to a POSITA. (D.I. 313, ex. 23 at ¶ 97; D.I. 327, ex. 29 at ¶ 107; id., ex. 31 at ¶¶ 39-41; see also D.I. 359 at 41-42) It is true that Parse’s expert Dr. Satija’s analysis on this point could have been a bit more fulsome, (see D.I. 391 at 19-20), but in light of the content of relevant portions of the Application (and their references to how a barcode might relate to the primer at issue), Parse has done enough to create an issue of disputed fact on this point. See Evonik Degussa GmbH v. Materia Inc., Civil Action Nos. 09-cv-636 (NLH/JS), 10-cv-200, 2016 WL 337378, at *6 (D. Del. Jan. 26, 2016). Ordered by Judge Christopher J. Burke on 10/09/2025. (sam) (Entered: 10/09/2025)
2025-10-09
1
MOTION for Reargument of Memorandum Opinion, (D.I. 466 ), Under Local Rule 7.1.5 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Cottrell, Frederick) Modified on 10/9/2025 (sam). (Entered: 10/09/2025)
2025-10-09
1
MOTION for Reargument of Memorandum Opinion, (D.I. 466 ), Under Local Rule 7.1.5 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Cottrell, Frederick) Modified on 10/9/2025 (sam). (Entered: 10/09/2025)
2025-10-09
2
[SEALED] RESPONSE to Motion re 448 MOTION for Sanctions Under Fed. R. Civ. P. 37(e) - (EXPEDITIED CONSIDERATION REQUESTED) Plaintiffs' Opposition to Parse's Motion for Trial Sanctions Under Fed. R. Civ. P. 37(e)(1) filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 Exhibit Z, # 3 Exhibit AA, # 4 Exhibit BB, # 5 Exhibit CC)(Farnan, Kelly) (Entered: 10/09/2025)
2025-10-09
1
SO ORDERED, D.I. 469 STIPULATION TO EXTEND TIME regarding public versions of sealed pretrial and trial filings (see Stipulation for details) to November 21, 2025 filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 10/09/2025. (sam)
2025-10-09
1
No Actions
Oral Order
2025-10-09
1
No Actions
SO ORDERED
2025-10-09
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Pretrial Conference held on 10/10/2025. During the time allotted for the pretrial conference, the Court heard oral argument on Scale Biosciences, Inc.'s Motion for Summary Judgment of Non-Infringement of the Asserted Parse Claims. (D.I. 300 ) (Court Reporter: Stacy Ingram; Clerk: W. Roberts) Appearances: F. Cottrell, K. Farnan, S. Metzler, C. Noyes, M. Powers, P. Ehrlich, A. Hadzimehmedovic, and W. Nelson for Plaintiffs; S. Rabinowitz, K. Pascale, A. Gaza, S. Wilson, B. Pickard, R. Powers, C. Vira, A. Phillips, and B. Gleason for Defendants. (sam)
2025-10-10
1
No Actions
ORAL ORDER: For the reasons discussed with the parties at last Friday’s hearing, the trial previously scheduled to begin on October 20, 2025 is CANCELLED. The Court hereby ORDERS that it will hear oral argument on certain pending motions in Courtroom 2A on the schedule that follows: (1) October 20, 2025 from 9:30 am to 5:00 pm; (2) October 21, 2025 from 9:30 am to 5:00 pm; and (3) October 22, 2025 from 9:30 am to 2:00 pm (if necessary). On these dates, argument will be held on the following motions (in the order set out below): (1) The remaining portion of Scale’s Motion for Summary Judgment of Invalidity of the Challenged Parse Claims, (D.I. 302 ); (2) The remaining portion of Parse’s Motion for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement, (D.I. 314 ); (3) Parse’s Motion for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features, (D.I. 316 ); (4) Parse’s Motion for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents, (D.I. 318 ); (5) Parse’s Motion for Trial Sanctions Under Fed. R. Civ. P. 37(e), (D.I. 448 ); and (6) Scale’s Motion for Reargument of Memorandum Opinion, (D.I. 466 ), Under Local Rule 7.1.5, (D.I. 473 ). The parties are advised that, with regard to these upcoming arguments: (1) To the extent counsel argues that a particular point is found in or amplified by a portion of the record, such as material found in an expert’s declaration or report, they will be expected to cite to the Court the particular paragraphs and lines of the declaration or report that they are referring to (as opposed to simply saying “That is also found [somewhere] in Dr. ____’s declaration/report.”).; (2) If a party is making an argument that is not fairly captured by the relevant prior briefing, that argument will be deemed waived or forfeited. Counsel should be prepared to advise the Court where in the prior briefing it raised the points it is making during argument, if the Court requests this.; and (3) Counsel should expect that if an argument they are making was not clearly raised in the prior briefing, supplemental briefing on that point will not be permitted. Ordered by Judge Christopher J. Burke on 10/14/2025. (sam) (Entered: 10/14/2025)
2025-10-14
1
Letter to the Honorable Christopher J. Burke from Karen L. Pascale regarding Parse/UW's Submission on Prosecution History Disclaimer. (Attachments: # 1 Exhibit 1)(Pascale, Karen) (Entered: 10/14/2025)
2025-10-14
1
Letter to the Honorable Christopher J. Burke from Karen L. Pascale regarding Parse/UW's Submission on Prosecution History Disclaimer. (Attachments: # 1 Exhibit 1)(Pascale, Karen) (Entered: 10/14/2025)
2025-10-14
2
1 - Terminate Deadlines AND 1 - Terminate Hearings AND Oral Order AND ~Util - Set Hearings
2025-10-14
1
No Actions
Pretrial Conference
2025-10-14
1
No Actions
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan, Esq. regarding Daubert motions - re 475 Oral Order. (Farnan, Kelly) Modified on 10/16/2025 (sam). (Entered: 10/15/2025)
2025-10-15
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) (Entered: 10/16/2025)
2025-10-16
1
MOTION for Exemption of Persons from the District of Delawares May 17, 2024 Standing Order on Personal Devices for Courtroom Technology and Setup for Trial - filed by Roche Sequencing Solutions, Inc.. (Attachments: # 1 Text of Proposed Order)(Farnan, Kelly) (Entered: 10/16/2025)
2025-10-16
1
ORDER Granting D.I. 478 MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Scale Biosciences, Inc. Signed by Judge Christopher J. Burke on 10/16/2025. (sam) (Entered: 10/16/2025)
2025-10-16
1
ORDER Granting D.I. 479 MOTION for Exemption of Persons from the District of Delawares May 17, 2024 Standing Order on Personal Devices - filed by Roche Sequencing Solutions, Inc. Signed by Judge Christopher J. Burke on 10/16/2025. (sam) (Entered: 10/16/2025)
2025-10-16
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 10/16/2025)
2025-10-16
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Parse Biosciences, Inc., The University of Washington. (Attachments: # 1 Text of Proposed Order)(Pascale, Karen) (Entered: 10/16/2025)
2025-10-16
2
ANSWERING BRIEF in Opposition re 473 MOTION for Reargument Under Local Rule 7.1.5 filed by Parse Biosciences, Inc. Reply Brief due date per Local Rules is 10/23/2025. (Pascale, Karen) Modified on 10/17/2025 (sam). (Entered: 10/16/2025)
2025-10-16
1
ORAL ORDER: The Court, having reviewed the parties’ October 15, 2025 joint letter, (D.I. 477 ), hereby ORDERS that it does not now expect to need oral argument on the pending Daubert motions identified by the parties, (D.I. 306 ; D.I. 310 ; D.I. 311 ; D.I. 312 ), and will plan to resolve these motions on the papers. As such, the parties should not expect to argue these motions next week during the time allotted for oral argument on all other pending motions identified in the Court’s prior order. (D.I. 475 ) Ordered by Judge Christopher J. Burke on 10/17/2025. (sam) (Entered: 10/17/2025)
2025-10-17
1
[SEALED] MEMORANDUM ORDER: D.I. 311 Motion to Preclude Drew D. Mooney, CPA, ABV, CFF's Opinions Relying on the Roche License for Failure to Apportion - filed by Parse Biosciences, Inc. is DENIED. (See Order for further details.) Any such redacted version shall be submitted no later than October 24, 2025 for review by the Court. Signed by Judge Christopher J. Burke on 10/17/2025. This order has been emailed to local counsel. (sam) (Entered: 10/17/2025)
2025-10-17
1
ORDER Granting D.I. 482 MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Parse Biosciences, Inc., The University of Washington. Signed by Judge Christopher J. Burke on 10/17/2025. (sam) (Entered: 10/17/2025)
2025-10-17
1
ORAL ORDER: The Court, having reviewed Parse’s Motion to Exclude Drew D. Mooney, CPA, ABV, CFF’s Opinions Relying Solely on an Unverified Conversation and Unsupported Deposition Testimony (“Motion”), (D.I. 310 ), and the briefing related thereto, (D.I. 325 at 42-45; D.I. 366 at 43-45; D.I. 395 at 22-24), and having considered the relevant legal standards relating to these Daubert Motions, see 360Heros, Inc. v. GoPro, Inc., 569 F. Supp. 3d 198, 201-02 (D. Del. 2021); Pers. Audio, LLC v. Google LLC, Civil Action No. 17-1751-CFC-CJB, 2021 WL 5038740, at *1-2 (D. Del. Oct. 25, 2021), hereby ORDERS that the Motion is DENIED for the reasons that follow: (1) As the Court has already noted, it is aware of no rule that says that an expert may never consider and utilize information that the expert receives via a conversation with another person, such as an employee of a client (especially when that employee is expected to testify at trial). And the caselaw on the issue is in accord with that conclusion. (See, e.g., D.I. 485 at 3-4) An expert may, inter alia, base his opinions on “facts or data in the case that the expert has been made aware of or personally observed.” Fed. R. Evid. 703. Information gleaned from an employee of Scale (in this case, Scale’s CEO, Ms. Prout) can qualify in that regard, even if there were no further corroboration for that information.; and (2) To the extent Parse is concerned that a key portion of Mr. Mooney’s testimony will rest solely on conversations with Ms. Prout as to certain subject matter—and yet when Parse sought to inquire further about that subject matter with Ms. Prout during her deposition, she claimed privilege and would not answer—this could potentially be a problem for Scale. (D.I. 395 at 23) That is because, typically, a party may not use the privilege as a sword rather than as a shield—and thereby divulge whatever information is favorable to its position, while also asserting privilege to preclude disclosure of detrimental facts. See, e.g., Princeton Digital Image Corp. v. Off. Depot Inc., C.A. No. 13-239-LPS, 2017 WL 3264068, at *2 (D. Del. Aug. 1, 2017). But it would be premature to grant the Motion on this ground now; instead, the Court will need to see how things play out at trial (i.e., as to what testimony Mr. Mooney and/or Ms. Prout actually offer in this regard, and how any sword/shield argument might apply to that testimony). Ordered by Judge Christopher J. Burke on 10/17/2025. (sam) (Entered: 10/17/2025)
2025-10-17
1
CORRECTING ENTRY: D.I. 483 has been modified to reflect the appropriate filer, Parse Bioscience, Inc., per the request of filing counsel. (sam)
2025-10-17
1
No Actions
Order on Motion to Preclude
2025-10-17
1
No Actions
- CORRECTING ENTRY
2025-10-17
1
No Actions
Oral Order
2025-10-17
1
No Actions
Letter to Honorable Christopher J. Burke from Kelly Farnan regarding cases ScaleBio/Roche may reference at argument - re 475 Oral Order. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Farnan, Kelly) Modified on 10/20/2025 (sam). (Entered: 10/19/2025)
2025-10-19
1
[SEALED] AMENDED Exhibit K to D.I. 448 Motion for Trial Sanctions Under Fed. R. Civ. P. 37(e) by Parse Biosciences, Inc. (Pascale, Karen) Modified on 10/20/2025 (sam). (Entered: 10/19/2025)
2025-10-19
1
Letter to the Honorable Christopher J. Burke from Karen L. Pascale regarding Corrected Version of Exhibit K to Parse's Motion for Trial Sanctions Under Fed. R. Civ. P. 37(e) - re 489 Amended Document, 448 MOTION for Sanctions Under Fed. R. Civ. P. 37(e) - (EXPEDITIED CONSIDERATION REQUESTED). (Pascale, Karen) (Entered: 10/19/2025)
2025-10-19
1
Minute Entry for proceedings held before Judge Christopher J. Burke - Oral argument held on October 20, 2025. The Court heard oral argument on Scale Biosciences, Inc.'s Motion for Summary Judgment of Invalidity of the Challenged Parse Claims. (D.I. 302 ) (Court Reporter: Bonnie Archer; Clerk: W. Roberts) Appearances: F. Cottrell, M. Powers, P. Ehrlich, A. Hadzimehmedovic, W. Nelson, C. Noyes, and S. Rabinowitz for Plaintiffs; K. Pascale, A. Gaza, S. Wilson, B. Pickard, R. Powers, C. Vira, and A. Phillips for Defendants. (sam)
2025-10-20
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Oral argument held on October 21, 2025. The Court heard oral argument on the remainder of Parse Biosciences, Inc.'s Motion for Summary Judgment No. 1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement. (D.I. 316 ) (Court Reporter: Bonnie Archer; Clerk: W. Roberts) Appearances: F. Cottrell, M. Powers, P. Ehrlich, A. Hadzimehmedovic, W. Nelson, C. Noyes, and S. Rabinowitz for Plaintiffs; K. Pascale, A. Gaza, S. Wilson, B. Pickard, R. Powers, C. Vira, and A. Phillips for Defendants. (sam)
2025-10-21
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Oral argument held on October 22, 2025. The Court heard oral argument on Parse Biosciences, Inc.'s Motion for Summary Judgment No. 2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features. (D.I. 316 ) (Court Reporter: Bonnie Archer; Clerk: W. Roberts) Appearances: F. Cottrell, M. Powers, P. Ehrlich, A. Hadzimehmedovic, W. Nelson, C. Noyes, and S. Rabinowitz for Plaintiffs; K. Pascale, A. Gaza, S. Wilson, B. Pickard, R. Powers, C. Vira, and A. Phillips for Defendants. (sam)
2025-10-22
1
No Actions
Oral Argument
2025-10-22
1
No Actions
NOTICE of of Lodging Demonstratives by Scale Biosciences, Inc. re Oral Argument,, Oral Argument,, Pretrial Conference,, Oral Argument,, (Attachments: # 1 Tab 1, # 2 Tab 2, # 3 Tab 3, # 4 Tab 4)(Farnan, Kelly) (Entered: 10/23/2025)
2025-10-23
1
NOTICE of of Lodging Demonstratives by Scale Biosciences, Inc. re Oral Argument,, Oral Argument,, Pretrial Conference,, Oral Argument,, (Attachments: # 1 Tab 1, # 2 Tab 2, # 3 Tab 3, # 4 Tab 4)(Farnan, Kelly) (Entered: 10/23/2025)
2025-10-23
2
NOTICE of of Lodging Demonstratives by Scale Biosciences, Inc. re Oral Argument,, Oral Argument,, Pretrial Conference,, Oral Argument,, (Attachments: # 1 Tab 1, # 2 Tab 2, # 3 Tab 3, # 4 Tab 4)(Farnan, Kelly) (Entered: 10/23/2025)
2025-10-23
2
NOTICE of of Lodging Demonstratives by Scale Biosciences, Inc. re Oral Argument,, Oral Argument,, Pretrial Conference,, Oral Argument,, (Attachments: # 1 Tab 1, # 2 Tab 2, # 3 Tab 3, # 4 Tab 4)(Farnan, Kelly) (Entered: 10/23/2025)
2025-10-23
2
NOTICE of of Lodging Demonstratives by Scale Biosciences, Inc. re Oral Argument,, Oral Argument,, Pretrial Conference,, Oral Argument,, (Attachments: # 1 Tab 1, # 2 Tab 2, # 3 Tab 3, # 4 Tab 4)(Farnan, Kelly) (Entered: 10/23/2025)
2025-10-23
2
ORAL ORDER: The Court, having now heard extensive oral argument on four of the pending summary judgment motions in this case, hereby advises the parties as follows, in order to assist them in planning ahead: (1) The Court’s current inclination is to GRANT Scale’s Motion for Summary Judgment of Non-Infringement of the Asserted Parse Claims, (D.I. 300 ), to GRANT the remaining unresolved portion of Scale’s Motion for Summary Judgment of Invalidity of the Challenged Parse Claims, (D.I. 302 ), and to DENY the remaining unresolved portion of Parse’s Motion for Summary Judgment #1: The Asserted Claims of the '442, '752, and '256 Patents are Invalid for Lack of Written Description and Enablement (i.e., as it relates to the asserted claims of the '442 and '256 patents), (D.I. 314 ). The Court is UNCERTAIN as to how it will resolve Parse’s Motion for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features, (D.I. 316 ), though it notes that it considered that motion, as briefed, to potentially have merit.; and (2) As discussed during the recent oral arguments, the Court will work to issue opinions regarding these motions in due course. It is of course possible that in finalizing its work on these opinions, the Court’s ultimate decision could turn out to be different from the inclinations expressed above. Ordered by Judge Christopher J. Burke on 10/23/2025. (sam) (Entered: 10/23/2025)
2025-10-23
1
Oral Order
2025-10-23
1
No Actions
NOTICE of Lodging of Demonstratives from Pretrial Conference and October 20, 2025 through October 22, 2025 Oral Argument by Parse Biosciences, Inc., The University of Washington (Attachments: # 1 Tabs 1 through 4)(Gaza, Anne) (Entered: 10/24/2025)
2025-10-24
1
NOTICE of Lodging of Demonstratives from Pretrial Conference and October 20, 2025 through October 22, 2025 Oral Argument by Parse Biosciences, Inc., The University of Washington (Attachments: # 1 Tabs 1 through 4)(Gaza, Anne) (Entered: 10/24/2025)
2025-10-24
2
[SEALED] Unopposed MOTION to Seal Limited Portions of D.I. 485 Memorandum Order - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A, # 3 Exhibit B)(Farnan, Kelly) (Entered: 10/24/2025)
2025-10-24
1
DECLARATION of Azra M. Hadzimehmedovic re 494 Unopposed MOTION to Seal Limited Portions of D.I. 485 Memorandum Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 10/24/2025)
2025-10-24
1
Official Transcript of Oral Argument Day 1 held on 10/20/2025 before Judge Christopher J. Burke. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 11/19/2025. Redacted Transcript Deadline set for 12/1/2025. Release of Transcript Restriction set for 1/27/2026. (sam) (Entered: 10/29/2025)
2025-10-29
1
Official Transcript of Oral Argument Day 2 held on 10/21/2025 before Judge Christopher J. Burke. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 11/19/2025. Redacted Transcript Deadline set for 12/1/2025. Release of Transcript Restriction set for 1/27/2026. (sam) (Entered: 10/29/2025)
2025-10-29
1
Official Transcript of Pretrial Conference held on 10-10-2025 before Judge Burke. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/20/2025. Redacted Transcript Deadline set for 12/1/2025. Release of Transcript Restriction set for 1/28/2026. (Ingram, Stacy) (Entered: 10/30/2025)
2025-10-30
1
MEMORANDUM OPINION. Signed by Judge Christopher J. Burke on 11/04/2025. (sam) (Entered: 11/04/2025)
2025-11-04
1
ORDER: For the reasons stated in the Memorandum Opinion issued this same date, (D.I. 499 ), IT IS HEREBY ORDERED that the motion for summary judgment of non-infringement of U.S. Patent Nos. 10,900,065, 11,168,355, and 11,427,856 filed by Plaintiff Scale Biosciences, Inc. pursuant to Federal Rule of Civil Procedure 56, (D.I. 300 ), is GRANTED. Signed by Judge Christopher J. Burke on 11/04/2025. (sam) (Entered: 11/04/2025)
2025-11-04
1
REDACTED VERSION of 474 Response to Motion, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 Exhibit Z, # 3 Exhibit AA, # 4 Exhibit BB, # 5 Exhibit CC)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
1
REDACTED VERSION of 474 Response to Motion, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 Exhibit Z, # 3 Exhibit AA, # 4 Exhibit BB, # 5 Exhibit CC)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 474 Response to Motion, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 Exhibit Z, # 3 Exhibit AA, # 4 Exhibit BB, # 5 Exhibit CC)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 474 Response to Motion, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 Exhibit Z, # 3 Exhibit AA, # 4 Exhibit BB, # 5 Exhibit CC)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 474 Response to Motion, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 Exhibit Z, # 3 Exhibit AA, # 4 Exhibit BB, # 5 Exhibit CC)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 474 Response to Motion, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Table of Exhibits, # 2 Exhibit Z, # 3 Exhibit AA, # 4 Exhibit BB, # 5 Exhibit CC)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 447 Letter, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 11/21/2025)
2025-11-21
1
REDACTED VERSION of 448 MOTION for Sanctions Under Fed. R. Civ. P. 37(e) - (EXPEDITIED CONSIDERATION REQUESTED) by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 11/21/2025)
2025-11-21
1
REDACTED VERSION of 450 Proposed Pretrial Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
1
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
1
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 451 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 452 Exhibit to a Document, Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
1
REDACTED VERSION of 452 Exhibit to a Document, Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 452 Exhibit to a Document, Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 452 Exhibit to a Document, Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 452 Exhibit to a Document, Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 452 Exhibit to a Document, Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 452 Exhibit to a Document, Proposed Pretrial Order Volume II (Exhibits 10-15) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 10, # 2 Exhibit 11, # 3 Exhibit 12, # 4 Exhibit 13, # 5 Exhibit 14, # 6 Exhibit 15)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 453 Exhibit to a Document, Proposed Pretrial Order Volume III (Exhibits 16-18) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 16, # 2 Exhibit 17, # 3 Exhibit 18)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
1
REDACTED VERSION of 453 Exhibit to a Document, Proposed Pretrial Order Volume III (Exhibits 16-18) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 16, # 2 Exhibit 17, # 3 Exhibit 18)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 453 Exhibit to a Document, Proposed Pretrial Order Volume III (Exhibits 16-18) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 16, # 2 Exhibit 17, # 3 Exhibit 18)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
REDACTED VERSION of 453 Exhibit to a Document, Proposed Pretrial Order Volume III (Exhibits 16-18) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 16, # 2 Exhibit 17, # 3 Exhibit 18)(Farnan, Kelly) (Entered: 11/21/2025)
2025-11-21
2
Official Transcript of Oral Argument Day 3 held on 10/22/2025 before Judge Christopher J. Burke. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 12/26/2025. Redacted Transcript Deadline set for 1/5/2026. Release of Transcript Restriction set for 3/3/2026. (sam) (Entered: 12/03/2025)
2025-12-03
1
MEMORANDUM ORDER: The remaining portion of Parse Biosciences, Inc.'s Motion for Summary Judgment #1 is DENIED. (See Memorandum Order for further details.) Signed by Judge Christopher J. Burke on 12/10/2025. (sam) (Entered: 12/10/2025)
2025-12-10
1
Supplemental Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent QIAGEN North American Holdings, Inc., Other Affiliate QIAGEN N.V., Other Affiliate QIAGEN Luxembourg SARL for Parse Biosciences, Inc. filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 12/18/2025)
2025-12-18
1
NOTICE requesting Clerk to remove Emma L. Frank as co-counsel. Reason for request: Left Firm. (Farnan, Kelly) (Entered: 01/05/2026)
2026-01-05
1
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding request for discovery teleconference. (Farnan, Kelly) (Entered: 01/13/2026)
2026-01-13
1
MOTION for Teleconference to Resolve Discovery Dispute - filed by Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 01/13/2026)
2026-01-13
1
ORAL ORDER: The Court, having reviewed the parties' January 13, 2026 letter regarding Plaintiffs' discovery dispute, (D.I. 512), hereby ORDERS as follows: (1) By January 22, 2026, Plaintiffs shall file with the Court a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the issues in dispute and their position on those issues.; (2) By January 29, 2026, Defendants may file a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, outlining the reasons for their opposition.; (3) By February 5, 2026, Plaintiffs shall file with the Court a reply letter brief, not to exceed one (1) single-spaced page, in no less than 12-point font.; (4) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; and (5) The Court will plan to resolve the disputes on the papers, unless it determines after reviewing the briefing that oral argument is needed. Ordered by Judge Christopher J. Burke on 1/15/2026. (mlc) (Entered: 01/15/2026)
2026-01-15
1
Oral Order
2026-01-15
1
No Actions
[SEALED] Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Discovery Dispute - re 514 Oral Order,,,,. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/22/2026)
2026-01-22
1
ORAL ORDER: The Court, having reviewed Parse’s motion to exclude the opinions of Scale’s expert Maria Fe Paz de Paz, M.D., Ph.D., MBA (“Dr. Paz”) regarding her definition of the relevant market and competition between Parse and Scale (“Motion”), (D.I. 312 ), and the briefing related thereto, (D.I. 325 at 45-50; D.I. 366 at 45-50; D.I. 395 at 24-25), and having considered the relevant legal standards relating to Daubert motions, see, e.g., (D.I. 487 ), hereby ORDERS that the Motion is DENIED for the reasons that follow: (1) Regarding Parse’s assertion that Dr. Paz does not have sufficient experience to provide an expert opinion on the relevant market and the extent to which Scale and Parse compete—i.e., because she does not have sufficient exposure to or an understanding of the RNA single-cell analysis market, (D.I. 325 at 47)—the Court disagrees. Dr. Paz has over 20 years of experience in the healthcare and biotechnology fields, including experience with “provid[ing] advice regarding business development and the identification of business opportunities in anticipation of market evolution, strategic planning, competitive intelligence, market access advice, partnership and collaboration opportunities, and technology assessment for due diligence.” (D.I. 328, ex. 9 at ¶¶ 5-6; see also id. at ¶¶ 4, 7-12 (Dr. Paz’s opening report, noting that her relevant experience also includes founding an investment fund focused on companies in the healthcare, diagnostics, and precision medicine fields, as well as testifying in federal court regarding market and regulatory requirements in the sequencing space); D.I. 376, ex. S at 120-21 (Dr. Paz describing her past work with a client that required an understanding of the single-cell analysis market)) Pursuant to the “liberal” standard relating to Rule 702’s qualification requirement, Dr. Paz need not necessarily be a “market expert in RNA single-cell analysis” in order to provide the testimony at issue. (D.I. 325 at 47 (emphasis added); see also D.I. 366 at 46-47 (citing cases)) Instead, her more “generalized qualifications” (i.e., her experience with assessing markets in significantly related fields) can suffice. See FinancialApps v. Envestnet, Inc., Civil Action No. 19-1337-GBW-CJB, 2023 WL 5289444, at *8-9 (D. Del. Aug. 14, 2023) (declining to exclude an expert with “deep experience in the software development field” from testifying about, inter alia, data integration and synchronization regarding multi-factor authentication (“MFA”) software, and noting that “to suggest that an expert with deep experience in the software development field cannot provide an opinion on MFA (for example) simply because his entire career has not been focused on MFA, or because he has not personally written code for an MFA-related program, seems an unduly rigid approach to the Daubert ‘qualifications’ prong”) (citing cases)); (2) As to Parse’s argument that Dr. Paz’s opinions are insufficiently reliable because she “did not follow any methodology”—i.e., in that she purportedly did not speak to certain “key opinion leaders, influencers,... customers or users[,]” (D.I. 325 at 48)—this too is not basis to grant the Motion. In addition to relying on her own experience (as described above) to form her opinions, Dr. Paz explained that she also drew on: (a) her prior conversations with certain experts in the relevant field (some of whom she listed during her deposition), (D.I. 329, ex. 23 at 110-15); (b) deposition testimony from both Scale and Parse witnesses in this case, (D.I. 366 at 49 (citing D.I. 328, ex. 9 at ¶¶ 55, 62-63)); and (c) her familiarity with examples in related fields, (e.g., D.I. 328, ex. 17 at ¶ 31). Parse’s arguments that Dr. Paz should have cast a wider net and should have drawn on a greater array of sources is a point for cross-examination, not a basis to strike her opinions. See, e.g., Leonard v. Stemtech Health Scis., Inc., Civil Action No. 08-067-LPS-CJB, 2013 WL 5311295, at *7 (D. Del. Sept. 23, 2013). Relatedly, certain of Parse’s disputes with Dr. Paz (such as about whether Parse and Scale truly compete in a two entity sub-market, or whether Parse’s early entry into the market hurt Scale) read like disputes over the proper weight to be given to certain evidence—e.g., over which portion of a particular deposition or document should be considered more impactful than another—nothing more. Compare (D.I. 325 at 49-50 (Parse asserting that Dr. Paz “ignored” certain portions of a 2023 report and certain portions of a Parse presentation that she cited in support of the view that Parse and Scale were the only two competitors in a market, or that Dr. Paz did not know key facts relevant to the early entry issue and had not spoken to the right people about that issue) (citations omitted)), and (D.I. 395 at 24-25 (same) (citations omitted)), with (D.I. 328, ex. 9 at ¶¶ 55, 62-63 (Dr. Paz citing to aspects of certain deposition testimony in support of her view about the market) (citations omitted)), (id. at ¶¶ 64, 68-69 (Dr. Paz citing to various sources to bolster her opinion on the early entry issue) (citations omitted)); and (D.I. 329, ex. 30 at PARSE0392992, PARSE0392996-97 (portions of the Parse presentation, which includes content that is potentially both helpful and hurtful to Dr. Paz’s opinion about a two-competitor market)). Cf. ZF Meritor, LLC v. Eaton Corp., 696 F.3d 254, 290 (3d Cir. 2012) (noting that while some of an expert’s testimony “may have been contradicted by other evidence, including the testimony of [another] expert, the existence of conflicting evidence was not a basis on which to exclude [an expert’s] testimony.”); FinancialApps, LLC v. Envestnet, Inc., Civil Action No. 19-1337-GBW-CJB, 2023 WL 4936007, at *2 n.3 (D. Del. July 28, 2023) (“As a general matter, in a case like this one—where there are hundreds (if not thousands) of facts that might be considered and/or documents that might be cited—an expert’s failure to cite to or focus on one particular fact or one particular document that the other side is fixated on does not strike the Court as necessarily amounting to the use of an unreliable methodology.”).; and (3) The Court acknowledges that when it comes to Dr. Paz’s opinions regarding the connection between split-pool barcoding and scalability (and how that relates to her assessment of the relevant market), the record is a bit more opaque. (D.I. 325 at 48-49; D.I. 395 at 25) It didn’t help that Scale did not appear to directly address this issue in its answering brief. (D.I. 366 at 45-50) But because the issue relates to only one sub-component of Dr. Paz’s overall market analysis, because Dr. Paz does appear to have come to this opinion by relying on certain sources (and reviewing them in light of her many years of experience in related industries), (D.I. 329, ex. 23 at 183-84, 228-31), and because the Court simply does not have a clear enough record to deem Dr. Paz’s testimony on this point entirely unreliable, the Court cannot use this as a vehicle to grant Parse’s motion. Again, Parse can pursue any strong points they have on this matter on cross-examination. See, e.g., Leonard, 2013 WL 5311295, at *7. Ordered by Judge Christopher J. Burke on 01/29/2026. (sam) (Entered: 01/29/2026)
2026-01-29
1
STIPULATION TO EXTEND TIME deadline for discovery dispute letter in opposition and discovery dispute letter in reply (D.I. 514) to 8:00 p.m. (from 5:00 p.m.) on January 29, 2026 (Parse opposition) and 8:00 p.m. (from 5:00 p.m.) on February 5, 2026 (ScaleBio reply) - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 01/29/2026)
2026-01-29
1
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
1
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
REDACTED VERSION of 515 Letter, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Text of Proposed Order)(Farnan, Kelly) (Entered: 01/29/2026)
2026-01-29
2
[SEALED] Letter to the Honorable Christopher J. Burke from Karen L. Pascale regarding Parse Biosciences, Inc.'s Responsive Letter Brief Regarding Scale Biosciences Inc.'s Discovery Dispute - re 515 Letter,. (Attachments: # 1 Exhibit A-G)(Pascale, Karen) (Entered: 01/29/2026)
2026-01-29
1
SO ORDERED, D.I. 517 STIPULATION TO EXTEND TIME deadline for discovery dispute letter in opposition and discovery dispute letter in reply (D.I. 514) to 8:00 p.m. (from 5:00 p.m.) on January 29, 2026 (Parse opposition) and 8:00 p.m. (from 5:00 p.m.) on February 5, 2026 (ScaleBio reply) filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 01/29/2026. (sam)
2026-01-29
1
No Actions
SO ORDERED
2026-01-29
1
No Actions
Order on Motion to Preclude
2026-01-29
1
No Actions
REDACTED VERSION of 519 Letter, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 02/05/2026)
2026-02-05
1
[SEALED] Letter to The Honorable Christopher J. Burke from Sara M. Metzler regarding ScaleBio's Request for Discovery - re 519 Letter,. (Attachments: # 1 Exhibit 11)(Metzler, Sara) (Entered: 02/05/2026)
2026-02-05
1
REDACTED VERSION of 521 Letter by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 11)(Farnan, Kelly) (Entered: 02/12/2026)
2026-02-12
1
REDACTED VERSION of 521 Letter by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 11)(Farnan, Kelly) (Entered: 02/12/2026)
2026-02-12
2
MEMORANDUM ORDER: Plaintiff Scale Biosciences, Inc.'s motion to exclude certain expert opinions of Dr. DeForest McDuff, (D.I. 306 ), is GRANTED-IN-PART and DENIED-IN-PART. Any such redacted version shall be submitted no later than February 25, 2026 for review by the Court. Signed by Judge Christopher J. Burke on 02/20/2026. This order has been emailed to local counsel. (sam) Unsealed on 2/25/2026 (sam). (Entered: 02/20/2026)
2026-02-20
1
Remark: D.I. 523 Memorandum Order was unsealed after counsel jointly advised the Court that the parties would not be requesting any redactions. (sam)
2026-02-25
1
No Actions
Document Unsealed
2026-02-25
1
No Actions
ORAL ORDER: The Court hereby ORDERS that, by no later than March 30, 2026, the parties shall meet and confer and submit a joint letter providing the Court with a list of all of the one-week periods from June 2026 through August 2026 in which they are jointly available to try the case as to any then-remaining claims and defenses. Ordered by Judge Christopher J. Burke on 03/23/2026. (sam) (Entered: 03/23/2026)
2026-03-23
1
Oral Order
2026-03-23
1
No Actions
ORAL ORDER: The Court, having reviewed Plaintiffs’ unopposed motion to seal (“Motion”) limited portions of the Court’s October 17, 2025 Memorandum Order (“October 17 MO”), (D.I. 494 ), hereby ORDERS that for the reasons set out in the Motion, the Motion is GRANTED. The proposed redactions relate to Plaintiffs’ non-public licensing terms and the strategic considerations that led to those terms, and the Court agrees that this “is the kind of information that courts will protect[.]” (Id. at 3); In re Avandia Mktg., Sales Pracs. & Prods. Liab. Litig., 924 F.3d 662, 672 (3d. Cir. 2019) (internal quotation marks and citation omitted). The proposed redactions are limited in scope, totaling about 14 lines of text in 5-page order, (D.I. 494, exs. A-B), and Plaintiffs have made a sufficient showing that disclosure of the material “will work a clearly defined and serious injury to” them by revealing Plaintiffs’ royalty burden, negotiation posture, and strategic licensing considerations “in a way that competitors and future counterparties could exploit.” (Id. at 2, 4-5); see also In re Avandia, 924 F.3d at 672 (internal quotation marks and citation omitted). Therefore, any and all publicly-available copies of the October 17 MO, including but not limited to copies that are or will be available by remote electronic access, shall be redacted as delineated in Exhibit B of the Motion. (D.I. 494, ex. B) Ordered by Judge Christopher J. Burke on 03/26/2026. (sam) (Entered: 03/26/2026)
2026-03-26
1
REDACTED VERSION of D.I. 485 Memorandum Order. Signed by Judge Christopher J. Burke on 10/17/2025. (sam) (Entered: 03/26/2026)
2026-03-26
1
Order on Motion to Seal
2026-03-26
1
No Actions
Joint Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Response to the Court's March 23, 2026 Order - re 524 Oral Order,. (Farnan, Kelly) (Entered: 03/30/2026)
2026-03-30
1
ORAL ORDER: The Court hereby ORDERS as follows: (1) The trial is rescheduled to begin on August 24, 2026 at 9:30 a.m. in Courtroom 2A.; (2) The pretrial conference is scheduled for August 7, 2026 at 10:00 a.m. in Courtroom 2A.; and (3) The proposed pretrial order shall be filed by July 31, 2026. Ordered by Judge Christopher J. Burke on 03/31/2026. (sam) (Entered: 03/31/2026)
2026-03-31
1
Oral Order AND ~Util - Set Hearings
2026-03-31
1
No Actions
MEMORANDUM ORDER Granting Portion of Plaintiff Scale Biosciences, Inc.'s Discovery Dispute Motion. (D.I. 513 ) Signed by Judge Christopher J. Burke on 04/13/2026. This order has been emailed to local counsel. (sam) UNSEALED on 9/15/2026 per D.I. 652 Oral Order (sam). (Main Document 529 replaced on 9/15/2026) (sam). (Entered: 04/13/2026)
2026-04-13
1
STIPULATION TO EXTEND TIME to Submit Proposed Redacted Version of 529 Memorandum Order to 4/20/2026 - filed by Parse Biosciences, Inc., The University of Washington. (Wilson, Samantha) (Entered: 04/16/2026)
2026-04-16
1
SO ORDERED, D.I. 530 STIPULATION TO EXTEND TIME to Submit Proposed Redacted Version of 529 Memorandum Order to 4/20/2026 filed by Parse Biosciences, Inc., The University of Washington. Ordered by Judge Christopher J. Burke on 04/16/2026. (sam)
2026-04-16
1
No Actions
Order on Motion on Stipulation to Extend Time
2026-04-16
1
No Actions
MEMORANDUM ORDER re D.I. 513 MOTION for Teleconference to Resolve Discovery Dispute - filed by Scale Biosciences, Inc. Signed by Judge Christopher J. Burke on 04/20/2026.This order has been emailed to local counsel. (sam) UNSEALED on 9/15/2026 per D.I. 652 Oral Order (sam). (Main Document 531 replaced on 9/15/2026) (sam). (Entered: 04/20/2026)
2026-04-20
1
[SEALED] Unopposed MOTION to Seal and Redact Limited Portions of the April 13, 2026 Memorandum Order (D.I. 529) re 529 Memorandum and Order - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A, # 3 Exhibit B)(Wilson, Samantha) (Entered: 04/20/2026)
2026-04-20
1
[SEALED] DECLARATION of Alex Rosenberg, Ph.D. re 532 Unopposed MOTION to Seal and Redact Limited Portions of the April 13, 2026 Memorandum Order (D.I. 529) re 529 Memorandum and Order by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 04/20/2026)
2026-04-20
1
NOTICE of Supplemental Authority by Scale Biosciences, Inc. re 473 MOTION for Reargument Under Local Rule 7.1.5 (Attachments: # 1 Exhibit A)(Farnan, Kelly) (Entered: 04/22/2026)
2026-04-22
1
NOTICE of Supplemental Authority by Scale Biosciences, Inc. re 473 MOTION for Reargument Under Local Rule 7.1.5 (Attachments: # 1 Exhibit A)(Farnan, Kelly) (Entered: 04/22/2026)
2026-04-22
2
REDACTED VERSION of 532 Unopposed MOTION to Seal and Redact Limited Portions of the April 13, 2026 Memorandum Order (D.I. 529) re 529 Memorandum and Order by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 04/23/2026)
2026-04-23
1
REDACTED VERSION of 533 Declaration, by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 04/23/2026)
2026-04-23
1
[SEALED] Unopposed MOTION to Seal and Redact Limited Portions of the April 20, 2026 Memorandum Order (D.I. 531) re 531 Order on Motion for Miscellaneous Relief, - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A, # 3 Exhibit B)(Wilson, Samantha) (Entered: 04/23/2026)
2026-04-23
1
[SEALED] DECLARATION of Alex Rosenberg, Ph.D. re 537 Unopposed MOTION to Seal and Redact Limited Portions of the April 20, 2026 Memorandum Order (D.I. 531) re 531 Order on Motion for Miscellaneous Relief, by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 04/23/2026)
2026-04-23
1
STATEMENT re 534 Notice (Other) Parse Biosciences, Inc.'s Response to Scale Biosciences, Inc.'s Notice of Supplemental Authority by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 04/24/2026)
2026-04-24
1
REDACTED VERSION of 537 Unopposed MOTION to Seal and Redact Limited Portions of the April 20, 2026 Memorandum Order (D.I. 531) re 531 Order on Motion for Miscellaneous Relief, by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 04/30/2026)
2026-04-30
1
REDACTED VERSION of 538 Declaration, by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 04/30/2026)
2026-04-30
1
NOTICE requesting Clerk to remove Sidhi Gosain as co-counsel. Reason for request: Left firm. (Farnan, Kelly) (Entered: 05/05/2026)
2026-05-05
1
NOTICE of the Withdrawal of Appearance of Danielle I. Bell by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Farnan, Kelly) (Entered: 05/11/2026)
2026-05-11
1
REQUEST for Oral Argument by Scale Biosciences, Inc. re 318 MOTION for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents, 473 MOTION for Reargument Under Local Rule 7.1.5. (Farnan, Kelly) (Entered: 05/15/2026)
2026-05-15
1
ORAL ORDER Setting Videoconference: The Court, having reviewed Plaintiffs’ request for oral argument, (D.I. 544 ), hereby ORDERS as follows: (1) At this time, the Court does not expect to need to hear oral argument on Parse’s Motion for Summary Judgment #3 regarding the '442 and '256 patents, (D.I. 318 ), in order to resolve it, so it will plan to resolve that motion on the papers.; and (2) With respect to Parse’s Motion for Trial Sanctions Under Fed. R. Civ. P. 37(e), (D.I. 448 ), and Scale’s Motion for Reargument on the Court’s October 8, 2025 Memorandum Opinion, (D.I. 473 ), a videoconference to hear argument on those two motions is set for 6/24/2026 at 10:00 AM before Judge Christopher J. Burke via the Microsoft Teams platform. Three hours total will be allocated for argument on both motions, to be split equally between the sides. By no later than June 18, 2026, the parties shall send an e-mail to the Court’s Courtroom Deputy, Ms. Miller, indicating the names and e-mail addresses of all individuals who will participate in the hearing. Ordered by Judge Christopher J. Burke on 5/21/2026. (mlc) (Entered: 05/21/2026)
2026-05-21
1
Oral Order AND Order Setting Videoconference
2026-05-21
1
No Actions
NOTICE of of Withdrawal of Richa B. Patel, Esq. by Scale Biosciences, Inc. (Metzler, Sara) (Entered: 06/02/2026)
2026-06-02
1
MEMORANDUM OPINION regarding D.I. 302 .. Signed by Judge Christopher J. Burke on 6/17/2026. (mlc) (Entered: 06/17/2026)
2026-06-17
1
ORDER: For the reasons stated in the Memorandum Opinion issued this same date, IT IS HEREBY ORDERED that the motion for summary judgment of invalidity of U.S. Patent Nos. 10,900,065, 11,168,355, and 11,427,856 filed by Plaintiff Scale Biosciences, Inc. pursuant to Federal Rule of Civil Procedure 56, (D.I. 302 ), is GRANTED. Signed by Judge Christopher J. Burke on 6/17/2026. (mlc) (Entered: 06/17/2026)
2026-06-17
1
Order on Motion for Summary Judgment
2026-06-17
1
No Actions
NOTICE of Lodging Demonstrative that was used during the June 24, 2026 Hearing by Scale Biosciences, Inc. (Attachments: # 1 1)(Metzler, Sara) (Entered: 06/25/2026)
2026-06-25
1
NOTICE of Lodging Demonstrative that was used during the June 24, 2026 Hearing by Scale Biosciences, Inc. (Attachments: # 1 1)(Metzler, Sara) (Entered: 06/25/2026)
2026-06-25
2
NOTICE of of Lodging of demonstrative slides used during 6/24/26 oral argument on Plaintiffs' Motion for Reargument Under Local Rule 7.1.5 (D.I. 473) by Parse Biosciences, Inc. (Wilson, Samantha) (Entered: 06/25/2026)
2026-06-25
1
Minute Entry for proceedings held before Judge Christopher J. Burke - Videoconference held on 6/24/2026. The Court heard argument on Scale's Motion for Reargument on the Court's October 8, 2025 Memorandum Opinion, (D.I. 473 ), and Parse's Motion for Trial Sanctions Under Fed. R. Civ. P. 37(e), (D.I. 448 ). The Court took both motions under advisement. (Clerk: W. Roberts, J. Bell; Court reporter: Stacy Ingram) Appearances: F. Cottrell, P. Ehrlich, A. Hadzimehmedovic, D. Kazhdan, S. Rabinowitz, C. Noyes, and M. Laupheimer for Plaintiffs; K. Pascale, A. Gaza, S. Wilson, B. Pickard, R. Powers, C. Vira, and B. Gleason for Defendants.(sam)
2026-06-25
1
No Actions
Motion Hearing
2026-06-25
1
No Actions
ORAL ORDER: The Court, having reviewed Defendant Parse Biosciences Inc.’s (“Parse”) Motion for Trial Sanctions Under Fed. R. Civ. P. 37(e) (“Motion”), (D.I. 448 ), the briefing related thereto, (D.I. 448 ; D.I. 474 ), and having heard oral argument related to the Motion on June 24, 2026, hereby ORDERS that the Motion is DENIED for the reasons that follow: (1) As Parse’s counsel confirmed during oral argument, the Motion is premised on Fed. R. Civ. P. 37(e)(1); Parse does not seek sanctions under Rule 37(e)(2). Rule 37(e)(1) states that “[ 1 ] [i]f electronically stored information that should have been preserved in the anticipation or conduct of litigation is [ 2 ] lost because a party failed to take reasonable steps to preserve it, and [ 3 ] it cannot be restored or replaced through additional discovery, the court . . . [ 4 ] upon finding prejudice to another party from loss of the information, may order measures no greater than necessary to cure the prejudice . . . .” Fed. R. Civ. P. 37(e)(1). While Rule 37(e) “does not place a burden of proving or disproving prejudice on one party or the other[,]” in some situations “the content of the lost information may be fairly evident, the information may appear to be unimportant, or the abundance of preserved information may appear sufficient to meet the needs of all parties[,]” such that “[r]equiring the party seeking curative measures to prove prejudice may be reasonable[.]” Rule 37(e)(1) advisory committee’s notes to 2015 amendment. During oral argument, counsel for Parse acknowledged that under the circumstances at issue here, Parse bears the burden to demonstrate that the threshold requirements of Rule 37(e)(1) are met and that prejudice was established. See Eshelman v. Puma Biotechnology, Inc., No. 7:16-CV-18-D, 2017 WL 2483800, at *5 (E.D.N.C. June 7, 2017).; (2) With these relevant legal standards set out, here the Court concludes that even assuming that the threshold elements of Rule 37(e)(1) have been met (and the Court has serious doubts that this is the case, as to, for example, the element requiring that the information at issue be shown to have actually existed and thereafter to have been “lost[,]” or the element requiring that any lost information be such that it could not have been “restored or replaced through additional discovery”), the Court cannot determine that Parse has suffered “prejudice . . . from loss of the information[.]” Fed. R. Civ. P. 37(e)(1); see also CIGNEX Datamatics, Inc. v. Lam Rsch. Corp., C.A. No. 17-320 (MN), 2019 WL 1118099, at *4-5 (D. Del. Mar. 11, 2019) (denying a request for Rule 37(e)(1) sanctions, where the potential prejudice suffered “appears to be speculation”).; (3) In explaining why this is so, the Court first turns to the allegedly lost information at issue. What is it said to be? Here, Parse asserts that it amounts to documents or information from 41 of up to 125 experiments related to QBC technology that were conducted by Dr. Maeve O’Huallachain or the inventor of the patents-in-suit (hereafter, “the lost information”). (D.I. 448 at 8) Parse speculates that experimental records that were part of this lost information “would have been relevant to Parse’s . . . written description and enablement defenses.” (Id. at 9) Regarding written description, Parse guesses that the lost information might have helped show that the patents-in-suit “encompass broad genera of antibodies and aptamers but fail to disclose a representative number of species falling within that broad scope.” (Id.) Regarding enablement, Parse proffers that the lost information “would likely have shown that undue experimentation was necessary to make and use the full scope of the claimed inventions.” (Id.); (4) However, as Plaintiffs point out—and as Parse’s counsel confirmed during oral argument—Parse has not previously advanced either of these specific invalidity theories (i.e., theories relying on Plaintiff Roche Sequencing Solutions, Inc.’s (“Roche’s”) experimental work) in this case. (D.I. 474 at 9) Parse certainly had the ability to identify such defenses earlier in the case, in light of the discovery it did receive via numerous other Roche-related experiments on QBC technology. And yet, despite having prior access to at least 84 such experiments, Parse did not press those defenses. For example, Parse didn’t cite to any of this experimental data in its expert reports. (Id. at 9-10 & n.3) Nor did Parse question Dr. O’Huallachain or any other witness about these experiments during depositions. (See id.) If Parse had truly meant to rely on these types of lack of written description and enablement theories in the case, it surely could have done so via the discovery it had obtained. (Id. at 9 (“Had Parse truly intended to make a [Section] 112 argument based on Roche experimental work, it could have done so.”)) And if Parse thought that the discovery provided by Plaintiffs regarding these Roche experiments was insufficient (in light of the 41 “missing” experiments, or otherwise), it could have earlier taken additional steps to try to obtain more information about that subject matter. (D.I. 474 at 6, 8) But Parse did none of this.; and (5) In sum, Parse cannot be prejudiced due to the loss of the ability to cite to records from the 41 missing experiments in order to bolster certain experimentation-based written description and enablement defenses, when it never raised (and thus now does not have) such defenses in the first place. (D.I. 474 at 10) The lost information (even to the extent it once existed and is in fact “lost”—as to which, again, the Court has its doubts), thus “appear[s] to be unimportant” to this case. Fed. R. Civ. P. 37(e)(1) advisory committee’s notes to 2015 amendment; see also Marshall v. Dentfirst, P.C., 313 F.R.D. 691, 697 (N.D. Ga. 2016) (“Where, as here, the moving party is not able to establish that the allegedly destroyed evidence is critical to the case, courts have consistently refused to impose spoliation sanctions.” (internal quotation marks and citation omitted)). Indeed, Parse’s requested relief, which included a proposed jury instruction indicating that the jury “may consider what effect, if any, the unavailability of [the lost] information to Parse has had on its ability to support the positions that it has advanced during this trial[,]” (D.I. 448 at Proposed Order), would have encouraged the jury to speculate about how such allegedly missing documents “support . . . positions” that Parse itself would not be advancing. That is not permissible. See Allstate Ins. Co. v. Papanek, Case No. 3:15-cv-240, 2019 WL 6698342, at *9 (S.D. Ohio Dec. 9, 2019) (denying a motion for sanctions, where the allegedly lost information at issue was of “minimal relevance to the claims and defenses to be tried”); see also CIGNEX Datamatics, 2019 WL 1118099, at *5 (“That there is insufficient evidence of prejudice means that a curative measure under Rule 37(e)(1) is inappropriate.”). Ordered by Judge Christopher J. Burke on 06/30/2026. (sam) Modified on 7/1/2026 (sam). (Entered: 06/30/2026)
2026-06-30
1
ORAL ORDER: The Court, having reviewed Scale’s Motion for Reargument Under Local Rule 7.1.5 (“Motion”) regarding the Court’s October 8, 2025 Memorandum Opinion (“October 8 MO”), (D.I. 473 ), and the briefing related thereto, (D.I. 473 ; D.I. 483 ; D.I. 534 ; D.I. 539 ), and having heard oral argument related to the Motion on June 24, 2026, hereby ORDERS that the Motion is DENIED for the reasons that follow: (1) “[M]otions for reargument should be granted sparingly.” Stairmaster Sports/Med. Prods., Inc. v. Groupe Procycle, Inc., 25 F. Supp. 2d 270, 292 (D. Del. 1998), aff’d, 232 F.3d 909 (Fed. Cir. 2000); D. Del. L.R. 7.1.5(a). Courts have recognized three narrow grounds on which this type of motion may typically be based: (1) “where the Court has patently misunderstood a party,” (2) “[where the Court] has made a decision outside the adversarial issues presented to the Court by the parties,” or (3) “[where the Court] has made an error not of reasoning but of apprehension.” Id. (internal quotation marks and citation omitted). Here, Scale has confirmed that it brings its Motion primarily under the third prong, arguing that “[t]he Court’s new [claim] construction [of the ‘APS oligonucleotides’ term, which is found in the asserted claims of United States Patent No. 11,634,752 (the ‘'752 patent’)—a construction that the Court adopted in the October 8 MO] misapprehends both the parties’ positions on the scope of the terms at issue and the downstream effects for the [']752 [p]atent” regarding the question of invalidity. (D.I. 473 at 1 (emphasis added)); (2) Importantly, “[a] motion for [reargument] may not be used to argue that a court rethink a decision already made, nor may it be used to argue new facts or issues that were inexcusably not presented to the court in the matter previously decided.” Talley v. Christiana Care Health Sys., Civil Action No. 17-926-CJB, 2019 WL 2605589, at *1 (D. Del. June 25, 2019); see also Allergan, Inc. v. Revance Therapeutics, Inc., Civil Action No. 21-1411-RGA, 2025 WL 1906171, at *1 (D. Del. July 10, 2025) (“Because I conclude that [the motion for reconsideration] raises issues [the movant] could have, and should have, raised earlier, it is [denied].”); Skretvedt v. E.I. DuPont de Nemours & Co., Civil Action No. 98–61–MPT, 2009 WL 1649495, at *2 (D. Del. June 12, 2009) (noting that a motion for reconsideration or reargument “may not be used to advance arguments that a party could have made before judgment, but neglected to do so”). With its Motion, Scale does just this—it makes arguments it could have (but did not) make in an earlier summary judgment proceeding, and it essentially asks the Court for a re-do of the invalidity decision the Court issued via its October 8 MO.; (3) More specifically, with the instant Motion, Scale takes issue with the Court’s decision in the October 8 MO to construe “APS oligonucleotides” in claim 1 of the '752 patent to encompass “APS oligonucleotides that include[] a [unique binding agent, or] UBA.” (D.I. 466 at 14-16 & n.10; see also D.I. 473 at 4-7) The Court came to this conclusion in significant part due to: (a) dependent claim 5’s requirement that “the APS oligonucleotides of at least one of the sets of APS oligonucleotides [in claim 1] comprise a unique binding agent (UBA)”; and (b) the traditional meaning ascribed to the term “comprise[s]” in patent law (i.e., one typically indicating that the term found before the word “comprise” includes, but is not limited to, the term found after “comprise”). (D.I. 466 at 14-15 & n.10; '752 patent, col. 58:14-16 (emphasis added)) Scale argues that by doing so, the “Court settled on a construction proposed by neither party[,]” and did so without “the benefit of [] briefing on whether this definition of ‘APS oligonucleotides... comprise’ in claim 5 squares with the intrinsic evidence[.]” (D.I. 473 at 1, 3) Indeed, it is Scale’s position that Parse never even made the argument that the Court attributed to it in the October 8 MO (i.e., that the “APS oligonucleotides” in claim 1 encompass an embodiment that includes a UBA)—and that this claim construction issue was not properly joined by the parties in the summary judgment record. (See D.I. 473 at 1, 4-5); (4) The Court disagrees. In the beginning of its opening brief requesting summary judgment of invalidity, Parse began by putting forward just this argument: i.e., by asserting that: (a) “[c]laim 1 requires, in relevant part, ‘at least two sets of... []APS[] oligonucleotides’”; and that (b) “[c]laim 5 narrows that APS limitation [of claim 1] such that the APSs ‘comprise a unique binding agent (UBA)’”; and thus (c) “[c]laim 1’s APSs therefore encompass APSs comprising UBAs.” (D.I. 325 at 5 (cited in D.I. 483 at 2, 5)) In its answering brief, Scale cited to this very portion of Parse’s opening brief, noted Parse’s argument, and then responded with its contrary argument: i.e., it there argued that Parse’s assertion that “UBAs are... part of the invention as claimed” in claim 1 was not correct, and stated that although “Parse relies on claim 5” for its contrary position in light of claim 5’s use of the term “‘comprise[,]’” this argument was off base, since “UBAs are not embodiments of the ‘APS oligonucleotides’ recited in the [asserted claims], but are an additional feature that might optionally be included in the kits defined by [those claims] (and are required only by claim 5).” (D.I. 366 at 2 (citing D.I. 325 at 5) (cited in D.I. 483 at 2-3)) After Parse responded to this view via its summary judgment reply brief, (D.I. 395 at 5 (cited in D.I. 483 at 3)), the parties proceeded to oral argument on the invalidity-based summary judgment motion—an argument that lasted approximately an hour and a half (and thus permitted each side ample time to make any additional points about the issue that it wished to make). When Parse’s counsel rose to address the issue during that hearing, the very first thing he did was to reiterate Parse’s position, set out above: i.e., he re-stated Parse’s view that “[c]laim 1 recites the APS oligonucleotides... [a]nd then [c]laim 5, it doesn’t just add UBAs as another feature of the [claimed] kits... [but instead it] narrows the claimed APSs of the independent claim to also include or comprise the UBAs” such that “UBAs are an embodiment of APSs[ of claim 1.]” (D.I. 419 at 99-100) Thereafter, the Court engaged with Scale’s counsel on that very same issue, (see e.g., id. at 115-16, 132-33, 136-37), including by discussing what Parse had said on this point in its opening summary judgment brief, (id. at 138, 147). And after all of that process, the Court then wrote its October 8 MO. In doing so, it described the parties’ dispute just as they had briefed and argued it (citing, inter alia, to the exact portion of Parse’s opening summary judgment brief discussed above, wherein Parse had first set out the argument). (D.I. 466 at 15-16 (citing D.I. 325 at 5)) For all of these reasons, the Court cannot agree with Scale that it mischaracterized Parse’s claim construction position in the October 8 MO, or that this issue was not fairly joined by the parties in the underlying summary judgment record.; (5) Ultimately, Scale’s argument about how the Court committed an error of apprehension is twofold. On the one hand, Scale asserts that the Court’s construction of “APS oligonucleotides” (motivated in significant part by claim 5’s “comprise” language) “is incompatible with the [']752 [p]atent’s specification[,]” because certain embodiments of the claimed invention shown in Figures 2 and 4 “depict[] the UBA and APS as separate elements that are added together... rather than a UBA being a part of an APS[.]” (D.I. 473 at 5-6) Alternatively, Scale argues that even if the Court were to maintain its “construction in which the UBA is part of the APS oligonucleotide, [then] only certain nucleic acid UBA structures could be included in claim 1, not the ‘billions’ of UBAs relied on by Parse[,]” such that there is actually a dispute of fact as to whether the full scope of the asserted claims (so narrowed) has been sufficiently described and enabled. (Id. at 7-8) But these are both arguments that Scale could have (but did not) make during the summary judgment stage of the case, when this invalidity issue was in the balance. In light of the caselaw set out above, such positions cannot now be belatedly offered via a motion for reargument. Nor can the fact that Scale brought on new counsel after the summary judgment argument amount to an excuse permitting it to elide the rules in this regard. See, e.g., Johnson v. Hanover Ins. Co., Civil Action No. 1:23-cv-1294-KMW-AMD, 2026 WL 295193, at *2 (D.N.J. Feb. 4, 2026); and (6) Although not necessary for resolution of the Motion, it is also worth noting that Scale has not convinced the Court that its prior claim construction decision is actually incorrect. With regard to the portion of the October 8 MO that focused on the meaning of the word “comprise” in claim 5, during argument on the instant Motion, Scale’s counsel confirmed that the Court’s analysis was entirely in line with the meaning this term is typically understood to have when it is found in patent claims like this one (i.e., that the Court’s decision aligned on that score with that of many opinions from the United States Court of Appeals for the Federal Circuit, which the Court had cited in the October 8 MO). (D.I. 466 at 15-16 & n.10) In its briefing on the Motion, Scale cited to no opinion in which a court came to a different conclusion in assessing claim language like this (e.g., an opinion wherein the term “comprise” was found not to carry its typical meaning, and instead to mean something more akin to “further comprise”). Moreover, Scale’s citations here to two figures from the '752 patent (figures that are perfectly in line with other embodiments of what claim 1 could cover) certainly does not provide sufficient reason to contravene the typical meaning of “comprise.” (See also D.I. 483 at 6-8) And again, if Parse’s claim construction position is in fact correct (as the Court had previously determined it to be), then it was previously undisputed by the parties that such an outcome leads to the challenged claims of the '752 patent being found invalid for lack of written description and enablement. (D.I. 466 at 27-28 (the Court noting that Scale’s only argument regarding these invalidity issues was a legal one, not a factual one)) Ordered by Judge Christopher J. Burke on 06/30/2026. (sam) (Entered: 06/30/2026)
2026-06-30
1
Order on Motion for Sanctions
2026-06-30
1
No Actions
Order on Motion for Reargument
2026-06-30
1
No Actions
NOTICE to Take Deposition of Giovanna Prout on July 9, 2026 filed by Parse Biosciences, Inc..(Wilson, Samantha) (Entered: 07/02/2026)
2026-07-02
1
NOTICE to Take Deposition of Michael "Mike" Yamamoto on July 10, 2026 filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/06/2026)
2026-07-06
1
MOTION to Strike [Parse Biosciences, Inc.'s Motion to Strike Dr. Michael Schnall-Levin from Scales Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooneys Second Supplemental Expert Report that Rely on Information from Dr. Schnall-Levin] - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Gaza, Anne) (Entered: 07/17/2026)
2026-07-17
1
MOTION to Strike [Parse Biosciences, Inc.'s Motion to Strike Dr. Michael Schnall-Levin from Scales Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooneys Second Supplemental Expert Report that Rely on Information from Dr. Schnall-Levin] - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Gaza, Anne) (Entered: 07/17/2026)
2026-07-17
2
[SEALED] Letter to the Honorable Christopher J. Burke from Karen Pascale regarding Parse's Opening Letter Brief in Support of its Motion to Strike Dr. Michael Schnall-Levin from Scales Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooneys Second Supplemental Expert Report that Rely on Information from Dr. Schnall-Levin - re 555 Parse Biosciences, Inc.'s MOTION to Strike Dr. Michael Schnall-Levin from Scales Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooneys Second Supplemental Expert Report that Rely on Information from Dr. Schnall-Levin. (Gaza, Anne) (Main Document 556 replaced on 7/20/2026) (sam). Modified on 7/20/2026 (sam). (Entered: 07/17/2026)
2026-07-17
1
[SEALED] EXHIBIT re 556 Letter,, Exhibits A-O (Parts 1 and 2) by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A-O (Part 2 of 2))(Gaza, Anne) (Entered: 07/17/2026)
2026-07-17
1
- CORRECTING ENTRY
2026-07-20
1
No Actions
CORRECTING ENTRY: Main document at D.I. 556 Letter Opening Brief replaced per request of filing counsel to correct formatting errors. (sam)
2026-07-20
1
No Actions
NOTICE OF SERVICE of Defendant's Identification of Prior Art Pursuant to 35 U.S.C. § 282 filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 07/24/2026)
2026-07-24
1
[SEALED] RESPONSE to Motion re 555 MOTION to Strike [Parse Biosciences, Inc.'s Motion to Strike Dr. Michael Schnall-Levin from Scales Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooneys Se Opposition to Parse's Motion to Strike Dr. Schnall-Levin and Related Opinions in Mr. Mooney's Expert Report filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Farnan, Kelly) (Entered: 07/24/2026)
2026-07-24
1
[SEALED] MOTION for Leave to File Daubert Motions Out of Time to Exclude Mr. Drew Mooney's Reasonable Royalty Opinions (Exped Consideration requested) - filed by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit 1-5 (Motion for Leave), # 2 Certificate of Service)(Pascale, Karen) (Entered: 07/24/2026)
2026-07-24
1
[SEALED] EXHIBIT re 560 MOTION for Leave to File Daubert Motions Out of Time to Exclude Mr. Drew Mooney's Reasonable Royalty Opinions (Exped Consideration requested) by Parse Biosciences, Inc.. (Attachments: # 1 7.1.1 Certification, # 2 Certificate of Service)(Pascale, Karen) (Entered: 07/24/2026)
2026-07-24
1
[SEALED] EXHIBIT re 560 MOTION for Leave to File Daubert Motions Out of Time to Exclude Mr. Drew Mooney's Reasonable Royalty Opinions (Exped Consideration requested) Appendix A (Proposed Motion and Papers) by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 07/24/2026)
2026-07-24
1
[SEALED] EXHIBIT re 560 MOTION for Leave to File Daubert Motions Out of Time to Exclude Mr. Drew Mooney's Reasonable Royalty Opinions (Exped Consideration requested) Appendix B (Proposed Motion and Papers) by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 07/24/2026)
2026-07-24
1
EXHIBIT re 563 Exhibit to a Document, (Certificate of Service) by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 07/27/2026)
2026-07-27
1
STIPULATION TO EXTEND TIME to File Redacted Public Versions of Motion Papers related to Parse's Motion to Strike (D.I. 556) to August 21, 2026 - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 07/27/2026)
2026-07-27
1
[SEALED] Letter to The Honorable Christopher J. Burke from Karen J. Pascale regarding reply letter brief in support of motion to strike - re 555 MOTION to Strike [Parse Biosciences, Inc.'s Motion to Strike Dr. Michael Schnall-Levin from Scales Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooneys Se. (Attachments: # 1 Exhibit P-U)(Pascale, Karen) (Entered: 07/27/2026)
2026-07-27
1
Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding parties' request for teleconference to address Parse's motion to strike - re 555 MOTION to Strike [Parse Biosciences, Inc.'s Motion to Strike Dr. Michael Schnall-Levin from Scales Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooneys Se. (Pascale, Karen) (Entered: 07/27/2026)
2026-07-27
1
ORAL ORDER: Having reviewed Parse’s expedited motion for leave to file Daubert motions out of time, (D.I. 560 ), IT IS HEREBY ORDERED that: (1) Any responsive briefing to the motion for leave shall be due by July 30, 2026 and shall not exceed six (6) double-spaced pages.; (2) By July 31, 2026, even if the Court has not resolved the motion for leave by then, Parse shall docket its Daubert motions.; (3) By August 5, 2026, even if the Court has not resolved the motion for leave by then, any responsive briefing to the Daubert motions shall be filed and shall not exceed a total of ten (10) double-spaced pages between the two motions.; and (4) No reply briefing shall be permitted. Ordered by Judge Christopher J. Burke on 07/27/2026. (sam) (Entered: 07/28/2026)
2026-07-27
1
Order on Motion on Stipulation to Extend Time
2026-07-27
1
No Actions
SO ORDERED, D.I. 565 STIPULATION TO EXTEND TIME to File Redacted Public Versions of Motion Papers related to Parse's Motion to Strike (D.I. 556 ) to August 21, 2026 filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 07/27/2026. (sam)
2026-07-27
1
No Actions
STIPULATION TO EXTEND TIME to File Proposed Pretrial Order to 5:00pm ET on Saturday, August 1, 2026 - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 07/28/2026)
2026-07-28
1
ORAL ORDER: Having reviewed Parse’s letter requesting a teleconference to address the pending motion to strike, (D.I. 567 ), the Court hereby ORDERS that it will either: (1) resolve the motion to strike prior to the Pre-trial Conference (“PTC”) without argument, or (2) if it does not do so and determines that it needs argument on the motion, it will hear such argument during the PTC. Ordered by Judge Christopher J. Burke on 07/28/2026. (sam) (Entered: 07/28/2026)
2026-07-28
1
Oral Order
2026-07-28
1
No Actions
Order on Motion on Stipulation to Extend Time
2026-07-28
1
No Actions
SO ORDERED, D.I. 569 STIPULATION TO EXTEND TIME to File Proposed Pretrial Order to 5:00pm ET on Saturday, August 1, 2026 filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 07/28/2026. (sam)
2026-07-28
1
No Actions
[SEALED] MOTION to Exclude Opinions and Testimony of Mr. Drew Mooney Improperly Relying on the Book of Wisdom (Expedited Consideration Requested) - filed by Parse Biosciences, Inc.. (Attachments: # 1 7.1.1 Certification, # 2 Text of Proposed Order, # 3 Exhibit A-D)(Pascale, Karen) (Entered: 07/29/2026)
2026-07-29
1
[SEALED] MOTION to Exclude Opinions and Testimony of Mr. Drew Mooney Based on a Legally Erroneous Hypothetical Negotiation Date (Expedited Consideration Requested) - filed by Parse Biosciences, Inc.. (Attachments: # 1 7.1.1 Certification, # 2 Text of Proposed Order, # 3 Exhibit A-K)(Pascale, Karen) (Entered: 07/29/2026)
2026-07-29
1
MOTION to Strike Parse's Motion to Strike Certain Documents from Plaintiffs' Trial Exhibit List, Preclude Related Evidence and Testimony, and Strike Opinions from Mr. Mooney's Second Supplemental Report that Rely on Such Documents or Exceed the Scope of Supplementation Authorized by the Court - filed by Parse Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certificate of Service)(Pascale, Karen) (Entered: 07/29/2026)
2026-07-29
1
[SEALED] Letter to the Honorable Christopher J. Burke from Karen Pascale regarding Parse's Opening Letter Brief in Support of its Motion to Strike - re 573 MOTION to Strike Parse's Motion to Strike Certain Documents from Plaintiffs' Trial Exhibit List, Preclude Related Evidence and Testimony, and Strike Opinions from Mr. Mooney's Second Supplemental Report that Rely on Such Documents. (Attachments: # 1 Exhibit A-J, # 2 Certificate of Service)(Pascale, Karen) (Entered: 07/29/2026)
2026-07-29
1
MOTION for Pro Hac Vice Appearance of Attorney Igor Helman - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 07/30/2026)
2026-07-30
1
Pro Hac Vice Fee - Credit Card Payment received for Igor Helman. ( re 575 MOTION for Pro Hac Vice Appearance of Attorney Igor Helman )( Payment of $ 50, receipt number ADEDC-5029637).(Wilson, Samantha) (Entered: 07/30/2026)
2026-07-30
1
[SEALED] RESPONSE to Motion re 560 MOTION for Leave to File Daubert Motions Out of Time to Exclude Mr. Drew Mooney's Reasonable Royalty Opinions (Exped Consideration requested) Plaintiffs' Opposition to Parse's Motion for Leave to File Daubert Motions Out of Time to Exclude Mr. Drew Mooney's Reasonable Royalty Opinions filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Farnan, Kelly) (Entered: 07/30/2026)
2026-07-30
1
NOTICE OF SERVICE of Second Supplemental Reply Expert Report of Drew D. Mooney filed by Scale Biosciences, Inc..(Metzler, Sara) (Entered: 07/30/2026)
2026-07-30
1
Order on Motion to Appear Pro Hac Vice
2026-07-30
1
No Actions
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2026-07-30
1
No Actions
SO ORDERED, D.I. 575 Motion for Pro Hac Vice Appearance of Attorney Igor Helman - filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 07/30/2026. (sam)
2026-07-30
1
No Actions
NOTICE OF SERVICE of Second Supplemental Expert Report of Deforest McDuff, Ph. D. filed by Parse Biosciences, Inc..(Wilson, Samantha) (Entered: 07/31/2026)
2026-07-31
1
[SEALED] Proposed Pretrial Order Joint [Proposed] Final Pretrial Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 08/01/2026)
2026-08-01
1
[SEALED] EXHIBIT re 580 Proposed Pretrial Order Volume I (Exs. 1-12) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Farnan, Kelly) (Entered: 08/01/2026)
2026-08-01
1
[SEALED] EXHIBIT re 580 Proposed Pretrial Order Volume II (Exs. 13-19) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 13, # 2 Exhibit 14, # 3 Exhibit 15, # 4 Exhibit 16, # 5 Exhibit 17, # 6 Exhibit 18, # 7 Exhibit 19)(Farnan, Kelly) (Entered: 08/01/2026)
2026-08-01
1
ORAL ORDER: The Court, having reviewed Defendant Parse Biosciences, Inc.’s (“Parse”) motion for leave to file Daubert motions out of time to exclude Mr. Drew Mooney’s reasonable royalty opinions (“Motion”), (D.I. 560 ), and the briefing related thereto, (id.; D.I. 577 ), will now address the portion of the Motion relating to Parse’s Daubert motion requesting exclusion of Mr. Mooney’s opinions predicated on a legally incorrect hypothetical negotiation date, (D.I. 560 at 4-6; see also D.I. 572 ). For the reasons discussed herein, the Court hereby ORDERS that this portion of the Motion is DENIED: (1) With this portion of the Motion, Parse asks the Court to alter the Scheduling Order in this case to allow Parse to file a Daubert motion even though the deadline for filing such motions has long since passed. (D.I. 560 at 1, 3) “A schedule may be modified only for good cause and with the judge’s consent.” Fed. R. Civ. P. 16(b(4). In determining whether the party seeking leave to modify a court’s scheduling order has demonstrated good cause, courts first consider the threshold question of the diligence of that party. See, e.g., Brit. Telecommc’ns PLC v. IAC/InterActiveCorp, Civil Action No. 18-366-WCB, 2020 WL 3047989, at *2 (D. Del. June 8, 2020); GlaxoSmithKline LLC v. Glenmark Pharms. Inc., USA, Civil Action No. 14-877-LPS-CJB, 2016 WL 7319670, at *1 (D. Del. Dec 15, 2016). Whether a party acted diligently depends in part on whether the movant possessed, or though exercise of reasonable diligence should have possessed, the knowledge necessary to file the motion before the deadline expired (and otherwise was diligent in filing when they did). See, e.g., The Nielsen Co. (US), LLC v. TVision Insights, Inc., Civil Action No. 22-57-CJB, 2025 WL 5081334, at *2 (D. Del. Apr. 10, 2025).; (2) The actions taken by Parse here are not indicative of diligence. As Plaintiffs note, as early as October 2024, Mr. Mooney filed an expert report stating his opinion that February 2021—i.e., just before Parse allegedly launched the first accused product at issue in this litigation—is the proper date of the hypothetical negotiation for purposes of determining a reasonable royalty. (D.I. 577 at 2-3; id., ex. B at ¶ 116) And even if Parse were able to identify a reason why it could not have raised its concerns with Mr. Mooney’s hypothetical negotiation date via a Daubert motion filed by the original Daubert motion deadline in February 2025, then by September 2025, Parse surely should have known of the need to do so (since in that month, Parse and Plaintiffs began arguing about that very dispute). (D.I. 560 at 1-2; id. at 5 (“Plaintiffs have been on notice of Parse’s position that Mr. Mooney identified the wrong hypothetical negotiation date since at least September 2025[.]”); D.I. 577 at 2, 5; see D.I. 450 at ¶¶ 152-68) And yet despite being aware of this dispute since at least September 2025, Parse delayed almost a year in seeking leave to file a Daubert motion on this hypothetical negotiation date issue—ensuring that said motion would be briefed and addressed only at the last minute, during the weeks leading up to the now-scheduled August 24, 2026 trial date. (See D.I. 577 at 5 (Plaintiffs, noting the same)) And nothing about the fact that Mr. Mooney chose not to change his opinion about the date of the hypothetical negotiation in his more recent supplemental damages report alters the fact that Parse has known about this dispute for many months. (D.I. 560 at 5; D.I. 577 at 5) Because Parse simply was not diligent, there cannot be good cause to permit the filing now under Rule 16(b).; and (3) In light of the Court’s decision herein, it also hereby ORDERS that Parse’s motion to exclude opinions and testimony of Mr. Drew Mooney based on a legally erroneous hypothetical negotiation date, (D.I. 572 ), is DENIED as MOOT. As such, Plaintiffs no longer need to submit a responsive brief related thereto. Ordered by Judge Christopher J. Burke on 08/03/2026. (sam) (Entered: 08/03/2026)
2026-08-03
1
ORAL ORDER: The Court, having reviewed Defendant Parse Biosciences, Inc.’s (“Parse”) motion for leave to file Daubert motions out of time to exclude Mr. Drew Mooney’s reasonable royalty opinions (“Motion”), (D.I. 560 ), and the briefing related thereto, (id.; D.I. 577 ), will now address the Motion as it relates to Parse’s Daubert motion to exclude Mr. Mooney’s opinions and testimony relying on the incorrect application of the Book of Wisdom, (D.I. 560 at 3-4; see D.I. 571 ). For the reasons discussed herein, the Court hereby ORDERS that this portion of the Motion is GRANTED: (1) The Court incorporates by reference its prior discussion of the “good cause” standard for addressing a party’s motion to alter the case schedule (and to thus be permitted to file a Daubert motion after the deadline for such motions has already long since passed). (D.I. 583) In contrast with Parse’s efforts laid out in connection with the other portion of the Motion (i.e., as to the hypothetical negotiation date issue), here the Court finds that Parse did act diligently in raising this Book of Wisdom Daubert-related issue. That’s because the portion of Mr. Mooney’s supplemental expert report at issue: (a) was only submitted recently, on July 14, 2026, (D.I. 560 at 3; see D.I. 577, ex. G); and (b) relates to a November 2025 acquisition of Parse, which in turn became the subject of discovery in this case only in April 2026, (D.I. 531 ). Because the acquisition took place about 9 months after the original Daubert motion filing deadline, and because Parse moved for leave to file its Daubert motion within 10 days after the submission of Mr. Mooney’s supplemental expert report at issue, then at least from a diligence perspective, it seems fair to allow Parse to file the proposed (narrow) Daubert motion and challenge the new information and opinions at issue found in the supplemental report. See e.g., Helios Software LLC v. SpectorSoft Corp., Civil Action No. 12-81-LPS, D.I. 546 (D. Del. Jan. 22, 2015).; (2) Nor have Plaintiffs identified any other compelling reason to put the brakes on that briefing process. See Brit. Telecommc’ns PLC v. IAC/InterActiveCorp, Civil Action No. 18-366-WCB, 2020 WL 3047989, at *2 (D. Del. June 8, 2020) (setting out additional considerations, aside from diligence, that often go into a “good cause” assessment). The only consideration Plaintiffs raise on this front is their assertion that the Daubert motion at issue will be futile. (D.I. 577 at 6) Plaintiffs may be right that they’ll ultimately prevail on the Daubert challenge relating to the Book of Wisdom issue. But that question will be better assessed after the Court reviews the relevant briefs in full.; and (3) In light of the Court’s decision to grant this portion of the Motion, Plaintiffs shall submit its responsive brief to Parse’s Motion to exclude opinions and testimony of Mr. Drew Mooney improperly relying on the Book of Wisdom, (D.I. 571 ), in the manner contemplated by the Court’s prior order, (D.I. 568 ). Ordered by Judge Christopher J. Burke on 08/03/2026. (sam) (Entered: 08/03/2026)
2026-08-03
1
Proposed Preliminary Jury Instructions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Farnan, Kelly) Modified on 8/4/2026 (sam). (Entered: 08/03/2026)
2026-08-03
1
Proposed Final Jury Instructions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Farnan, Kelly) Modified on 8/4/2026 (sam). (Entered: 08/03/2026)
2026-08-03
1
Proposed Voir Dire by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 08/03/2026)
2026-08-03
1
Parse's Proposed VERDICT SHEET by Parse Biosciences, Inc. (Pascale, Karen) Modified on 8/4/2026 (sam). (Entered: 08/03/2026)
2026-08-03
1
Plaintiffs' Proposed VERDICT SHEET by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. (Farnan, Kelly) Modified on 8/4/2026 (sam). (Entered: 08/03/2026)
2026-08-03
1
Order on Motion for Leave to File AND Order on Motion for Miscellaneous Relief
2026-08-03
1
No Actions
Oral Order
2026-08-03
1
No Actions
MOTION to Preclude Plaintiffs' Motion to Strike Certain Opinions from DeForest McDuff, Ph.D.'s Second Supplemental Report - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 7.1.1 Certification, # 2 Text of Proposed Order)(Farnan, Kelly) (Entered: 08/04/2026)
2026-08-04
1
[SEALED] Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Opening Letter Brief - re 590 MOTION to Preclude Plaintiffs' Motion to Strike Certain Opinions from DeForest McDuff, Ph.D.'s Second Supplemental Report. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)(Farnan, Kelly) (Entered: 08/04/2026)
2026-08-04
1
MEMORANDUM OPINION re D.I. 318 Motion for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents - filed by Parse Biosciences, Inc. Signed by Judge Christopher J. Burke on 08/04/2026. (sam) (Entered: 08/04/2026)
2026-08-04
1
ORDER: For the reasons stated in the Memorandum Opinion issued this same date, (D.I. 592 ), IT IS HEREBY ORDERED that Defendant Parse Biosciences, Inc.'s "Motion for Summary Judgment #3: Parse Does Not Literally Infringe the '442, '256, or '752 Patents[,]" (D.I. 318 ), filed pursuant to Federal Rule of Civil Procedure 56, is DENIED. Signed by Judge Christopher J. Burke on 08/04/2026. (sam) (Entered: 08/04/2026)
2026-08-04
1
[SEALED] RESPONSE to Motion re 573 MOTION to Strike Parse's Motion to Strike Certain Documents from Plaintiffs' Trial Exhibit List, Preclude Related Evidence and Testimony, and Strike Opinions from Mr. Mooney's Second Supplemental Report that Rely on Such Documents (Opposition) filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16)(Farnan, Kelly) (Entered: 08/05/2026)
2026-08-05
1
[SEALED] RESPONSE to Motion re 571 MOTION to Exclude Opinions and Testimony of Mr. Drew Mooney Improperly Relying on the Book of Wisdom (Expedited Consideration Requested) (Opposition) filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Farnan, Kelly) (Entered: 08/05/2026)
2026-08-05
1
STIPULATION TO EXTEND TIME (See Stipulation for Details) to September 28, 2026 - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 08/06/2026)
2026-08-06
1
ORAL ORDER: The Court advises the parties that at tomorrow's Pre-trial Conference, it will review courtroom procedures relating to trial and hear argument on any disputes referenced in the body of the proposed Pretrial Order, (D.I. 580 ), as well as on motions in limine. The parties should be prepared to argue those issues tomorrow. Ordered by Judge Christopher J. Burke on 08/06/2026. (sam) (Entered: 08/06/2026)
2026-08-06
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Electronic Devices - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 08/06/2026)
2026-08-06
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for August 7, 2026 Pretrial Conference - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 08/06/2026)
2026-08-06
1
ORDER Granting D.I. 598 Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Electronic Devices - filed by Parse Biosciences, Inc. Signed by Judge Christopher J. Burke on 08/06/2026. (sam) (Entered: 08/06/2026)
2026-08-06
1
ORDER granting D.I. 599 MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for August 7, 2026 Pretrial Conference - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Signed by Judge Christopher J. Burke on 08/06/2026. (sam) (Main Document 601 replaced on 8/6/2026) (sam). (Entered: 08/06/2026)
2026-08-06
1
[SEALED] Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding reply letter brief in support of motion to strike - re 573 MOTION to Strike Parse's Motion to Strike Certain Documents from Plaintiffs' Trial Exhibit List, Preclude Related Evidence and Testimony, and Strike Opinions from Mr. Mooney's Second Supplemental Report that Rely on Such Documents or Exceed the Scope of Supplementation Authorized by the Court. (Attachments: # 1 Exhibit K-O)(Pascale, Karen) Modified on 8/6/2026 (sam). (Entered: 08/06/2026)
2026-08-06
1
Oral Order
2026-08-06
1
No Actions
- CORRECTING ENTRY
2026-08-06
1
No Actions
CORRECTING ENTRY: Docket text of D.I. 602 has been modified per request of filing counsel to link letter brief to correct motion. NEF regenerated. (sam)
2026-08-06
1
No Actions
Order on Motion on Stipulation to Extend Time
2026-08-07
1
No Actions
SO ORDERED, D.I. 596 STIPULATION TO EXTEND TIME (See Stipulation for Details) to September 28, 2026 filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 08/07/2026. (sam)
2026-08-07
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Pretrial Conference held on 8/7/2026. The Court discussed issues relating to the upcoming trial with the parties. The Court ordered that each side will receive 12 hours of trial time. The Court resolved various disputes raised in the proposed pretrial order and ordered the parties to submit a final revised pretrial order by close of business on August 11, 2026 consistent with the Courtis guidance. Additionally, the Court ordered the parties to further meet and confer regarding certain disputes and to submit a joint letter by close of business on August 14, 2026 that indicates whether the disputes have been resolved and, if not, indicates what remains of those disputes. Further, the Court ordered the parties to submit revised versions of the proposed final jury instructions and verdict form (along with their positions on any disputes contained therein) by no later than August 19, 2026. The Court also ordered the parties to have another substantive discussion regarding settlement before trial. Finally, the Court heard argument on certain of the motions in limine. The Court will issue rulings on those motions in limine and other remaining pending motions shortly. Defendant made an oral motion to seal the transcript of the pretrial conference and will file a motion to redact in accordance with the Court's policies. Appearances: K. Farnan, S. Metzler, M. Powers, A. Hadzimehmedovic, P. Ehrlich, S. Jameson, D. Kazhdan, J. Pierce, and M. Laupheimer for Plaintiffs; K. Pascale, A. Gaza, S. Wilson, B. Pickard, R. Powers, C. Vira, A. Phillips, B. Gleason, and I. Helman for Defendant. (Clerk: W. Roberts, J. Bell; Court reporter: Stacy Ingram) (sam)
2026-08-07
1
No Actions
Pretrial Conference
2026-08-10
1
No Actions
FINAL Voir Dire Questions to be read in open court. (sam) (Entered: 08/11/2026)
2026-08-11
1
[SEALED] Proposed Pretrial Order Revised Joint [Proposed] Final Pretrial Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 08/11/2026)
2026-08-11
1
[SEALED] EXHIBIT re 604 Proposed Pretrial Order Volume I (Exs. 1-12) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Farnan, Kelly) (Entered: 08/11/2026)
2026-08-11
1
[SEALED] EXHIBIT re 604 Proposed Pretrial Order Volume II (Exs. 13-19) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 13, # 2 Exhibit 14, # 3 Exhibit 15, # 4 Exhibit 16, # 5 Exhibit 17, # 6 Exhibit 18, # 7 Exhibit 19)(Farnan, Kelly) (Entered: 08/11/2026)
2026-08-11
1
[SEALED] Letter to The Honorable Christopher J. Burke from Karen L. Pascale regarding Parses Opposition to Plaintiffs Motion to Strike Certain Opinions from Dr. DeForest McDuff's Second Supplemental Expert Report - re 590 MOTION to Preclude Plaintiffs' Motion to Strike Certain Opinions from DeForest McDuff, Ph.D.'s Second Supplemental Report. (Pascale, Karen) (Main Document 607 replaced on 8/12/2026) (mpb). (Entered: 08/11/2026)
2026-08-11
1
[SEALED] EXHIBIT re 607 Letter, Exhibits A-L in Support of Parse's Opposition to Plaintiffs' Motion to Strike Certain Opinions from Dr. DeForest McDuff's Second Supplemental Expert Report by Parse Biosciences, Inc.. (Pascale, Karen) (Main Document 608 replaced on 8/12/2026) (mpb). (Entered: 08/11/2026)
2026-08-11
1
MOTION for Pro Hac Vice Appearance of Attorney Hadia S. Ahsan - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 08/12/2026)
2026-08-12
1
Pro Hac Vice Fee - Credit Card Payment received for Hadia S. Ahsan. ( re 609 MOTION for Pro Hac Vice Appearance of Attorney Hadia S. Ahsan )( Payment of $ 50, receipt number ADEDC-5039996).(Wilson, Samantha) (Entered: 08/12/2026)
2026-08-12
1
MEMORANDUM ORDER regarding Defendant Parse Biosciences, Inc.'s motion in limine #2. Signed by Judge Christopher J. Burke on 8/12/2026.This order has been emailed to local counsel. (mlc) Unsealed on 9/30/2026, no redactions requested from parties. (sam). (Main Document 611 replaced on 9/30/2026) (sam). (Entered: 08/12/2026)
2026-08-12
1
[SEALED] SO ORDERED, re 604 Proposed Revised Joint Final Pretrial Order filed by Scale Biosciences, Inc., Roche Sequencing Solutions, Inc.. Signed by Judge Christopher J. Burke on 8/12/2026.This order has been emailed to local counsel. (mlc) (Entered: 08/12/2026)
2026-08-12
1
MEMORANDUM ORDER regarding Defendant Parse Biosciences, Inc.'s motion in limine #1. Signed by Judge Christopher J. Burke on 8/12/2026.This order has been emailed to local counsel. (mlc) Unsealed on 9/30/2026, no redactions requested from parties. (sam). (Main Document 613 replaced on 9/30/2026) (sam). (Entered: 08/12/2026)
2026-08-12
1
- CORRECTING ENTRY
2026-08-12
1
No Actions
-District Court Pro Hac Vice Fee - 01 Attorney Credit Card Payment
2026-08-12
1
No Actions
CORRECTING ENTRY: Per Counsel's request, the main documents of D.I. 607 and 608 have been replaced to reflect the removal of typographical errors. (mpb)
2026-08-12
1
No Actions
[SEALED] Letter to The Honorable Christopher J. Burke from Kelly E. Farnan - re 590 MOTION to Preclude Plaintiffs' Motion to Strike Certain Opinions from DeForest McDuff, Ph.D.'s Second Supplemental Report. (Attachments: # 1 Exhibit 8, # 2 Exhibit 9, # 3 Exhibit 10)(Farnan, Kelly) (Entered: 08/14/2026)
2026-08-14
1
Joint Letter regarding Representative Products. (Attachments: # 1 Exhibit 1)(Farnan, Kelly) (Entered: 08/14/2026)
2026-08-14
1
Joint Letter regarding Representative Products. (Attachments: # 1 Exhibit 1)(Farnan, Kelly) (Entered: 08/14/2026)
2026-08-14
2
ORAL ORDER Setting Teleconference: The Court, having reviewed Defendant Parse Bioscience, Inc.’s motion to strike, (D.I. 555 ), hereby ORDERS that a teleconference is set for August 18, 2026 at 3:00 p.m. before Judge Christopher J. Burke. By no later than 5:00 p.m. on August 17, 2026 the parties shall provide the Court's Courtroom Deputy, Ms. Miller, with the names and e-mail addresses of all individuals who will participate in the teleconference and a dial-in number for the call via e-mail. Ordered by Judge Christopher J. Burke on 08/17/2026. (sam) (Entered: 08/17/2026)
2026-08-17
1
ORAL ORDER: The Court, having reviewed the parties’ August 14, 2026 joint letter regarding representative products, (D.I. 615 ), hereby ORDERS that the parties should be prepared to briefly discuss this issue on tomorrow’s teleconference. It appears that in concept, the parties may be able to agree that there are six representative products, and that the dispute that remains is over whether Parse’s two evidence presentation issues (“conditions”) should be agreeable as well. At first glance, what Parse is proposing there as to those two conditions seems to track with how the Court would typically understand a representativeness agreement to work. On the teleconference, the parties should be prepared to discuss Parse’s two conditions, and why they are/are not appropriate. Ordered by Judge Christopher J. Burke on 08/17/2026. (sam) (Entered: 08/17/2026)
2026-08-17
1
ORAL ORDER: The Court, having reviewed Plaintiffs Scale Biosciences, Inc. and Roche Sequencing Solutions, Inc.’s (collectively, “Scale”) motion in limine #1 (“Motion”) and the briefing related thereto, (D.I. 582, ex. 14), via which Scale asks the Court to preclude Defendant Parse Biosciences, Inc. (“Parse”) from presenting evidence at trial related to, or otherwise arguing that, Parse “lacked the belief, intent [i.e., the relevant mental state], and affirmative steps for indirect infringement[,]” (id. at Reply Brief at 1), hereby orders the Motion is GRANTED-IN-PART and DENIED-IN-PART in the manner and for the reasons that follow: (1) Scale’s “motion in limine” is really a motion to strike—with Scale seeking to strike what it labels as Parse’s “new non-infringement contentions” as to certain elements of the indirect infringement inquiry. (Id. at Opening Brief at 1) That said, the Court will consider and resolve that Motion here, as it sees no undue prejudice to Parse in doing so (since Scale could have filed this Motion separately as a motion to strike, and instead, essentially gave up one of its motions in limine to do so).; (2) The Court first addresses Scale’s arguments regarding Parse’s mental state. In response to Scale’s assertion that Parse never disclosed a non-infringement position as to these elements during discovery (or otherwise prior to July 2026), Parse pointed to certain of its prior statements, including the content of a pre-suit letter it sent to Scale, certain of its non-infringement contentions, and to portions of its expert’s non-infringement report. (Id. at Answering Brief at 1-2) Those citations weren’t slam dunks, in that in those documents, Parse never substantive and explicitly addressed the mental state-related elements of indirect infringement claims that are at issue here. Instead, therein, Parse tended to simply articulate why there was no underlying act of direct infringement by its customers. (Id.) That said, while those statements may not have directly addressed Parse’s mindset regarding infringement in specific terms, they did repeatedly communicate Parse’s view that there was no direct infringement. And it is axiomatic that “where there has been no direct infringement, there can be no [indirect] infringement under [Section] 271[.]” Limelight Networks, Inc. v. Akamai Techs., Inc., 572 U.S. 915, 922 (2014). And so the content of Parse’s statements weren’t far afield from an assertion that it did not knowingly indirectly infringe, or do so with the requisite intent. Moreover, it appears Scale understood that Parse was contesting its mental state for purposes of indirect infringement, as in Scale’s Final Infringement Contentions, it repeatedly acknowledged as much. (D.I. 582, ex. 2 at 42 (“Even if Parse did not know it was infringing the [asserted claims] when it first learned of the [asserted patents] Parse knew it was infringing when the District Court rejected Parse’s construction of ‘unique binding agent.’ ... Moreover, once this litigation determines that making, using, offering for sale, and/or selling of the [accused products] infringes the [asserted claims], Parse will know that it is inducing infringement of the [asserted patents].”)) Therefore, with regard to Parse’s mental state, the Court cannot conclude that Parse’s disclosures at issue were untimely; thus, this portion of Scale’s Motion is DENIED.; (3) However, with respect to whether Parse took “affirmative steps” to indirectly infringe, Scale’s motion is GRANTED. 35 U.S.C. Section 271(b) requires “‘activ[e],’ not passive, inducement[,]” and for the accused infringer to take “‘affirmative steps to bring about the desired result’ of infringement.” Hikma Pharms. USA Inc. v. Amarin Pharma, Inc., 146 S. Ct. 1391, 1402 (2026) (citations omitted). In all the cited contentions, interrogatory responses, and expert reports, the Court could find no mention, even obliquely, to suggest that Parse had ever raised some separate dispute as to whether it took affirmative steps to indirectly infringe (e.g., by disputing that a particular part of a relevant user manual could amount to encouragement of infringement). So any recent assertion otherwise would be untimely. And generally for the reasons indicated by Scale in its Motion—and particularly now that trial is now just a week away—the Pennypack factors indicate that this late disclosure cannot be substantially justified or harmless. See Bausch & Lomb Inc. v. SBH Holdings LLC, No. 20-1463-GBW-CJB, D.I. 250 (D. Del. Feb. 5, 2025).; and (4) In sum, Parse is precluded at trial from introducing evidence or argument that it did not indirectly infringe due to a failure to take “affirmative steps” to bring about infringement. But Parse can introduce evidence or argument that it lacked the belief, intent, or mental state to indirectly infringe. Ordered by Judge Christopher J. Burke on 08/17/2026. (sam) (Entered: 08/17/2026)
2026-08-17
1
MEMORANDUM ORDER GRANTING-IN-PART and DENYING-IN-PART, Plaintiffs Scale Biosciences, Inc., and Roche Sequencing Solutions, Inc.'s motion in limine #2, (D.I. 582, ex. 15). Any such redacted version shall be submitted no later than September 28, 2026 for review by the Court. Signed by Judge Christopher J. Burke on 08/17/2026. This order has been emailed to local counsel. (sam) Unsealed on 9/30/2026, no redactions requested from parties. (sam). (Main Document 619 replaced on 9/30/2026) (sam). (Entered: 08/17/2026)
2026-08-17
1
Order Setting Teleconference
2026-08-17
1
No Actions
Order on Motion to Appear Pro Hac Vice
2026-08-17
1
No Actions
Oral Order
2026-08-17
1
No Actions
SO ORDERED, D.I. 609 Motion for Pro Hac Vice Appearance of Attorney Hadia S. Ahsan - filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 08/17/2026. (sam)
2026-08-17
1
No Actions
ORAL ORDER: The Court, having reviewed Parse’s motion to exclude opinions and testimony of Plaintiffs’ expert Mr. Drew Mooney due to his reliance on the Book of Wisdom (“Motion”), (D.I. 571 ), and the briefing related thereto, (D.I. 571 ; D.I. 595 ), hereby ORDERS that the Motion is DENIED for the reasons set out in Plaintiffs’ answering brief, (see generally D.I. 595 ). The Daubert standard regarding reliability is a forgiving one, see 360Heros, Inc. v. GoPro, Inc., 569 F. Supp. 3d 198, 201 (D. Del. 2021), and Plaintiffs and Mr. Mooney have sufficiently articulated how, as to the subjects at issue (i.e., the prospect of a Parse/Qiagen merger and the consideration that might be paid in such a transaction, the future value of Parse’s relevant products and assets, Parse’s likely future revenues, sales and profits, the future validity of Parse’s patents, and Parse’s future market status), these are the types of subjects that would have been contemplated by the hypothetical negotiators in 2021 and that this evidence would have been foreseeable to those negotiators. And nothing in the United States Court of Appeals for the Federal Circuit’s recent decision in 4DD Holdings, LLC v. United States, 181 F.4th 1363 (Fed. Cir. 2026)—a case relied on heavily by Parse in support of its Motion—precludes the application of the Book of Wisdom to such potentially foreseeable events here. Id. at 1372-74; see also (D.I. 595 at 7-8). Instead, Parse’s disputes with Mr. Mooney’s analysis on those fronts are more properly raised at trial. See I-Mab Biopharma v. Inhibrx, Inc., Civil Action No. 22-276-CJB, 2024 WL 4555870, at *3 (D. Del. Oct. 17, 2024). To the extent any of Mr. Mooney’s testimony is challenged on some different ground in other pending motions, the Court’s Order here does not speak to those issues. Ordered by Judge Christopher J. Burke on 08/18/2026. (sam) (Entered: 08/18/2026)
2026-08-18
1
MEMORANDUM OPINION re D.I. 316 Parse's Motion for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features. (See Memorandum Opinion for further details.) Signed by Judge Christopher J. Burke on 08/18/2026. (sam) (Entered: 08/18/2026)
2026-08-18
1
ORDER: Parse Biosciences, Inc.'s Motion for Summary Judgment #2: The Asserted Claims are Invalid Under Section 112 for Failing to Claim Essential Features[,] (D.I. 316 ), filed pursuant to Federal Rule of Civil Procedure 56, is DENIED. Signed by Judge Christopher J. Burke on 08/18/2026. (sam) (Entered: 08/18/2026)
2026-08-18
1
Pro Hac Vice Attorney Hadia S. Ahsan for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (slk)
2026-08-18
1
No Actions
Add Attorneys - PHV only
2026-08-18
1
No Actions
Order on Motion for Miscellaneous Relief
2026-08-18
1
No Actions
Telephone Conference
2026-08-18
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Teleconference held on 8/18/2026. The Court heard argument on Parse's Motion to Strike Dr. Michael Schnall-Levin from Scale's Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooney's Second Supplemental Expert Report that Rely on Information from Dr. Schnall-Levin ("Motion"), (D.I. 555 ). The Court informed the parties of its decision on the Motion. An oral order resolving the Motion will follow. The Court also addressed a dispute identified in the parties' August 14, 2026 joint letter regarding representative products, (D.I. 615). (Clerk: W. Roberts, J. Bell; Court reporter: Stacy Ingram) Appearances: S. Metzler, M. Powers, A. Hadzimehmedovic, and M. Laupheimer for Plaintiffs; K. Pascale, A. Gaza, S. Wilson, B. Pickard, R. Powers, C. Vira, and A. Phillips for Defendant. (sam)
2026-08-18
1
No Actions
MEMORANDUM ORDER: Plaintiffs Scale Biosciences, Inc. and Roche Sequencing Solution, Inc.'s motion in limine #3, (D.I. 582, ex. 16), is DENIED. Signed by Judge Christopher J. Burke on 08/19/2026. This order has been emailed to local counsel. (sam) Unsealed on 9/30/2026, no redactions requested from parties. (sam). (Main Document 623 replaced on 9/30/2026) (sam). (Entered: 08/19/2026)
2026-08-19
1
ORAL ORDER: The Court, having reviewed Parse’s “Motion to Strike Dr. Michael Schnall-Levin from Scale’s Second Supplemental Rule 26 Disclosures, to Preclude Dr. Schnall-Levin from Testifying at Trial, and to Strike Opinions in Mr. Drew Mooney’s Second Supplemental Expert Report that Rely on Information from Dr. Schnall-Levin” (“Motion”), (D.I. 555 ), the briefing related thereto, (D.I. 556 ; D.I. 559 ; D.I. 566 ), and having heard argument on the Motion on a teleconference held on August 18, 2026, hereby ORDERS that Motion is GRANTED-IN-PART and DENIED-IN-PART, in that it is GRANTED as to evidence and testimony relating to the asserted fact “that Scale[]’s QuantumScale and Parse’s accused Evercode products compete directly in a subset of the single-cell analysis market” (the “direct competition evidence”) and DENIED as to evidence and testimony relating to “the current post-merger commercial activity by Scale[] and 10x [Genomics, Inc. (‘10x’)], including that they continue to sell and support Scale[]’s QuantumScale products” (the “post-merger commercial activity evidence,” and together with the “direct competition evidence,” the “two categories at issue”). (D.I. 559 at 1) The Court does so for the reasons that follow: (1) There is little question that Plaintiffs’ June 2026 supplemental Fed. Rule Civ. P. 26 disclosure identifying Dr. Schnall-Levin as a witness was untimely pursuant to Rule 26; indeed, Scale does not strongly argue to the contrary in its answering brief. (See id. at 1-5) As to either of the two categories at issue, Scale could have and should have anticipated the need to advise Parse of Dr. Schnall-Levin’s assertedly necessary testimony (and to engage in any related discovery that Parse might have sought thereafter) many months before June 2026. Indeed, when it came to other evidence arising in 2025/2026 (i.e., certain acquisition-related evidence) that Scale thought would be relevant to our current trial, Scale knew to front the issue promptly and to seek to reopen discovery—well before June 2026. (D.I. 513 ; D.I. 529 ; D.I. 531 ) But Scale did not do so as to the two categories at issue here until the eleventh hour.; (2) Because Scale’s efforts here were clearly untimely, nearly all of the parties’ briefing focuses on the Pennypack factors—and on whether Scale’s late disclosure was substantially justified or harmless, pursuant to Fed. R. Civ. P. 37(c). On that score, the outcome differs, depending on the category of evidence at issue.; (3) Scale’s late disclosure was not justified or harmless as to the direct competition evidence. That’s because there, Scale seeks to have Mr. Mooney, relying on Dr. Schnall-Levin’s testimony, bolster his damages opinion by asserting that Scale’s QuantumScale products directly compete with the accused Parse products—a complicated, nuanced topic, on which Parse should have (but did not) get the opportunity to take fulsome discovery. Instead, earlier in the case, Scale admits it refused to provide Parse with significant discovery on these QuantumScale products, including as to an ESI collection. (D.I. 559 at 4; see also D.I. 556 at 2) And now, it is entirely too late for Parse to be able to accomplish that type of discovery, as we are less than a week from the trial date. See Liqwd, Inc. v. L’Oreal USA, Inc., Civil Action No. 17-14-JFB-SRF, 2019 WL 7945247, at *1-2 (D. Del. June 25, 2019). Nor does the direct competition evidence seem particularly crucial to Mr. Mooney’s damages opinions, given that even Mr. Mooney “acknowledges that the evidence [on that score] do[es] not change his opinion that ‘the parties would have agreed to a reasonable royalty of 14%.’” (D.I. 556 at 3 (citation omitted)) Given the unjustified prejudice to Parse, the lack of ability to cure that prejudice through additional discovery, the proximity of trial, and the lack of relative importance of this evidence, “this is decidedly not a situation where the schedule [can or] should flex to accommodate” Scale’s late disclosure. Corteva Agriscience LLC v. Inari Agric., Inc., CIVIL ACTION NO. 23-1059, 2026 WL 574624, *4 (D. Del. Mar. 2, 2026).; and (4) That said, the picture seems different with regard to the post-merger commercial activity evidence. During the teleconference, Scale assured the Court that this category of evidence would be narrow and cabined. Moreover, the Court understands Scale’s desire to have a knowledgeable current employee/party representative speak about its current state as a company—in part, so that the jury is not left “with the false impression that Scale[] no longer sells anything at all.” (D.I. 559 at 3) On this topic, the prejudice of the late disclosure to Parse is minimal. And any prejudice can be cured through a short deposition of Dr. Schnall-Levin (which Scale has been offering for weeks) without disrupting next week’s trial. Parse may take Dr. Schnall-Levin’s deposition on that limited subject matter if it wishes; if Parse does seek to do so, the Court will permit a no more than two-hour deposition on the subject to occur prior to the start of trial (with the parties to work out the details). Ordered by Judge Christopher J. Burke on 08/19/2026. (sam) (Entered: 08/19/2026)
2026-08-19
1
ORAL ORDER: The Court, having reviewed Plaintiffs’ “Motion to Strike Certain Opinions from DeForest McDuff, Ph.D.’s Second Supplemental Report” (“Motion”), (D.I. 590 ), and the briefing related thereto, (D.I. 591 ; D.I. 607 ; D.I. 614 ), hereby addresses the Motion as it relates to four out of the five disputes discussed by the parties in their briefing. These disputes all relate to certain portions of Dr. McDuff’s Second Supplemental Expert Report dated July 24, 2026 (“Dr. McDuff’s July 2026 report” or the “July 2026 report”). In assessing the Motion, the Court has considered Fed. R. Civ. P. 26, Fed. R. Civ. P. 37, and (to the extent necessary) the Pennypack factors. It hereby ORDERS as follows: (1) As to the parties’ dispute over Dr. McDuff’s challenges to Plaintiff’s damages expert Mr. Drew Mooney’s royalty base calculations and methodology, (D.I. 591 at 2; D.I. 607 at 4; D.I. 614 at 2), which in turn relates to the opinions found in paragraphs 71-74 of Dr. McDuff’s July 2026 report, (D.I. 591, ex. 3 at ¶¶ 71-74), Plaintiffs’ request is DENIED. The Court declines to find these opinions untimely pursuant to Rule 26(a). This is because Parse alleges (and Plaintiffs do not seriously dispute) that: (a) Mr. Mooney’s methodology for determining the appropriate royalty base (i.e., using a particular methodology to determine whether certain sales were for infringing cell fixation uses or non-accused nuclei fixation uses) was first raised only in Mr. Mooney’s September 9, 2025 Supplemental Expert Report; and (b) Dr. McDuff did not, pursuant to the case schedule, have any expert report due thereafter in which he could have responded to Mr. Mooney’s newly-raised methodology. Had the trial in this case taken place as previously scheduled in October 2025, Dr. McDuff would have been given some leeway to respond to Mr. Mooney’s new methodology, even though Dr. McDuff’s opinions in that regard would not have been formally laid out in any expert report. And so, the fact that Dr. McDuff has now put that response in writing in his July 2026 report is not problematic here (indeed, it helps Plaintiffs, as they now have a good sense of what he will say on the matter).; (2) As to the parties’ dispute over Dr. McDuff’s new opinions regarding the appropriate hypothetical negotiation date, (D.I. 591 at 2; D.I. 607 at 4; D.I. 614 at 2), which are found in paragraph 37 of Dr. McDuff’s July 2026 report, (D.I. 591 at 2), Plaintiffs’ request is GRANTED. Dr. McDuff’s new opinion that the date of the hypothetical negotiation should be May 2020 (instead of February 2021—the date relied on by both parties and their experts throughout much of this case, (id. (citing D.I. 519 at 2); see also D.I. 591, ex. 6 at ¶ 109)), is super untimely pursuant to Rule 26(a). There is simply no justification for why Dr. McDuff could not have introduced this view back in 2024 as part of his November 12, 2024 expert report, especially since all of the sources that Dr. McDuff relies on for this new opinion date back to 2024. (See D.I. 591, ex. 3 at ¶ 37 nn.86-92) And even if Dr. McDuff and Parse didn’t think to provide this new opinion back in November 2024, at a minimum, they should have put it forward well before July 2026 (i.e., only one month before trial). Nor does the Court see how this new opinion could be considered rebuttal testimony to Mr. Mooney’s July 14, 2026 Supplemental Expert Report, because it is not responsive to any new opinions or information found in that report. Moreover, the Pennypack factors could not save Parse here, as there is not sufficient time before the upcoming trial to permit the parties to make a reasoned examination about whether a new and different hypothetical negotiation date is appropriate (in light of all of the associated impacts that such a date might have on the damages landscape).; (3) With regard to the parties’ dispute over Dr. McDuff’s opinions about the effect that the recent invalidation of the Parse asserted parents would have on the use of the UW License in determining the reasonable royalty rate, (D.I. 591 at 2-3; D.I. 607 at 4-5; D.I. 614 at 2), Plaintiffs request is DENIED. Dr. McDuff’s opinions on this score, (D.I. 591, ex. 3 at ¶ 44), are directly responsive to Mr. Mooney’s new opinions about the impact of the invalidation (that only occurred in June 2026), (see D.I. 608, ex. E at ¶ 64 (“The invalidation of UW’s patents would have created an upward pressure on the hypothetical negotiation[.]”)), and thus are not untimely. (D.I. 607 at 4) To the extent that Plaintiffs think that with these opinions, Dr. McDuff is contradicting certain of his prior views about the value or importance of the Parse patents, (see D.I. 614 at 2), they can cross examine him on that alleged inconsistency.; and (4) As to the parties’ dispute over Dr. McDuff’s opinions that rely on a September 2025 stipulation to critique Mr. Mooney’s built-in apportionment analysis, (D.I. 591 at 3; D.I. 607 at 5; D.I. 614 at 2), Plaintiffs’ request is DENIED. Regardless of whether the Court could find the content at issue (i.e., paragraphs 67-68 of Dr. McDuff’s July 2026 report) violative of Rule 26(a), the opinions should not be struck pursuant to Rule 37(c). That’s because their inclusion in Dr. McDuff’s July 2026 report is harmless, in that those opinions don’t appear substantively different from what Dr. McDuff timely said on the subject in paragraph 88 of his November 12, 2024 expert report. (D.I. 591, ex. 3 at ¶¶ 67-68; id., ex. 6 at ¶ 88) Ordered by Judge Christopher J. Burke on 08/19/2026. (sam) (Entered: 08/19/2026)
2026-08-19
1
ORAL ORDER: In light of the Court’s recent rulings, in which the Court struck evidence relating to Parse’s proposed May 2020 hypothetical negotiation date (such that the jury will not hear about that date at trial), (D.I. 625 ), and in which the Court found that Parse was precluded from filing a Daubert motion challenging Plaintiffs’ proposed February 2021 hypothetical negotiation date, (D.I. 583 ), the Court presumes that Parse’s motion in limine #3, (D.I. 582, ex. 19), is now MOOT. By no later than 5:00 p.m. on August 20, 2026, Parse shall file a one-page single-spaced letter indicating whether this is so (and if not, why not). Ordered by Judge Christopher J. Burke on 08/19/2026. (sam) (Entered: 08/19/2026)
2026-08-19
1
ORAL ORDER: The Court, having reviewed Parse’s Motion to Strike Certain Documents from Plaintiffs’ Trial Exhibit List, Preclude Related Evidence and Testimony, and Strike Opinions from Mr. Mooney’s Second Supplemental Report that Rely on Such Documents or Exceed the Scope of Supplementation Authorized by the Court (“Motion”), (D.I. 573 ), and the briefing related thereto, (D.I. 574 ; D.I. 594 ; D.I. 602 ), hereby ORDERS that the Motion is DENIED without prejudice to renew. It strikes the Court that: (1) some of its recent decisions should lend to the parties being able to resolve some or (hopefully) all of the remaining disputes referenced in the Motion on their own.; and (2) to the extent they can’t, these are the kinds of disputes that the Court would typically resolve on the morning of a trial day or, failing that, during trial (which is what it will do here, if need be). Ordered by Judge Christopher J. Burke on 08/19/2026. (sam) (Entered: 08/19/2026)
2026-08-19
1
Letter to The Honorable Christopher J. Burke from Kelly E. Farnan regarding Verdict Form Disputes. (Attachments: # 1 Exhibit A - Plaintiffs' Verdict Form, # 2 Exhibit B - Defendant's Verdict Form, # 3 Exhibit C - Proposed Final Jury Instructions)(Metzler, Sara) (Entered: 08/20/2026)
2026-08-19
1
Oral Order
2026-08-19
1
No Actions
Order on Motion to Strike
2026-08-19
1
No Actions
MOTION Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order)(Metzler, Sara) (Entered: 08/20/2026)
2026-08-20
1
MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Electronic Devices - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 08/20/2026)
2026-08-20
1
ORDER Granting D.I. 629 MOTION Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for Courtroom Technology Setup and Trial - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Signed by Judge Christopher J. Burke on 08/20/2026. (sam) (Entered: 08/20/2026)
2026-08-20
1
ORDER Granting D.I. 630 MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Electronic Devices - filed by Parse Biosciences, Inc. Signed by Judge Christopher J. Burke on 08/20/2026. (sam) (Entered: 08/20/2026)
2026-08-20
1
Proposed Jury Instructions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Preliminary Jury Instructions. (Metzler, Sara) (Entered: 08/20/2026)
2026-08-20
1
Proposed Voir Dire by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 08/20/2026)
2026-08-20
1
[SEALED] Letter to the Honorable Christopher J. Burke from Karen L. Pascale regarding Response to the Court's Order Regarding Parse's Motion in Limine No. 3 and Offer of Proof - re 626 Oral Order,,. (Pascale, Karen) (Entered: 08/20/2026)
2026-08-20
1
[SEALED] STATEMENT re 635 Letter Parse Biosciences, Inc.'s Offer of Proof Regarding May 2020 Hypothetical Negotiation Date by Parse Biosciences, Inc.. (Attachments: # 1 Certificate of Service)(Pascale, Karen) (Entered: 08/20/2026)
2026-08-20
1
(Revised) FINAL Voir Dire Questions to be read in open court. (sam) (Entered: 08/21/2026)
2026-08-21
1
FINAL Preliminary Jury Instructions to be read in open court. (sam) (Entered: 08/21/2026)
2026-08-21
1
NOTICE to Take Deposition of Dr. Michael Schnall-Levin on August 22, 2026 filed by Parse Biosciences, Inc..(Wilson, Samantha) (Entered: 08/21/2026)
2026-08-21
1
ORAL ORDER: The Court, having reviewed Plaintiffs’ “Motion to Strike Certain Opinions from DeForest McDuff, Ph.D.’s Second Supplemental Report” (“Motion”), (D.I. 590 ), and the briefing related thereto, (D.I. 591 ; D.I. 607 ; D.I. 614 ), hereby addresses the Motion as it relates to the one remaining dispute discussed by the parties in their briefing that was not addressed in the Court’s August 19, 2026 Order, (D.I. 625 ). Here, Plaintiffs ask the Court to strike as untimely the allegedly new apportionment methodology that Dr. McDuff uses to determine the ultimate informative royalty rate of the licenses at issue (the “apportionment analysis at issue”)—an opinion found in paragraph 65(d) of Dr. McDuff’s Second Supplemental Expert Report dated July 24, 2026 (“Dr. McDuff’s July 2026 report” or the “July 2026 report”). (D.I. 591 at 1-2; D.I. 607 at 2-3; D.I. 614 at 1-2; see D.I. 591, ex. 3 at ¶ 65(d) (“The parties might [] simply consider the downward pressure of other licensed IP in comparison with the upward pressure from the other economic factors described herein.”)) In assessing this portion of the Motion, the Court has again considered Fed. R. Civ. P. 26, Fed. R. Civ. P. 37, and the Pennypack factors. (See D.I. 625 ) It hereby ORDERS that Plaintiffs’ request is GRANTED for the reasons that follow: (1) To rely on expert opinion at trial, that expert’s opinions must be fairly and completely disclosed in a timely fashion pursuant to Rule 26(a) (or if not timely disclosed, then any late disclosure must be substantially justified or harmless under Rule 37). Here, in support of the assertion that Dr. McDuff’s apportionment analysis at issue was timely disclosed, Parse argues the following: (a) Dr. McDuff disclosed the apportionment analysis at issue in a single footnote (“footnote 274”) of his October 2024 opening report on damages, wherein he was discussing his analysis of the informative royalty rate from the UW license as it might relate to the hypothetical negotiation regarding Parse’s asserted patents, (D.I. 608, ex. G at ¶ 87 n.274 (cited in D.I. 607 at 3)); (b) Then, in his subsequent November 2024 rebuttal report regarding the damages analysis for infringement of Plaintiffs’ asserted patents, Dr. McDuff came to the conclusion that the informative royalty rate for the three relevant licenses (including the Roche license) should be the same as it was when he analyzed them for infringement of the Parse asserted patents in his affirmative October 2024 report, and said this was so “for the reasons detailed in [his October 2024] Report[,]” (D.I. 608, ex. D at ¶ 114 (emphasis added) (cited in D.I. 607 at 3)); and so (c) When Dr. McDuff relied on the apportionment analysis at issue in his July 2026 report, (D.I. 608, ex. C at ¶ 65(d)), it is Parse’s position that this was not a new opinion, but instead one that Dr. McDuff has relied on since his November 2024 rebuttal report (since that report’s “for the reasons” language should have prompted the reader to understand that Dr. McDuff was there invoking his analysis in footnote 274 of his October 2024 report). (D.I. 607 at 2-3); (2) The Court does not agree that Parse and Dr. McDuff timely disclosed such a theory as it relates to Plaintiffs’ asserted patents. (See D.I. 614 at 1) It cannot be the case that Dr. McDuff fairly put Plaintiffs on notice of his apportionment analysis at issue simply by vaguely citing to all of “the reasons detailed in [his October 2024] Report[,]” (D.I. 608, ex. D at ¶ 114), which Parse concedes only focused on the Parse patents, when: (a) the October 2024 report contained a detailed analysis relying on a royalty stacking provision in conducting apportionment (one that the Court has since excluded, (D.I. 523 at 2-3)); (b) Dr. McDuff only included the apportionment analysis at issue in a single footnote in that October 2024 report; and (c) in his November 2024 report—the report actually discussing apportionment in connection with Plaintiffs’ patents—Dr. McDuff never cited or substantively described the apportionment analysis at issue, and instead based his affirmative royalty rate opinion again on apportionment based on “license-based benchmarks[.]” (D.I. 614 at 1; D.I. 608, ex. D at ¶ 113(d)) It is fundamentally unfair for Plaintiffs to have been expected to understand that with Dr. McDuff’s who-knows-what-it-means “for the reasons” reference, Dr. McDuff intended to apply the particular reasoning found in a single footnote in different report about different patents to his analysis of apportionment regarding Plaintiffs’ patents. And this is especially unfair given the extensive amount of process afforded to the parties throughout this case to be able to develop their respective damages positions via expert discovery. The reference to the apportionment analysis at issue in Dr. McDuff’s July 2026 report is thus untimely, as it was sufficiently disclosed only one month before trial.; and (3) Under a Rule 37/Pennypack analysis, Parse’s untimely disclosure of Dr. McDuff’s new apportionment theory in July 2026 (regardless of whether it is deemed an entirely new theory or an old theory applied for the first time to a new factual setting) cannot be substantially justified or harmless. With trial about to begin, there is simply not sufficient time to allow Plaintiffs a full and fair opportunity to examine Dr. McDuff’s apportionment analysis at issue in the context of Plaintiffs’ patents. Ordered by Judge Christopher J. Burke on 08/21/2026. (sam) (Entered: 08/21/2026)
2026-08-21
1
ORAL ORDER: The Court, having reviewed Parse’s August 20, 2026 letter, (D.I. 635 ), hereby ORDERS as follows: (1) The Court is not sure it is fully understanding Parse’s position, in that it appears that Parse is still challenging the February 2021 hypothetical negotiation (“HN”) date via its motion in limine (“MIL”) #3, (D.I. 582, ex. 19), even though: (a) so far as things stand now, the February 2021 HN date is the only HN date that the jury will hear evidence or testimony about at trial; (b) it is the HN date that, throughout nearly the entirety of this many-year case, both sides’ damages experts—including Parse’s damages expert—used and relied on when putting forward their opinions on damages; (c) if one was going to properly challenge the appropriate HN date, a MIL does not seem like the right vehicle to use, (D.I. 582, ex. 19 at Answering Brief at 1); and (d) the Court has already ruled that Parse failed to timely challenge the use of the February 2021 HN date via the Daubert process (which, along with the summary judgment process, seems like the right vehicle by which to make a HN date challenge), (D.I. 583 ); see also Bos. Sci. Corp. v. Cordis Corp., 777 F. Supp. 2d 783, 791-95 (D. Del. 2011).; and (2) Therefore, the Court cannot see from either a logistical, procedural, or substantive perspective how any date other than the February 2021 HN date will be the HN date presented to the jury. That said, for now the Court will simply DENY Parse’s MIL #3 without prejudice to renew (if Parse thinks there is some basis to do so) on the morning prior to the start of trial (since the Court didn’t permit oral argument on this MIL during the Pretrial Conference). Ordered by Judge Christopher J. Burke on 08/21/2026. (sam) (Entered: 08/21/2026)
2026-08-21
1
ORAL ORDER: The Court hereby ORDERS that the prayer conference is set for August 26, 2026 after completion of testimony for the day. Ordered by Judge Christopher J. Burke on 08/21/2026. (sam) (Entered: 08/21/2026)
2026-08-21
1
Oral Order
2026-08-21
1
No Actions
Order on Motion to Preclude
2026-08-21
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Jury Trial Day 1 held on 8/24/2026. Jury selection completed; preliminary jury instructions read in open court. The parties presented opening statements. Plaintiffs began case-in-chief. Complete examination of Garry Nolan (sworn). Direct examination and partial cross examination of Giovanna (Prout) McKenzie (sworn). (Clerk: S. Miller, W. Roberts, and J. Bell; Court Reporter Michele Rolfe) APPEARANCES: M. Powers, S. Jameson, A. Hadzimehmedovic, P. Ehrlich, D. Hazhdan, J. Pierce, C. Noyes, F. Cottrell, K. Farnan, and S. Metzler for Plaintiffs; B. Pickard, C. Vira, R. Powers III, A. Phillips, I. Helman, K. Pascale, A. Gaza, and S. Wilson for Defendant. (sam)
2026-08-24
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Jury Trial Day 2 held on 8/25/2026. Examination completed of Giovanna (Prout) McKenzie (previously sworn). Complete examination of Michael Schnall-Levin (sworn), Sean Scott (video deposition), Georg Seelig (video deposition), Charles Roco (video deposition), Jennifer McCullar (video deposition), Joseph Musmacker (video deposition), Michael Skogen (video deposition), John Walsh (video deposition), Michael Yamamoto (video deposition), and Peter Sims (sworn)(expert). Partial direct examination of Drew Mooney (sworn)(expert). (Clerk: S. Miller, W. Roberts, and J. Bell; Court Reporter Heather Triozzi) APPEARANCES: M. Powers, S. Jameson, A. Hadzimehmedovic, P. Ehrlich, D. Hazhdan, J. Pierce, C. Noyes, F. Cottrell, K. Farnan, and S. Metzler for Plaintiffs; B. Pickard, C. Vira, R. Powers III, A. Phillips, I. Helman, K. Pascale, A. Gaza, and S. Wilson for Defendant. (sam)
2026-08-25
1
No Actions
Jury Trial - Begun
2026-08-25
1
No Actions
Jury Trial - Held
2026-08-26
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Prayer Conference held on 8/26/2026. (Clerk: W. Roberts and J. Bell; Court Reporter Michele Rolfe) APPEARANCES: K. Farnan, A. Hadzimehmedovic, and D. Hazhdan for Plaintiffs; S. Wilson, C. Gallo, A. Phillips, and K. Pascale for Defendant. (sam)
2026-08-26
1
No Actions
Minute Entry for proceedings held before Judge Christopher J. Burke - Jury Trial Day 3 held on 8/26/2026. Examination completed of Drew Mooney (previously sworn)(expert). Defense calls Alex Rosenberg (sworn), full examination completed. Plaintiffs rest. Defense present JMOL outside the presence of the jury. JMOL DENIED for reasons stated on the record. Complete examination of Sean Scott (video deposition), Jan Berka (video deposition), Thomas Albert (video deposition), Tod Bedilion (video deposition), Melanie Masuda (video deposition), and Frank Steemers (video deposition). Partial direct examination of Lior Pachter (sworn)(expert). (Clerk: S. Miller, W. Roberts, and J. Bell; Court Reporter Michele Rolfe) APPEARANCES: M. Powers, S. Jameson, A. Hadzimehmedovic, P. Ehrlich, D. Hazhdan, J. Pierce, C. Noyes, F. Cottrell, K. Farnan, and S. Metzler for Plaintiffs; B. Pickard, C. Vira, R. Powers III, A. Phillips, I. Helman, C. Gallo, K. Pascale, A. Gaza, and S. Wilson for Defendant. (sam)
2026-08-26
1
No Actions
VERDICT SHEET by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Proposed Final Verdict Form. (Farnan, Kelly) (Entered: 08/27/2026)
2026-08-27
1
Proposed Jury Instructions by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Proposed Final Jury Instructions. (Farnan, Kelly) (Entered: 08/27/2026)
2026-08-27
1
Minute Entry for proceedings held before Judge Christopher J. Burke - Jury Trial Day 4 held on 8/27/2026. Examination completed of Lior Pachter (previously sworn)(expert). Complete examination of Rahul Satija (sworn)(expert) and DeForest McDuff (expert)(sworn). Defense rests. Complete examination of Peter Sims (previously sworn)(expert). Plaintiffs rest their rebuttal case. Parties present their respective JMOL motions and responses. Motions DENIED for reasons stated on the record. The Court read a portion of the Final Jury Instructions to the jury. (Clerk: S. Miller, W. Roberts, and J. Bell; Court Reporter Heather Triozzi) APPEARANCES: M. Powers, S. Jameson, A. Hadzimehmedovic, P. Ehrlich, D. Hazhdan, J. Pierce, C. Noyes, F. Cottrell, K. Farnan, and S. Metzler for Plaintiffs; B. Pickard, C. Vira, R. Powers III, A. Phillips, I. Helman, C. Gallo, K. Pascale, A. Gaza, and S. Wilson for Defendant. (sam) Modified on 8/28/2026 (sam).
2026-08-27
1
No Actions
Jury Trial - Held
2026-08-27
1
No Actions
Miscellaneous Hearing
2026-08-27
1
No Actions
Final Jury Instructions read in open court. (sam) (Entered: 08/28/2026)
2026-08-28
1
FINAL Admitted Exhibit and Witness List from 8/24/2026-8/28/2026 Jury Trial.(sam) (Entered: 08/28/2026)
2026-08-28
1
VERDICT SHEET (Blank). (sam) (Entered: 08/28/2026)
2026-08-28
1
[SEALED] JURY VERDICT. (sam) (Entered: 08/28/2026)
2026-08-28
1
REDACTED VERSION of D.I. 648 SEALED Jury Verdict. (sam) (Entered: 08/28/2026)
2026-08-28
1
Minute Entry for proceedings held before Judge Christopher J. Burke - Jury Trial Day 5 completed on 8/28/2026. The Parties presented closing statements. Jury officer sworn. Verdict reached and read in open court. Jury polled. (Clerk: S. Miller, W. Roberts, and J. Bell; Court Reporter Michele Rolfe) APPEARANCES: M. Powers, S. Jameson, A. Hadzimehmedovic, P. Ehrlich, D. Hazhdan, J. Pierce, C. Noyes, F. Cottrell, K. Farnan, and S. Metzler for Plaintiffs; B. Pickard, C. Vira, R. Powers III, A. Phillips, I. Helman, C. Gallo, K. Pascale, A. Gaza, and S. Wilson for Defendant. (sam)
2026-08-28
1
No Actions
Jury Trial - Completed
2026-08-28
1
No Actions
Jury Trial - Held
2026-08-28
1
No Actions
ORAL ORDER: The Court hereby ORDERS that by no later than September 4, 2026 at 4:00 p.m., the parties shall jointly submit: (1) a proposed form of order to enter (non-final) judgment on the verdict; and (2) a status report that indicates how the case should proceed, including a listing of any other matters the Court must resolve, any post-trial motions each party intends to file, and any agreed-upon briefing schedule/page limits. Ordered by Judge Christopher J. Burke on 8/31/2026. (mlc) (Entered: 08/31/2026)
2026-08-31
1
Oral Order
2026-08-31
1
No Actions
STIPULATION TO EXTEND TIME to file proposed form of order to enter (non-final) judgment on the verdict and status report (see D.I. 650) to 4:00 p.m. ET September 8, 2026 - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 09/03/2026)
2026-09-03
1
ORAL ORDER: The Court, having reviewed Defendant Parse Biosciences Inc.’s (“Parse”) unopposed motion to seal and redact limited portions of the Court’s April 13, 2026 Memorandum Order (“April 13 MO”), (D.I. 532 ), and Parse’s unopposed motion to seal and redact limited portions of the Court’s April 20, 2026 Memorandum Order (“April 20 MO”), (D.I. 537 ), hereby ORDERS that the Motions are DENIED. In both the April 13 MO and April 20 MO, certain proposed redactions relate to assertedly confidential terms found in the merger agreement between Parse and third-party QIAGEN North American Holdings, Inc. (“QIAGEN”) that Parse argues would provide competitors with information about both entities’ negotiation strategies and would create “disadvantageous asymmetry” for Parse in its future business dealings. (D.I. 532 at 3-4; D.I. 537 at 3-5) But in the parties’ recent trial, similar information about these terms was shared publicly, in open court. As to the April 20 MO, Parse also proposes redactions of the specific costs and volume of certain materials relating to the merger between Parse and QIAGEN, and Parse argues that disclosure of such information would reveal confidential information about the size and complexity of the merger that could affect Parse’s competitive positioning in future negotiations. (D.I. 537 at 4-5; D.I. 538 at ¶¶ 5-9) But the reasons given for sealing are vague and unpersuasive. (D.I. 538 at ¶ 8 (stating only that disclosure of this information would “reveal to competitors the size and complexity of the... merger[,]” which would be expected by anyone to have been large and complex)) Ordered by Judge Christopher J. Burke on 09/04/2026. (sam) (Entered: 09/04/2026)
2026-09-04
1
SO ORDERED, D.I. 651 STIPULATION TO EXTEND TIME to file proposed form of order to enter (non-final) judgment on the verdict and status report (see D.I. 650 ) to 4:00 p.m. ET September 8, 2026 filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 09/04/2026. (sam)
2026-09-04
1
No Actions
Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief
2026-09-04
1
No Actions
Order on Motion on Stipulation to Extend Time
2026-09-04
1
No Actions
Joint STATUS REPORT by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A)(Farnan, Kelly) (Entered: 09/08/2026)
2026-09-08
1
ORAL ORDER: The Court, having reviewed the parties’ joint status report, (D.I. 653 ), hereby ORDERS as follows: (1) With regard to the parties’ dispute over page limitations, Plaintiffs’ proposal is ADOPTED. The parties shall be limited to a maximum of 25 pages of opening briefs, 25 pages of answering briefs and 12 pages of reply briefs relating to any post-trial motions filed by that side, no matter how many such motions are filed.; and (2) With regard to the parties’ dispute regarding the relevant dates as to post-trial briefing, the parties’ motions and opening briefs in support thereof shall be due on October 7, 2026. The parties' responsive briefs to each of the motions shall be due on November 4, 2026. The parties’ reply briefs in support of each of their motions shall be due on November 18, 2026. Ordered by Judge Christopher J. Burke on 09/09/2026. (sam) (Entered: 09/09/2026)
2026-09-09
1
Non-Final JUDGMENT After Jury Verdict in favor of Scale Biosciences, Inc. and Roche Sequencing Solutions, Inc. against Parse Biosciences, Inc. This Judgment is not a final judgment, and instead serves to trigger the time for filing post-trial motions only on issues that were decided by the jury. (See Judgment for complete details and deadlines.) Signed by Judge Christopher J. Burke on 09/09/2026. (sam) (Entered: 09/09/2026)
2026-09-09
1
Oral Order
2026-09-09
1
No Actions
ORAL ORDER: The Court, having reviewed the parties’ joint status report, (D.I. 653 ), hereby additionally ORDERS as follows: (1) Any motion for attorneys’ fees or motion pursuant to 35 U.S.C. § 285 shall be filed no later than 21 days following issue of a mandate following any appeal, or, if no party files an appeal, 21 days after the expiration of the time to file a notice of appeal.; and (2) All post-trial briefing shall cite to the final trial transcripts that will be docketed in this matter. Ordered by Judge Christopher J. Burke on 09/10/2026. (sam) (Entered: 09/10/2026)
2026-09-10
1
Oral Order
2026-09-10
1
No Actions
MOTION for Pro Hac Vice Appearance of Attorney David Bilsker and Matthew Traupman - filed by Parse Biosciences, Inc.. (Wilson, Samantha) (Entered: 09/25/2026)
2026-09-25
1
Pro Hac Vice Fee - Credit Card Payment received for David Bilsker and Matthew Traupman. ( re 657 MOTION for Pro Hac Vice Appearance of Attorney David Bilsker and Matthew Traupman )( Payment of $ 100, receipt number ADEDC-5074369).(Wilson, Samantha) (Entered: 09/25/2026)
2026-09-25
1
-District Court Pro Hac Vice Fee - 02 Attorneys Credit Card Payment
2026-09-25
1
No Actions
REDACTED VERSION of 559 Response to Motion,, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Envelope 3)(Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 577 Response to Motion,, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 591 Letter, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)(Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 612 SO ORDERED by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 614 Letter, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 8, # 2 Exhibit 9, # 3 Exhibit 10)(Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 594 Response to Motion,, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16)(Metzler, Sara) (Attachment 2 replaced on 10/1/2026) (sam). (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 556 Letter,,, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 557 Exhibit to a Document by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 560 MOTION for Leave to File Daubert Motions Out of Time to Exclude Mr. Drew Mooney's Reasonable Royalty Opinions (Exped Consideration requested) by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 595 Response to Motion, to Exclude Opinions and Testimony of Dr. Drew Mooney by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Metzler, Sara) (Attachment 2 replaced on 10/1/2026) (sam). (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 561 Exhibit to a Document, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 562 Exhibit to a Document, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 580 Proposed Pretrial Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 582 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 13, # 2 Exhibit 14, # 3 Exhibit 15, # 4 Exhibit 16, # 5 Exhibit 17, # 6 Exhibit 18, # 7 Exhibit 19)(Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 581 Exhibit to a Document, Joint [Proposed] Final PreTrial Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Farnan, Kelly) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 602 Letter,, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 604 Proposed Pretrial Order by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 605 Exhibit to a Document, by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Metzler, Sara) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 607 Letter, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 606 Exhibit to a Document, Proposed Pretrial Order Volume II by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 13, # 2 Exhibit 14, # 3 Exhibit 15, # 4 Exhibit 16, # 5 Exhibit 17, # 6 Exhibit 18, # 7 Exhibit 19)(Farnan, Kelly) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 608 Exhibit to a Document, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 635 Letter by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
REDACTED VERSION of 636 Statement by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/28/2026)
2026-09-28
1
Order on Motion to Appear Pro Hac Vice
2026-09-28
1
No Actions
SO ORDERED, D.I. 657 Motion for Pro Hac Vice Appearance of Attorney David Bilsker and Matthew Traupman - filed by Parse Biosciences, Inc. Ordered by Judge Christopher J. Burke on 09/28/2026. (sam)
2026-09-28
1
No Actions
REDACTED VERSION of 563 Exhibit to a Document, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/29/2026)
2026-09-29
1
REDACTED VERSION of 566 Letter, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/29/2026)
2026-09-29
1
REDACTED VERSION of 572 MOTION to Exclude Opinions and Testimony of Mr. Drew Mooney Based on a Legally Erroneous Hypothetical Negotiation Date (Expedited Consideration Requested) by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/29/2026)
2026-09-29
1
REDACTED VERSION of 574 Letter,, by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/29/2026)
2026-09-29
1
REDACTED VERSION of 571 MOTION to Exclude Opinions and Testimony of Mr. Drew Mooney Improperly Relying on the Book of Wisdom (Expedited Consideration Requested) by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 09/30/2026)
2026-09-30
1
Deficiency re Redacted Documents
2026-09-30
1
No Actions
Document Unsealed
2026-09-30
1
No Actions
Add Attorneys - PHV only
2026-09-30
1
No Actions
Remark: Memorandum Orders at D.I. 611 ; D.I. 613 ; D.I. 619 ; and D.I. 623 unsealed. Parties advised that they will not be seeking any redactions. (sam)
2026-09-30
1
No Actions
REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of D.I. 321 ; D.I. 324 ; D.I. 489 ; D.I. 494 ; and D.I. 571 . (sam)
2026-09-30
1
No Actions
Pro Hac Vice Attorney David L. Bilsker & Matthew A. Traupman for Parse Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (slk)
2026-09-30
1
No Actions
REDACTED VERSION of 321 Declaration, by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 49, # 2 Exhibit 50, # 3 Exhibit 51, # 4 Exhibit 52, # 5 Exhibit 53)(Metzler, Sara) (Entered: 10/01/2026)
2026-10-01
1
REDACTED VERSION of 324 Declaration by Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 54-part 1, # 2 Exhibit 54-part 2, # 3 Exhibit 55)(Metzler, Sara) (Entered: 10/01/2026)
2026-10-01
1
- CORRECTING ENTRY
2026-10-01
1
No Actions
CORRECTING ENTRY: Attachment 2 to D.I. 664 and D.I. 668 replaced per request of filing counsel to include inadvertently removed pages. NEFs regenerated. (sam)
2026-10-01
1
No Actions
REDACTED VERSION of 494 Unopposed MOTION to Seal Limited Portions of D.I. 485 Memorandum Order by Scale Biosciences, Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A, # 3 Exhibit B)(Farnan, Kelly) (Entered: 10/02/2026)
2026-10-02
1
REDACTED VERSION of 489 Amended Document by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 10/02/2026)
2026-10-02
1
Official Transcript of Jury Trial Day 1 held on 8/24/26 before Judge Christopher J. Burke. Court Reporter/Transcriber Michele Rolfe, Email: Michele_Rolfe@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 10/28/2026. Redacted Transcript Deadline set for 11/9/2026. Release of Transcript Restriction set for 1/5/2027. (sam) (Entered: 10/07/2026)
2026-10-07
1
Official Transcript of Jury Trial Day 2 held on 08/25/2026 before Judge Christopher J. Burke. Court Reporter/Transcriber Heather Triozzi, Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 10/28/2026. Redacted Transcript Deadline set for 11/9/2026. Release of Transcript Restriction set for 1/5/2027. (sam) (Entered: 10/07/2026)
2026-10-07
1
Official Transcript of Jury Trial Day 3 held on 08/26/2026 before Judge Christopher J. Burke. Court Reporter/Transcriber Michele Rolfe, Email: Michele_Rolfe@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 10/28/2026. Redacted Transcript Deadline set for 11/9/2026. Release of Transcript Restriction set for 1/5/2027. (sam) (Entered: 10/07/2026)
2026-10-07
1
Official Transcript of Jury Trial Day 4 held on 08/27/2026 before Judge Christopher J. Burke. Court Reporter/Transcriber Heather Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 10/28/2026. Redacted Transcript Deadline set for 11/9/2026. Release of Transcript Restriction set for 1/5/2027. (sam) (Entered: 10/07/2026)
2026-10-07
1
Official Transcript of Jury Trial Day 5 held on 08/28/2026 before Judge Christopher J. Burke. Court Reporter/Transcriber Michele Rolfe,Email: Michele_Rolfe@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 10/28/2026. Redacted Transcript Deadline set for 11/9/2026. Release of Transcript Restriction set for 1/5/2027. (sam) (Entered: 10/07/2026)
2026-10-07
1
MOTION Post-Trial Motion - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] POST TRIAL BRIEF in Support of Their Post-Trial Motion by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] DECLARATION of Azra Hadzimehmedovic re 697 POST Trial Brief Volume I (Exs. 1-4 part 1 (AA-AI) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4-part 1)(Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] EXHIBIT re 698 Declaration, Volume II (Exhibit 4 part 2 (AJ-AS) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 4-part 2)(Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] EXHIBIT re 698 Declaration, Volume III (Exhibit 4 part 3 (AT-BH) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 4-part 3, # 2 Exhibit 4-part 4)(Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] EXHIBIT re 698 Declaration, Volume IV (Exhibit 4 part 4 (BI-CM) by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 4-part 5, # 2 Exhibit 4-part 6, # 3 Exhibit 4-part 7)(Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] EXHIBIT re 698 Declaration, Volume V (Exhibit 4 part 5 (CN) - Exhibit 11 by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Attachments: # 1 Exhibit 4-part 8, # 2 Exhibit 4-part 9, # 3 Exhibit 5, # 4 Exhibit 6, # 5 Exhibit 7, # 6 Exhibit 8, # 7 Exhibit 9, # 8 Exhibit 10, # 9 Exhibit 11)(Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] DECLARATION of Michael Schnall-Levin re 697 POST Trial Brief by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] DECLARATION of Drew Mooney re 697 POST Trial Brief by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] DECLARATION of Peter A. Sims, Ph.D. re 697 POST Trial Brief by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Farnan, Kelly) (Entered: 10/07/2026)
2026-10-07
1
MOTION for Judgment as a Matter of Law [Parse Biosciences, Inc.'s Renewed Motion for Judgment as a Matter of Law Pursuant to Rule 50(b) and, in the Alternative, Motion for a New Trial or Remittitur Pursuant to Rule 59 of the Federal Rules of Civil Procedure] - filed by Parse Biosciences, Inc.. (Pascale, Karen) (Entered: 10/07/2026)
2026-10-07
1
[SEALED] OPENING BRIEF in Support re 706 MOTION for Judgment as a Matter of Law [Parse Biosciences, Inc.'s Renewed Motion for Judgment as a Matter of Law Pursuant to Rule 50(b) and, in the Alternative, Motion for a New Trial or Remittitur Pursuant to Rule 59 of the Federal Rules of C filed by Parse Biosciences, Inc..Answering Brief/Response due date per Local Rules is 10/21/2026. (Pascale, Karen) (Entered: 10/07/2026)
2026-10-07
1
DECLARATION of Igor Helman in Support of Parse Biosciences, Inc.'s Renewed Motion for Judgment as a Matter of Law Pursuant to Rule 50(b) and, in the Alternative, Motion for a New Trial or Remittitur Pursuant to Rule 59 of the Federal Rules of Civil Procedure re 706 MOTION for Judgment as a Matter of Law [Parse Biosciences, Inc.'s Renewed Motion for Judgment as a Matter of Law Pursuant to Rule 50(b) and, in the Alternative, Motion for a New Trial or Remittitur Pursuant to Rule 59 of the Federal Rules of C by Parse Biosciences, Inc.. (Attachments: # 1 Exhibit A)(Pascale, Karen) (Entered: 10/07/2026)
2026-10-07
1
CORRECTING ENTRY: Previous transcript has been removed from the case. Filed in error. (sam)
2026-10-07
1
No Actions
- CORRECTING ENTRY
2026-10-07
1
No Actions
STIPULATION TO EXTEND TIME for the parties to submit redacted (public) versions of D.I. 697-705, D.I. 707, and all further sealed filings filed in connection with the post-trial motions to and including December 4, 2026 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 10/12/2026)
2026-10-12
1
SO ORDERED, D.I. 709 STIPULATION TO EXTEND TIME for the parties to submit redacted (public) versions of D.I. 697-705, D.I. 707, and all further sealed filings filed in connection with the post-trial motions to and including December 4, 2026 filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 10/13/2026. (sam) (Entered: 10/13/2026)
2026-10-13
1
Order on Motion on Stipulation to Extend Time
2026-10-13
1
No Actions
NOTICE of Intent to Request Redaction by Samantha G. Wilson re 691 Transcript,, 694 Transcript,, 692 Transcript,, 693 Transcript,, (Wilson, Samantha) (Entered: 10/14/2026)
2026-10-14
1
NOTICE to Take Deposition of Dr. Peter A. Sims on October 22, 2026 filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 10/19/2026)
2026-10-19
1
NOTICE to Take Deposition of Dr. Michael Schnall-Levin on October 21, 2026 filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 10/19/2026)
2026-10-19
1
NOTICE to Take Deposition of Mr. Drew D. Mooney on October 20, 2026 filed by Parse Biosciences, Inc..(Pascale, Karen) (Entered: 10/19/2026)
2026-10-19
1
STIPULATION TO EXTEND TIME the deadline for the parties to submit a motion to redact the trial transcripts for Trial Days 2-4, D.I. 692, 693, 694, and any supporting briefs or declarations to through and including November 12, 2026 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc.. (Metzler, Sara) (Entered: 10/30/2026)
2026-10-30
1
Set/Reset Transcript Deadlines
2026-10-30
1
No Actions
Order on Motion on Stipulation to Extend Time
2026-10-30
1
No Actions
SO ORDERED, D.I. 715 STIPULATION TO EXTEND TIME the deadline for the parties to submit a motion to redact the trial transcripts for Trial Days 2-4, D.I. 692, 693, 694, and any supporting briefs or declarations to through and including November 12, 2026 - filed by Roche Sequencing Solutions, Inc., Scale Biosciences, Inc. Ordered by Judge Christopher J. Burke on 10/30/2026. (sam)
2026-10-30
1
No Actions
Reset Transcript Deadlines re D.I. 692 Transcript, D.I. 693 Transcript, D.I. 694 Transcript, per D.I. 715 Stipulation. Redaction Request due 11/12/2026. (sam)
2026-10-30
1
No Actions